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ABSTRACT 
 
  Dendritic cells (DC) are sentinels of the immune system that display an 
extraordinary capacity to present antigen to naïve T cells and initiate immune 
responses. DCs are distributed throughout the lungs in the conducting airways of the 
tracheobronchial tree and in the parenchymal lung, and play a pivotal role in 
controlling the immune response to inhaled antigens. The respiratory surface is 
continually exposed to potentially injurious particulates and pathogenic organisms, to 
which tightly regulated innate and adaptive immunological responses are made. The 
airways are usually sterile in healthy individuals. However, patients with chronic 
obstructive pulmonary disease (COPD) and cystic fibrosis (CF) have increased 
susceptibility to microbial infections and increased neutrophil elastase (NE) in lung 
secretions.  
 
This thesis was designed to test the hypotheses that; (i) excess NE may result 
in a dysregulation of lung DCs function in pulmonary chronic diseases, and (ii) the 
natural NE inhibitors in the respiratory system are able to rescue the NE-mediated 
dysregulation of DCs and potentially enhance their antigen presenting activity. 
 
The data in this thesis demonstrate that purified human NE down-regulated 
murine bone marrow (BM)-derived DC co-stimulatory molecules (CSM; CD40, 
CD80 and CD86), which was due to its proteolytic activity. NE-treated LPS-matured 
DCs were less efficient at presenting ovalbumin (OVA) peptide to naïve OVA-
specific transgenic (D011.10) T cells. In addition, immature DCs (iDC) 
simultaneously treated with LPS and NE failed to mature fully and produced 
significantly less IL-12 and TNF-α than DCs matured in the presence of LPS alone. 
Similarly, treatment of mature DC (mDC) with pooled and individual COPD and CF 
sputum samples caused a reduction in CD80 and CD86 levels (but not CD40) which 
positively correlated with the NE concentration present in the samples.   
 
The demonstration that NE could adversely affect DC phenotype and 
function suggested that augmentation of NE inhibitors could reverse this process and   III
preserve DC function in inflammatory microenvironments. Over-expression of an 
NE specific inhibitor (elafin) in the lungs of mice (using either replication-deficient 
adenovirus [Ad] or elafin transgenic [eTg] mice) increased the number 
(immunofluorescence) and activation status (flow cytometric measurement) of 
CD11c
+/MHCII
+ lung DCs in in vivo models. Replication-deficient Ad vectors 
encoding NE inhibitors, namely elafin, secretory leukocyte protease inhibitor (SLPI) 
and α1-protease inhibitor (α1-PI), were also used to infect DCs in vitro, to further 
study the effect of these NE-inhibitors on DCs in isolation. 
 
These findings suggest that purified NE and NE-containing lung 
inflammatory secretions are powerful down-regulators of DC maturation, resulting in 
reduced capacity of these potent APCs to efficiently present antigens; whereas, NE 
inhibitors could boost immunity by increasing the activation state and/or number of 
DCs. 
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CHAPTER 1 
INTRODUCTION 
 
1.1. OVERVIEW 
 
The lung possesses the largest surface area of the body which is in contact with 
the external environment in order to facilitate efficient gaseous exchange. As normal 
respiration occurs, the upper and lower airways are repeatedly exposed to a multitude 
of airborne particles and microorganisams. Since these agents are frequently 
deposited on the surface of the respiratory tract, an elaborate system of defence 
mechanisms is present to maintain the sterility of the lung. Innate defences are 
primarily responsible for the elimination of bacterial organisms from the respiratory 
tracts and alveoli. Early bacterial clearance is mediated by a dual phagocytic system 
involving both alveolar macrophages (AM) and DCs, and neutrophils. DCs are of 
particular importance, playing a central role in initiating protective T cell immune 
responses within the respiratory tract due to their potent ability to present antigen. 
The airways and lungs contain a rich network of DCs that are localised near the 
surface, so that they are ideally located to signal the entry of foreign substances that 
are inhaled. As a result of these highly co-ordinated defence systems, the airways are 
usually sterile and non-inflamed in healthy individuals. Conversely, continuous 
infection episodes are a feature of lung diseases such as COPD and CF. Frequent 
bacterial colonisations and cigarette smoking are instrumental in the generation of 
COPD and CF disease exacerbations. Consequently, the lungs of both COPD and CF 
patients are highly inflamed and are characterised by intense neutrophilic 
inflammation and the release of high levels of cytotoxic molecules, such as NE, that 
overwhelm the natural NE inhibitors and innate immune defences. 
 
The work described in this thesis was therefore initiated by the following 
questions:  Firstly, are cigarette smoke (CS) and COPD/CF lung inflammatory 
secretions (containing high concentrations of NE) able to influence the behaviour or 
phenotype of DCs in such a way as to inhibit their ability to present antigens and, 
thus, initiate protective immunity to pathogens? If so, can genetic augmentation of Chapter 1: Introduction 
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natural NE inhibitors influence the activation status, function and/or number of lung 
DCs? 
 
Against this background, the following section will provide a brief overview of 
DCs, particularly the respiratory tract DCs. This section will be followed by a 
discussion of the CF and COPD lung diseases, with special emphasis on the 
influence of infections on their development and pathologies, before going on to 
discuss the effects of CS on the innate and adaptive immune systems of the 
respiratory system.  Finally, NE and endogenous NE inhibitors will be described in 
the latter part of this chapter.  
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1.2. DENDRITIC CELLS (DC) 
 
1.2.1. DC overview 
  Optimal defence against the diverse types of microorganisams that invade our 
body requires specialised classes of non-specific and antigen-specific immune 
responses. The innate immune system includes phagocytic cells, natural killer (NK) 
cells, complement factors, and interferons (IFN). Cells of the innate immune system 
use a variety of pattern recognition receptors to recognise patterns shared between 
pathogens, for instance bacterial lipopolycaccharide (LPS), carbohydrates, and 
double-stranded viral RNA (Muzio et al., 1998; Brighthill et al., 1999; Aliprantis et 
al. 1999). As a result of evolutionary pressure, adaptive immunity has developed 
alongside the innate immune system. The key features of adaptive immune system 
are (i) the ability to rearrange genes of immunoglobulin (Ig) family, permitting 
creation of a large diversity of antigen-specific clones, and (ii) immunological 
memory. However this highly sophisticated and potent system needs to be instructed 
and regulated by antigen-presenting cells (APC). DCs are bone marrow (BM)-
derived leukocytes and are the most potent type of APCs. They are responsible for 
the initiation of immune responses and hence function as the ‘sentinels’ of the 
immune system (Banchereau and Steinman, 1998). Paul Langerhans first described 
DCs in human
 skin but thought these were cutaneous nerve cells (Langerhans, 1868). 
Steinman
 and Cohn (1973) discovered these cells almost a century later in
 mouse 
spleen and applied the term ‘dendritic cells’ based on
 their unique morphology. DCs 
generally have a low buoyant density and are initially adherent to plastic but then 
readily detach (Steinman et al., 1979). In recent years, DCs have been increasingly 
studied for their role as critical adjuvants in vaccines for preventing microbial 
infection and allograft rejection and treatment of cancer and autoimmune diseases 
(see below).  
Various methods have been employed for isolation of rare DC populations 
from tissues. Early methods used enzymes such as collagenases to obtain enriched 
populations of DCs from tissues. Selection of low-buoyant-density cells enriches for 
mononuclear
 cells, and the adherence step helps eliminate T cells and B cells
 from Chapter 1: Introduction 
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the preparation. Further enrichment of DCs utilises various
  combinations of 
additional negative and positive selection steps.
  One negative selection
  step 
eliminates contaminating B cells, T cells, and NK cells from
 the preparation by a 
combination of immunophenotyping/immunomagnetic methods and cell
  sorting. 
Positive selection steps use various combinations of
 monoclonal antibodies (Ab) to 
isolate cells expressing important DC
 cell surface markers. With the
 use of multiple 
enrichment steps, pure populations of tissue-derived
  DCs have been
  obtained 
(Lipscomb and Masten, 2002). DCs can also be propagated in vitro from BM and 
blood using various combinations of growth factors, such as granulocyte 
macrophage-colony
 stimulating factor (GM-CSF), tumour necrosis factor-α (TNF-α),
 
interleukin (IL)-4, stem cell factor (SCF), transforming growth
 factor-β (TGF-β), IL-
3, and Fms-like tyrosine kinase 3 ligand (Flt3L) (Caux et al., 1992; Inaba et al., 1992; 
Strobl et al., 1997; Zhang et al., 1999). GM-CSF in combination with IL-4
 or TNF-α 
and other cytokines provide important growth factors
  for interstitial DCs and 
Langerhans cells (LC). In addition, LCs also require TGF-β for their differentiation 
(Strobl et al., 1997). Flt3L has been used to stimulate the proliferation of stem cells
 
and progenitor cells in vitro and expand and mobilise all DCs
 and their progenitors in 
vivo (Masten et al., 2004; Maraskovsky et al., 1996 and 2000). 
Since DCs have numerous cytoplasmic processes giving rise to their stellate 
appearance, they have a high surface area permitting intimate contact with a large 
number of surrounding cells, e.g., T cells, NK cells, neutrophils, epithelial cells etc. 
Consequently, in vitro DCs form large spherical aggregates with lymphocytes, and 
experimentally, only one mDC is required to stimulate 100-3000 T cells.  DC 
precursors migrate form the BM through the blood stream to almost every tissue, 
where they eventually become resident iDCs. LCs in the epidermis are the best 
studied example of iDCs, which show a high ability for antigen uptake but a low 
capacity for antigen presentation. Immature DCs possess an array of mechanisms for 
sampling antigen. These include macropinocytosis, where fluid from the extra-
cellular milieu is taken up into pinocytic vesicles and antigen is concentrated by 
expelling excess water via channels called aquaporins (Norbury et al., 1997). DCs 
also express a repertoire of receptors for efficient receptor-mediated antigen uptake. 
Additional receptors expressed by DCs include FcγRII (CD32), FcγRI (CD64) Chapter 1: Introduction 
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(Fanger et al., 1996), FcεRI (Maurer et al., 1998) and the C3bi complement receptors 
(CD11b) (Green et al., 1980) which increase the efficiency of immune complex 
endocytosis.  
 
  During pathogen invasion, resident iDCs capture intruder antigens, and 
quickly leave the tissue (Macatonia et al., 1986). They crawl through the cells, cross 
the endothelium of lymphatic vessels and migrate to the draining lymph nodes (LN; 
Del Prete et al., 2006). During their migration from the peripheral tissues, DCs 
undergo phenotypical and functional maturation. Most remarkably, they stop 
capturing antigens while up-regulating the expression of co-stimulatory molecules 
(CSM). After reaching the subcapsular sinus of the LN, DCs move to the areas (T 
cell zones) through which T cells, recruited from the blood, percolate. Here, the 
interdigitating DCs are actively involved in the presentation of antigens to T cells 
(Figure 1.1). The presentation of antigen to the appropriate T cells seems to be the 
ultimate mission of the DCs recruited from the periphery, as most of them disappear 
in the T cell areas, most likely by apoptosis. 
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Figure 1.1.  Dendritic cell life history 
DC life history can be subdivided into a number of phases, all with discrete cellular 
functionality. Transition between phases is mediated by diverse signals and is 
accompanied by changes in expression patterns of many surface markers and 
secreted factors. SCF, stem cell factor; GM-CSF, granulocyte–macrophage colony 
stimulating factor; TGF, transforming growth factor; HSP, heat shock protein. 
TRANCE, tumour necrosis factor-related activation-induced cytokine. Adapted from 
Stockwin et al. (2000). 
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1.2.2. DCs innate receptor repertoire 
The functional properties of DCs, as mentioned above, include their ability to 
sense the environment (i.e., respond to environmental factors such as cytokines) and 
to sample microbes (i.e., phagocytose microbes) at the mucosal sites. To exert these 
sampling and sensing functional activities, DCs have a broad innate receptor 
repertoire for the recognition of infectious non-self antigens (Janeway Jr and 
Medzhitov, 2002). In the mouse, this receptor repertoire includes the expression of 
Toll-like receptor (TLR) family members that bind a variety of microbial ligands 
(Takeda and Akira, 2005). Signalling through these receptors is mediated either via 
the myeloid differentiation factor-88 (MyD88) adaptor molecule, or via an 
independent pathway involving the Toll–IL-1 receptor domain-containing adaptor 
IFN-β (TRIF) molecule and the IFN regulatory factor-3 (IRF-3) transcription factor 
(Beutler, 2004). As a result of microbial activation through TLRs, the nuclear factor-
kappa B (NF-κB) family members are activated and translocate to the nucleus (Hofer 
et al., 2001), where they induce the transcription of many NF-κB-dependent genes- 
mostly immune and inflammatory genes encoding cytokines and chemokines. In 
addition, microbial activation might lead to the transcription of the IFN-inducible 
genes via IRF-3 (Trottein et al., 2004). DCs can also display surface molecules such 
as the macrophage receptor with collagenous structure (MARCO) receptor, which 
has been shown to be involved in significant remodelling of the actin cytoskeleton 
(Granucci et al., 2003). Other receptors expressed by DCs are DC-specific ICAM 
(intra-cellular adhesion molecule)-3 grabbing non-integrin (DC-SIGN) and C-type 
lectin receptors, which are capable of binding a variety of microorganisams, 
including viruses, such as HIV, and pathogenic bacteria, such as Mycobacterium 
tuberculosis (van Kooyk and Geijtenbeek, 2003;  Tailleux et al., 2003).  
 
1.2.3. Antigen processing by DCs 
 
Soluble and particulate antigens are efficiently captured by iDCs and targeted 
to major histocompatibility molecule class II (MHCII) compartments (Tan et al., 
1997; Inaba et al., 1997 and 1998). Immature DCs constantly accumulate MHCII 
molecules in lysosome-related intra-cellular compartments identified as MHCII-rich Chapter 1: Introduction 
  8
compartments (MIIC), with multivesicular and multilamelar structure (Nijman et al., 
1995; Kleijmeer et al., 1995). Whereas, in iDCs, class II molecules are rapidly 
internalised and have a short half-life, maturation/inflammatory stimuli lead to a 
burst of MHCII synthesis and translocation of the MHCII-peptide complexes to the 
cell surface where they remain stable for days and are available for recognition by 
CD4
+ T cells (Inaba et al., 1997; Cella et al., 1997; Pierre et al., 1997). To generate 
CD8
+ cytotoxic killer T cells, DCs present antigenic peptides on MHC class I (MHCI) 
molecules, which can be loaded through both an endogenous and an exogenous 
pathway (Pamer et al., 1998; Rock et al., 1999). 
 
1.2.4. DC-T cell interactions 
The ability to prime naïve T cells constitutes a unique and critical function of 
DCs both in vitro and in vivo. Recognition of MHC-peptide complexes on DCs by 
antigen-specific T cell receptors (TCR) constitutes "signal one" in DC–T cell 
interaction. DC–T cell clustering is mediated by several adhesion molecules, like 
integrins β1 and β2 and members of the Ig superfamily (CD2, CD50, CD54, and 
CD58) (Hart, 1997). The crucial factor, that constitutes "signal two", required to 
sustain T cell activation, is the interaction between CSMs expressed by DCs and 
their ligands expressed by T cells. The B7 family members, CD80 and CD86, on 
DCs are so far the most critical molecule for amplification of T cell responses (Wang 
and Chen, 2004). 
The TNF family of ligands and receptors, now totalling ~50, are also 
important co-stimulators in DC interactions with T cells. Particularly noteworthy is 
the interaction of CD40
 on DCs with CD40L (CD154) on T cells.
 T cells can activate 
DCs via CD40 ligand (CD40-L)-CD40 signalling leading to increased expression of 
CD80/CD86 and cytokine release (IL-1, TNF, chemokines, and IL-12) 
(Schoenberger et al., 1998). Engagement of receptor activator of NF-κB (RANK), a 
member of the TNFR family, by its ligand (RANKL/TRANCE) expressed on 
activated T cells, stimulates the secretion of cytokines like IL-1, IL6, and IL-12 by 
DCs. This results in increased DC survival, by inhibition of DC apoptosis and, in Chapter 1: Introduction 
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turn, in enhanced proliferative T cell responses in mixed lymphocyte reactions 
(Table 1.1). 
During the development of an adaptive immune response, the phenotype and 
function of DCs play an important role in initiating
 tolerance, memory, and polarised 
T-helper 1 (Th1), Th2 and Th17 differentiation. A Th1 response is characterised by 
the production
 of IFN-γ and TNF-α by T cells. It is the normal outcome after DC
 
exposure to viruses and is crucial for the control
 of intra-cellular bacteria such as 
Mycobacterium spp. Th2 differentiation usually occurs after contact with extra-
cellular parasites (e.g., helminths and schistosome worms) and involves production 
of cytokines
 such as IL-4, IL-5, IL-9, and IL-13, resulting
 in IgE production as well 
as accumulation of eosinophils and
  mast cells (Pearce and MacDonald, 2002). 
Allergens are non-pathogenic environmental antigens
 that elicit an inappropriate Th2 
response. Secretion or lack
 of secretion of factors by DCs, particularly IL-12, are 
instrumental
 in the final differentiation of T cells into type 1 or type 2
 effector T cells, 
respectively (signal 3, Figure 1.2). A third main outcome
  is the induction of 
tolerogenic or regulatory T cells (Treg) producing
 immunosuppressive cytokines, 
such as IL-10 or TGF-β. This is probably the most
 prevalent response in steady-state 
conditions. It forms a constant
 safeguard against the emergence of inappropriate 
inflammatory
  reactions to harmless antigen. In the absence of sufficient co-
stimulation,
 T cells exhibit anergy or undergo apoptosis. 
Dysregulated or uncontrolled effector T cell responses can lead to 
autoimmune diseases and allergies (Sakaguchi et al., 2000). Recent studies in this 
field have led to the identification of IL-17-producing (Th17) T cells (Figure 1.2 D). 
Th17 cells produce IL-17A (IL-17) and IL-17F and, to a lesser extent, TNF-α and IL-
6 (Langrish et al., 2005). It was initially proposed that Th17 and Th1 cells might be 
related and might originate from a common ‘pre-Th1’ precursor cell (Bettelli and 
Kuchroo, 2005). Accumulating data, however, suggest that Th17 cells (induced by 
IL-23) represent a distinct subset unrelated to Th1 or Th2 cells (Veldhoen et al., 
2006; Bettelli et al., 2006). The cytokine IL-23 is a heterodimeric molecule, sharing 
the p40 subunit with the Th1 cytokine IL-12 but differing from IL-12 because of its 
unique p19 subunit. While IL-12 plays a key role in the differentiation of naïve T Chapter 1: Introduction 
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cells to Th1 cells, IL-23 promotes the expansion of Th17 cells (Langrish et al., 2005). 
In adoptive transfer experiments, T cells producing IL-17 induced experimental 
allergic encephalomyelitis (EAE), but T cells producing IFN-γ could not, although 
both types of T cells could cross the blood-brain barrier (Langrish et al., 2005). 
Moreover, EAE severity was shown to be greatly reduced, though the disease was 
not abrogated, upon treatment with a monoclonal Ab to IL-17 in mice that were 
actively immunised with myelin antigen and adjuvant. Likewise, mice treated with 
Abs to IL-23 failed to develop EAE (Langrish et al., 2005). A critical role for IL-17 
in other autoimmune and allergic conditions has also been demonstrated: both 
collagen-induced arthritis and allergic airway hypersensitivity are suppressed in IL-
17-deficient mice (Nakae et al., 2003; Hellings et al., 2003). Experimental models 
suggest that Th17 cells may also be important for neutrophilic inflammation in acute 
airway inflammation (Hoshino et al., 2000; Hashimoto et al., 2005). Neutrophil 
infiltration is also observed in acute asthma attacks, including neutrophilia in 
bronchoalveolar lavage (BAL) fluids. Interestingly, sputum IL-17 mRNA was shown 
to correlate with CXCL8 and neutrophil counts (Bullens et al., 2006). 
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Table 1.1. Co-stimulation molecules for DC-T cell signals  
 
Adapted from Lipscomb and Masten (2002). 
 
DC  T cell  
B7 family and receptors 
B7-1 (CD80)  CD28, CTLA-4 (CD152) 
B7-2 (CD86)  CD28, CTLA-4 (CD152) 
B7RP-1 ICOS 
PD-L1 (B7-H1)  PD-1 
PD-L2 PD-1 
B7-H3  Not known  
TNF family ligand and receptors 
CD40 CD40L  (CD154) 
OX40L OX40  (CD134) 
TRANCE (RANK)  TRANCE (RANK-L) 
CD27 CD27L  (CD70) 
CD30L (CD153)  CD30  
Miscellaneous 
ICAM-1 (CD54)  LFA-1 (CD11a/CD18) 
DC-SIGN (CD209)  ICAM-3 (CD50), ICAM-2 (CD102) 
SLAM*(CD150) SLAM  (CD150) 
CD58 CD2 
TNF, tumour necrosis factor; ICOS, inducible co-stimulator; ICAM, PD-L, 
programmed death ligand; intra-cellular adhesion molecule; SLAM, signalling 
lymphocyte activation molecule. 
* SLAM binds to itself.  
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Figure 1.2. DC-T cell interactions  
 
Schematic diagram showing how DCs translate stimuli detected in the inhaled air 
into a specific immune response. Inert antigen is continuously sampled by DCs, 
which go through a constitutive program of migration and maturation. A) Invasion 
by pathogens activates DCs through their TLRs. This leads to enhanced migration to 
the mediastinal LNs, where antigen is presented in the context of Th1-inducing 
signals. The Th1 lymphocytes thus generated are crucial for a resolution of the 
infection.  B) Extra-cellular parasites and allergens can also cause DC activation, 
albeit through poorly defined molecular signals. Some allergens, such as house dust 
mite extracts, can proteolytically disrupt the integrity of the epithelial layer and 
activate underlying DCs. Alternatively, inert antigen can become allergenic because 
of the concomitant presence of a Th2-inducing environmental adjuvant such as diesel 
exhaust particles (not shown). C) Differentiation of Th17 cells from naïve precursors 
is induced by IL-1, TNF-α, IL-17 A/F and IL-6 in STAT1-, T-bet-, STAT4- and 
STAT6-independent manners. Rheumatoid arthritis and multiple sclerosis are 
emerging as models of IL-17-driven autoimmune inflammatory diseases. D) In the 
absence of inflammation, expression of tolerogenic receptors and soluble mediators 
is predominant. This leads to the generation of regulatory T lymphocytes capable of 
repressing any emerging immune response to this specific antigen. Activated DCs 
transport allergen to the draining LNs, where it is presented along with putative Th2-
biasing signals. ICOS-L, inducible co-stimulator ligand; PD-L1, programmed death 
ligand-1; PGE2, prostaglandin E2. Adapted from Vermaelen and Pauwels (2005). 
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1.2.5. DC trafficking 
 
Each step of DC trafficking involved in either their steady-state distribution 
in peripheral and lymphoid organs, or in their recruitment upon inflammation/injury, 
is controlled by soluble chemotactic factors known as chemokines. In vitro iDCs 
have been demonstrated to respond to a large spectrum of chemokines such as 
macrophage inhibitory protein (MIP)-1α, MIP-1β, MIP-3α, MIP-3β, monocyte 
chemotactic protein (MCP)-3, MCP-4, MCP-5 and regulated on activation normal T 
cell expressed and secreted (RANTES/CCL5) (D’Amico et al., 1998; Dieu et al., 
1998; Sozzani 2005 [Table 1.2 and Figure 1.3]). These chemokines transduce a 
chemotactic signal through CCR1, CCR2, CCR5, CCR6, CCR7 and CXCR4. In 
addition to chemokines, proteases, such as NE, which degrade several components of 
the extra-cellular matrix, have been shown to be highly expressed on DCs and may 
thus contribute to their migration through tissues (Banchereau et al., 2000). A 
comprehensive study by Hashimoto and co-workers (1999) analysed 17000 genes 
from a complementary-DNA library constructed from immature monocyte-derived 
DCs identified the expression of many genes presumably involved in cell migration, 
including a metalloprotease with elastolytic activity as well as a DC-specific HAI-2 
gene, a serine protease inhibitor of hepatocyte growth factor activator. Overall, the 
differentiation of monocytes to DCs was accompanied by significant changes in the 
expression of genes related to cell structure and motility. 
 
 
 
 
 
 
 
 
 
 
 Chapter 1: Introduction 
  14
 
Table 1.2.  Expression of chemokine receptors by dendritic cells  
MIP, macrophage inflammatory protein; RANTES, regulated on activation, normal T 
expressed and secreted; MCP, monocyte chemoattractant protein; TARC, thymus 
and activation-regulated chemokine; MDC, monophage derived chemokine; SDF, 
stromal derived factor; IL, interleukion; SLC, secondary lymphoid-tissue chemokine. 
Adapted from Banchereau et al. (2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Receptor  Ligands 
Immature DC    
CCR1 MIP-1α, RANTES, MCP-3, MIP-5 
CCR2 MCPs 
CCR4 TARC,  MDC 
CCR5 MIP-1α, MIP-1β, RANTES 
CCR6 (LC only)  MIP-3α 
CXCR1 IL-8 
CXCR4 SDF-1 
Mature DC    
CCR7 MIP-3β, SLC (6Ckine) Chapter 1: Introduction 
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Figure 1.3.  DC development and trafficking in vivo 
Progenitor CD34
+ cells are released into the blood stream from the bone marrow 
where they can differentiate into effort cells such as DCs and macrophages under the 
influence of cell-type specific colony stimulating factors. Precursor and iDCs that 
display CCR6 are attracted by the epithelium that expresses the specific ligand MIP-
3α. Upon antigen capture and activation, DCs CCR6 is replaced by CCR7, whose 
ligands are (i) 6Ckine, which is expressed on lymphatic vessel walls, and (ii) MIP-3β, 
which is expressed in the T cell areas of lymphoid organs. This may guide the 
maturing DCs to the T cell areas where they will start to produce chemokines that 
attract lymphocytes.
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1.2.6. DCs exhibit plasticity  
Although it is clear that distinct DC subpopulations exhibit distinct functions, 
there is also evidence that these DC functions can be altered by the cytokine 
environment. In particular, DCs exhibit considerable plasticity in their ability to skew 
Th responses, and DCs that normally induce Th1 profiles can be converted to Th2-
skewing cells when treated with anti-inflammatory cytokines such as IL-10 and 
TGF-β or with steroids (Piemonti et al., 1999). In this context, DC subsets isolated 
from different organs differently affect Th responses. For instance, mouse and rat 
spleen DCs induce Th1 responses, whereas those from Peyers patches elicit Th2 
responses (Iwasaki and Kelsall, 1999). Studies focusing on mucosal surfaces such as 
the gut (Mowat, 2003) and lung (Akbari et al., 2002; Dodge et al., 2003) clearly 
indicate that the baseline response to inert antigens at these sites displays a Th2 bias. 
These data indicate that resident lung DCs under steady-state conditions are 
programmed for induction of Th2-biased immunity (see section 1.2.10 for details). 
DC plasticity is also reflected in their differentiation, which may determine 
the fate of antigen (i.e., processing and presentation or degradation). This aspect is 
exemplified by the potential of macrophages to differentiate to DCs (Palucka et al., 
1998; Zou et al., 2000), a pathway that may permit high antigen capture 
(macrophage) and presentation (DC) (Figure 1.4).  
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Figure 1.4. The plasticity of DCs  
According to microenvironmental instructions (e.g., cytokines), DC functions can be 
altered. For instance DCs can become macrophages with higher phagocytic functions 
in response to macrophage-colony stimulating factor (M-CSF). Furthermore, IL-12 
secreting DCs that induce type 1 T cell differentiation can switch, in response to IL-
10 and prostaglandin E2, to DCs inducing T cell anergy or T cell differentiation into 
type 2 cells or regulatory T cells. Adapted from Banchereau et al. (2000). 
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1.2.7. Heterogeneity of DCs 
  Both human and murine DCs are heterogeneous populations and depending 
on their precursors, and the local environment in which they differentiate and reside 
in, would have distinct morphology and function as will be briefly discussed below. 
 
1.2.7.1. Human DCs 
In humans, DCs are found as precursor populations in BM and blood and as 
more mature forms in lymphoid and non-lymphoid
 tissues. Three distinct subtypes of 
human DCs have been delineated
 based on studies of skin DCs, DCs generated in 
vitro from
 CD34
+ hematopoietic progenitors, and blood DC precursors (Shortman 
and Liu, 2002). Human skin contains two of the three DC subtypes
 in immature form: 
LCs and interstitial DCs. Both subtypes emerge
 in cultures from CD34
+ BM and 
CD11c
+ blood precursors
 in the presence of GM-CSF and either IL-4 or TNF-α 
(Caux et al., 1999). The CD11c
+ DC precursor expresses myeloid markers, including
 
CD13 and CD33. Upon activation by CD40L, immature myeloid DCs
  undergo 
maturation and produce IL-12 (Cella et al., 1996). LCs and interstitial DCs also share 
the capacity to activate both
 CD4 and CD8 naïve T cells and secrete IL-12. One 
striking difference between LCs and interstitial DCs is the ability of interstitial
 DCs, 
but not LCs, to induce the differentiation of naïve B cells
 into Ig-secreting plasma 
cells (Caux et al., 1997).  
Plasmacytoid DCs (pDC) are a third type of DC and are so named because at 
the ultra-structural level they resemble Ig-secreting plasma
 cells. These DCs are 
found in the T cell zones of lymphoid organs
 and in the thymus and blood and were 
previously described as plasmacytoid
 T cells or plasmacytoid monocytes (Facchetti 
et al., 1999; Sorg et al., 1999). pDCs are characterised by a unique phenotype,
 
CD11c
-CD4
+CD123
+CD45RA
+HLA-DR
+, and possess the unique ability
 to secrete 
large amounts of IFN-α/β upon viral stimulation
 (Cella et al., 1999; Grouard et al., 
1997). Unlike LCs and interstitial
 DCs,  pDCs require IL-3 for their differentiation 
and
 are derived from a CD11c
- blood precursor that has low expression
 of GM-CSF 
receptor, lacks the myeloid markers CD14, CD13, and
  CD33, lacks mannose Chapter 1: Introduction 
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receptors, and expresses high amounts of CD123
 (Grouard et al., 1997). pDCs do not 
express LPS-sensing receptors but typically express TLR7 and TLR9 (the receptor 
for unmethylated microbial DNA sequence) (Ito et al., 2005;  Cao and Liu, 2006). 
Nevertheless, pDCs share a common function with LCs
 and interstitial DCs in having 
the capacity to activate CD4 and
 CD8 naïve T cells and secrete IL-12 upon CD40L 
activation (Cella et al., 2000). 
 
1.2.7.2. Murine DCs 
 
At least two distinct pathways of DC development have been identified in 
mice, myeloid and lymphoid. Evidence for the myeloid origin of DCs comes mainly 
from  in vitro studies in which myeloid-committed precursors give rise to both 
granulocytes/monocytes and myeloid DCs under the influence of GM-CSF (Inaba et 
al., 1992). DCs can also arise from lymphoid-committed precursors (Wu et al., 1996). 
Lymphoid and myeloid DCs differ in phenotype, localisation, and function. Both 
subsets express high levels of CD11c, MHCII, and the CSMs CD80, CD86 and 
CD40. To date, the most reliable marker to distinguish these two subsets is CD8α, 
which is expressed as a homodimer on the lymphoid DC, but is absent from the 
myeloid subset. Other markers such as DEC-205 and CD1d are expressed at higher 
levels on lymphoid DCs, but they can be up-regulated on myeloid DCs by in vitro 
culture or LPS treatment. Lymphoid DCs are localised in the T cell-rich areas of the 
periarteriolar lymphatic sheaths in the spleen and LNs. In contrast, myeloid DCs are 
in the marginal zone bridging channels of the spleen (Wu et al., 1996; Pulendran et 
al., 1997). 
 
The mouse equivalent of human pDCs has been identified in the recent years 
(Nakano et al., 2001; Bjorck, 2001). These cells have a unique surface phenotype: 
CD45RA
highB220
+CD11c
lowCD11b
-MHCII
low. Although similar to their human 
counterparts, mouse pDCs showed notable differences in the expression of a few 
surface molecules. In contrast to human pDCs which express high levels of IL-3R 
and are negative for CD8, mouse pDCs lack of high expression of IL-3R and some 
express CD8α. Currently, the biological role of CD8α expression on mouse DCs and Chapter 1: Introduction 
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pDCs is not yet clear. Similar to human pDCs, mouse pDCs express TLR7 and TLR9, 
and could produce large amounts of type I IFNs in response to viral stimulation or 
bacterial oligonucleotides containing CpG motifs (Hochrein and O'Keeffe; 2002).  
 
1.2.7.3. Murine versus Human DCs 
 
Murine DCs have been widely employed by researchers investigating the 
roles of DCs in the generation and regulation of specific
 immunity. Although it is 
clear that differences exist between
 murine and human DCs, it is evident that murine 
DCs are relevant
 to human DCs and provide an appropriate model for human cells
 in 
most cases. Like human DCs, murine DCs 1) originate from CD34
+ BM stem cells, 2) 
are found in blood and tissues, 3)
 are able to take up and degrade antigen to antigenic 
peptides,
 4) express MHCII molecules complexed with antigenic peptide,
 5) express 
CSMs, 6) mature and migrate in response
 to danger signals, and 7) are responsive to 
the microenvironment
 with a controlled release of chemokines and cytokines. 
 
1.2.8. DCs and disease 
DCs have been studied in a number of common autoimmune conditions. 
Despite the diverse nature and tissue distribution of autoimmune diseases, DCs share 
certain common characteristics irrespective of the disease and sites from which they 
are recovered. These include increased numbers of tissue DCs, particularly in a 
perivascular distribution, DC infiltration at the earliest stage of disease and an altered 
DC phenotype. Early DC infiltration contributes to the recruitment of other immune 
cells. 
The cell-mediated arm of the immune system plays an important role in the 
detection and elimination of malignant cells. T lymphocyte responses to tumour cells 
will require initial antigen presentation by professional APCs such as the DC. DCs 
infiltration into tumours has for many years been linked to increased patient survival 
and reduction in the number of metastases in a variety of malignancies (including 
endometrial, gastric and lung cancers) (Coppola et al., 1998; Tsujitani et al., 1993; 
Zeid and Muller, 1993). However this is tempered by the observation that DCs Chapter 1: Introduction 
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isolated from many cancer patients show an impaired ability to present antigen as a 
product of decreased surface expression of the co-stimulators CD80 and CD86 
(Chaux et al., 1996; Gabrilovich et al., 1997; Perrot et al., 2007). It also appears that 
many sporadic tumours actively exploit immunosuppressive pathways to interfere 
with antigen presentation. For example, tumour-derived IL-10 acts directly on tissue 
DCs to prevent maturation and therefore subsequent immunogenic presentation to T 
lymphocytes (Wittke et al., 1999). Increased expression of FasL on tumour cells may 
also induce apoptosis in DC and T cell effectors (Strand et al., 1999; Gratas et al., 
1998). Vascular endothelial growth factor (VEGF) is produced by a majority of 
carcinomas and has been shown to inhibit maturation of DCs within the tumour and 
to impair differentiation of haemopoietic progenitors into DCs (Gabrilovich et al., 
1996). 
 
1.2.9. Therapeutic applications of DCs 
  The observation that DCs are the most potent APCs and play important roles 
in the progression and severity of many diseases has led many researchers to 
investigate how modulation of DC function could be therapeutically exploited. The 
influence of activated DCs could be used in cancer/intra-cellular parasitic infections 
to redirect an immune response towards defective (malignant)/infected cells that 
have evaded immunodetection. Alternatively, DCs could be suppressed to alleviate 
the symptoms of autoimmunity and allotransplant rejection. Some of these strategies 
are discussed in more details in this section.  
There are currently two main procedures that exploit DCs as therapeutic 
agents in experimental and clinical trials worldwide, (i) gene transfer (see below for 
more details), and (ii) cellular immunotherapy. Both of these methodologies have 
proved to be extremely powerful in eradicating established infections as well as 
tumours (Moll, 2004; Reichardt et al., 2004; Wei et al., 2005). Adoptive transfer of 
pulsed DCs, presenting tumour antigens to resting naïve T cells, is currently of 
tremendous interest. Adoptive immunotherapy may ultimately have its greatest use in 
patients undergoing cellular rescue after ablative chemotherapy; the infusion of 
immunocompetent T cells, genetically modified stem cells, or programmed DCs may Chapter 1: Introduction 
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offer the opportunity to direct a patient's immune response to eliminate residual 
microscopic diseases. Gene transfer techniques may offer more optimal ways to 
generate therapeutic DCs as will be discussed below. 
 
1.2.9.1. Adenoviral gene therapy to modulate DCs 
 
  Viral vectors have provided effective in vivo gene delivery methods for 
therapeutic purposes. The ability of viruses to infect a wide variety of cell types in 
vitro and in vivo has been exploited for several applications. Adenoviruses (Ad) are 
non-enveloped DNA viruses with ~30 kb genomes. There are more than 50 human 
Ad serotypes. However, most of the recombinant Ad vectors used in gene therapy 
applications are based on serotypes 2 and 5 (Jooss and Chirmule, 2003). The viral 
capsid consists of 252 capsomeres (240 hexons and 12 penton molecules). The viral 
capsids interact with the coxsackievirus Ad receptor (CAR) and co-receptors like 
integrins α5β1, αvβ3, αvβ5, αMβ2 to infect permissive cells. Subsequent to entering 
the cells, the virus escapes endosomal lysis and enters the nucleus by traversing 
microtubules, binds to the nuclear envelope and inserts its genome through nuclear 
pore complexes. Various Ad strains have been associated with a number of infectious 
diseases in normal subjects, for example upper respiratory infections and in 
conjunctivitis. A wide range of cell types, for example, respiratory epithelial cells, 
endothelial cells, myoblasts, glial cells, DCs, macrophages and hepatocytes have 
been shown to be infectible with Ad vectors, albeit to different degrees (Liu and 
Muruve, 2003).  
 
  Ad vectors have the potential of activating both innate and adaptive immune 
systems both in vitro and in vivo (Jooss and Chirmule, 2003). The innate immune 
response to Ad represents the most significant hurdle in clinical application of Ad 
vectors for gene therapy, but it is an attractive feature for vaccine development. 
Incidentally, recent studies demonstrate that Ad vectors elicit innate immune 
responses through a MyD88/TLR9-dependent and/or -independent manner according 
to cell type (Zhu et al., 2007; Yamaguchi et al., 2007).  
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DCs pulsed ex vivo with antigens have the potential use as cell-based 
vaccines against tumours. Viral vectors derived from Ad have also been extensively 
used to pulse DCs ex vivo by delivering genes encoding immunomodulatory 
molecules and tumour antigens, since these vectors are relatively safe, effective in 
inducing the maturation of DCs, and can accommodate large expression cassettes 
encoding antigens (Miller et al., 2003). One of the hurdles for gene delivery to DCs 
by Ad vectors, however, is low transfection efficiency of DCs due to the paucity of 
Ad receptor on DCs. To overcome this obstacle, targeted Ad vectors have been made 
by modifying viral capsid proteins. These targeted Ad vectors not only enhance the 
gene delivery to DCs, but also allow in vivo gene delivery to DCs, thus avoiding ex 
vivo manipulation of DCs (Wu et al., 2005; Xia et al., 2006). On the other hand, a 
few methods have been developed in recent years which significantly enhance the 
Ad infection efficiency of DCs both in vitro and in vivo, such as centrifugal methods 
(Nishimura et al., 2001a and 2001b), and use of polycation complexes (Di Nicola et 
al., 2000).  
 
A considerable wealth of literature is available on the use of genetically 
engineered DCs in combating infections and established tumours in experimental 
animals. Brown and co-workers (2003) recently provided the first validation in a 
primate model
 for the use of Ad vectors to induce robust T cell immunity
 to a virus 
via DCs. These findings are in agreement with the findings of previous in
 vitro and in 
vivo studies (e.g., murine models) showing the efficacy of this approach. 
Investigators from Crystal’s laboratory have shown that genetic Ad modification of 
murine DCs to express CD40L accomplishes the goal of directly activating B cells to 
induce functionally relevant antigen-specific humoral immune responses that lead to 
protection against the lethal infection in a microbe-specific manner (Kikuchi et al., 
2000). A recent study by Nakamura and co-workers (2005) showed that DCs 
transduced (using an Ad vector) with the natural tumour antigen provided a 
remarkably higher therapeutic efficacy in comparison to using antigen-pulsed DCs. 
Similarly, whole organ gene therapy using agents that are able to induce DC survival 
and differentiation have been employed to augment DC numbers in vivo. In this 
regard, Wang et al. (2000) investigated the role of GM-CSF on the differentiation of Chapter 1: Introduction 
  24
DCs during
 pulmonary viral infection by using a mouse model
 of GM-CSF transgene 
expression (Ad-GMCSF). They concluded that GM-CSF promotes the differentiation 
and activation of a myeloid
 DC population primarily by acting on macrophages 
during pulmonary
 immune
 responses. In a similar study, Miller et al. (2002) used an 
Ad-GMCSF vector in mice and found that up to 24% of splenocytes became
 CD11c
+ 
and the number of DCs increased up to 260-fold. They demonstrated that following 
intravenous (i.v.) administration of Ad-GMCSF, the splenic DC numbers remained 
substantially elevated even 75
  days after treatment. Relatedly, Ad vaccination 
protocols exploiting DC function have been successfully tested out in animal 
experiments (e.g., Tuting et al., 1999; Murakami et al., 2004; Gyorffy et al., 2005;  
Malowany et al., 2006), in in vitro protocols (e.g., Jonuleit et al., 2000; Yang et al., 
2006; Tokunaga et al., 2005) and in human clinical trials (e.g., Kusumoto et al., 2001; 
Trudel  et al., 2003) which appear to have promising applications in both 
immunosuppressed and immunostimulatory scenarios. 
 
 
1.2.10. Pulmonary DCs 
  The lung, representing the largest epithelial surface area of the body, is 
continuously exposed to a vast array of airborne particles and invading organisms 
during respiration. In order to protect the host against these recurrent challenges, a 
complex defence system has evolved. The normal host defence responses of the 
lungs, as in any other organ, include both the innate and acquired immune responses. 
Innate defences consist of the structural defences, the antimicrobial peptides 
generated in the airways (discussed in section 1.7), and the phagocyte defences 
provided by the resident macrophages and the neutrophils which are recruited to the 
lung in response to pulmonary infection/inflammation.  Acquired immune defence is 
the antigen-specific mechanism of the lung host defence including cell-mediated and 
Ab-mediated immune responses, important for the eradication of infections caused 
by virulent encapsulated bacteria, viruses, and intra-cellular pathogens that survive 
within the resident macrophages and epithelial cells lining the respiratory tract.   Chapter 1: Introduction 
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  A growing body of experimental evidence indicates that the ‘sentinel’
 
paradigm of DC function applies extremely well to the respiratory
 system. This 
implies (i) a constant recruitment of DCs into
 the lung, (ii) a capacity for these cells 
to sense and capture
 inhaled antigens, and (iii) an efficient transport of processed
 
antigens to the draining pulmonary LNs, where DCs decide which
 type of immune 
response will ensue, as discussed in detail below.
 Sertl and colleagues (1986) were 
one of the first pioneer groups to describe the
  presence of DCs in the airway 
epithelium, lung parenchyma, and
 visceral pleura of human and mouse specimens. 
These cells displayed
 a typical dendritic morphology, expressed copious amounts of 
MHCII on their surface, and acted as potent T cell stimulators
 in vitro. Later studies 
have provided more detail into the features
 and localisation of DCs in the different 
pulmonary compartments.  DCs form a tightly meshed network within antigen-
exposed tissues of the upper airway, bronchial mucosa, lung interstitium and pleura 
(Sertl et al., 1986; Holt and Schon-Hegrad, 1987; von Garnier et al, 2005). In general, 
a few different phenotypes of DCs are found in the lungs, including conducting 
airway DCs, alveolar DCs, and interstitial DCs (Figure 1.5). Within the bronchial 
epithelium,
 DCs are found with typical features of LCs, such as the presence
 of 
Birbeck granules, the expression of CD1a, and Langerin (Demedts et al., 2005). 
Recently, pDCs have been identified in both human and murine lungs (Asselin-
Pature et al., 2003; Demedts et al., 2005). Lung pDCs express low levels of CD11c, 
and are positive for Gr1, B220 and 120G8 as previously reported in lymphoid tissues 
(Asselin-Pature et al., 2003), and produce large amounts of IFN-α in response to 
virus infections. 
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1.5. Distribution of DCs in the lungs.   
Airway DCs are located as a network immediately above and beneath the basement 
membrane, in between basal epithelial cells. Interstitial DCs (stained for CD11c) are 
composed of a B220
+Gr1
+ pDC subset and a B220
- myeloid DC subset. Alveolar 
DCs can consistently be recovered by bronchoalveolar lavage (BAL) in humans, rats 
and mice, particularly when inflammation is induced. Adapted from Lambrecht and 
Hammad (2003). 
 
 Chapter 1: Introduction 
  27
The density of DCs in the airways is related to the extent of antigen exposure, 
being greatest in the proximal airways, and diminishing towards the periphery. A 
variety of pro-inflammatory stimuli induce a marked increase in the density of lung 
DCs, including exposure to bacterial and viral particles, IFN-γ, and allergen 
inhalation in previously sensitised animals (McWilliam et al., 1996). It has been 
estimated that, in the absence of
 inflammation, DCs are distributed at an average 
density of several
  hundred cells per millimeter squared in the large airways, 
decreasing
  to less than a hundred DCs per millimeter squared within smaller
 
intrapulmonary airways (Schon-Hegrad et al., 1991). DCs in the lung parenchyma 
are
 present in larger numbers. They are mostly found within inter-alveolar
 septa (Holt 
et al., 1987). Following antigen uptake, some airway DCs are able to rapidly 
transport antigen to the T cell zones of regional LNs (Vermaelen et al., 2001), 
although it is clear that a significant proportion of antigen-loaded DCs also remain 
within the lung where they are able to activate T cells locally, long after antigen 
exposure (Julia et al., 2002). Pulmonary DCs, like immature monocyte-derived DCs, 
express both CCR1 and CCR5, whereas mDCs migrating towards lymphoid structure 
no longer express these two receptors, but acquire CCR7 (Cochand et al., 1999). 
Even in the absence of overt inflammation, DCs or their precursors
 are constantly 
recruited from the blood into the lung. Holt
 and co-workers (1994) were the first to 
demonstrate that respiratory
 tract DCs are continuously replenished by a steady-state 
BM output. Not surprisingly, inflammatory stimuli in the inhaled air have
 a profound 
impact on these steady-state dynamics. In a series
  of hallmark experiments, 
McWilliam and colleagues (1994) described
  how the inhalation of pathogenic 
material, such as bacteria
 or viral particles, induced a very rapid influx of DCs into
 
the airways of rats, in some cases peaking already 2 hours after
  challenge. 
Remarkably, this DC recruitment was as fast or sometimes
 ahead of the prototypic 
neutrophil influx. This surprising discovery overthrew the classical
 theory which 
stated that neutrophils were the first leukocytes infiltrating the inflammatory tissues.
 
This further confirms the view that DC recruitment is an integral part of the
 early 
phase of the innate immune response, with the potential
  to progress toward a 
powerful adaptive defence. Consequent resolution of the inflammation usually 
restores baseline numbers
 of pulmonary DCs. Chapter 1: Introduction 
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  One of the most crucial specialised functions of pulmonary DCs, as any other 
specialised resident DC, is the
 capture and delivery of antigens to local lymphoid 
tissues. Using a mouse model, Vermaelen and colleagues (2001) elegantly 
demonstrated that antigen uptake by airway
 DCs can proceed without any breach to 
the mucosal barrier, and
 in the absence of any inflammatory stimulus. By instilling 
inert fluorescent macromolecules into the
  airways they were able to track DCs 
migrating and transporting antigen
 from the airway mucosa toward pulmonary LNs.
 
This transport was rapid, occurred constitutively (i.e., in
  the absence of 
inflammation), and the migratory DCs were seen
 to specifically penetrate the T cell 
zones of the mediastinal
 LNs. Analogous conclusions have been reached using intra-
tracheal (i.t.) transfer
 of in vitro-derived DCs (Havenith et al., 1993;  Lambrecht et 
al., 2000), although these cultured
 DCs might not reflect the exact nature of the 
endogenous pulmonary
 DC populations in terms of phenotype, activation level, and
 
antigen-uptake capacity.
  
As mentioned above, the current hypothesis states that to counter the 
potential inflammatory tissue injury of chronic Th1-mediated responses against 
antigens, mucosal sites may skew toward Th2 immune responses. In this regard, a 
number of mechanisms exist to regulate DC function within the lungs. Freshly 
isolated lung DCs exhibit a poor capacity for antigen presentation and express only 
low levels of CSMs (Cochand et al., 1999). However, culturing purified lung DCs 
for short periods in the absence of exogenous stimuli is sufficient to elicit 
spontaneous DC activation, suggesting that the tissue environment in the lung 
provides inhibitory signals that counteract DC activation in vivo (Holt et al., 1992). 
AMs are known to maintain lung DCs in an immature state through the release of 
nitric oxide and it is likely that airway epithelial cells also regulate DC function 
through the release of soluble mediators such as TGF-β and nitric oxide, and through 
adhesion molecules such as the cadherins and integrins (Holt et al., 1993). In the 
steady state, lung DCs do not synthesise IL-12 and preferentially stimulate Th2 
rather than Th1 immunity (Stumbles et al., 1998; Constant et al., 2002). This 
phenomenon has also been shown to be associated with expression of both IL-10 and 
IL-6 by resident myeloid DCs within the lung. Recent studies by Akbari and co-
workers (2002) showed that IL-10 production by DCs is critical for the induction of Chapter 1: Introduction 
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tolerance, and that phenotypically mature pulmonary DCs mediate tolerance induced 
by respiratory exposure to antigen. Relatedly, Dodge and colleagues (2003) 
demonstrated that IL-6 negatively regulates IL-12 production, as pulmonary DCs 
from IL-6
-/- mice produced significant levels of IL-12 and induced Th1 polarisation 
of naïve CD4
+ T cells. The most recent finding to explain this phenomenon is the 
intriguing observation showing that murine pulmonary interstitial CD11c
+ APCs 
suppressed T cell responses in vitro and in vivo by production of indoleamine 2,3-
dioxygenase (IDO), an enzyme that catabolises tryptophan to its by-product, 
kynurenine (Swanson et al., 2004). The production of IDO was also shown to be 
unique to pulmonary APCs, as cells isolated from the liver or spleen did not produce 
IDO, constitutively, or even in response to INF-γ, the most potent inducer of IDO 
expression (Swanson et al., 2004). 
 
Last but not least, an
 integrin expressed by gut DCs has been shown to give 
Treg cells the green light for suppression. CD103 has been reported to be essential 
for the adhesion of human and mouse intestinal lymphocytes to epithelial cells 
through the interactions with E-cadherin (Cepek et al., 1994). Annacker and 
colleagues (2005) showed that DCs
 expressing the integrin CD103 are required for 
Treg cells to
 subdue gut-attacking effector T cells in a mouse model of inflammatory
 
bowel disease (IBD). CD103 has been shown to be expressed on 30-50% of the lung-
derived CD11c
+ DCs migrating to the bronchial LNs (Hintzen et al., 2006). A recent 
report has identified the CD103
+ DC in mice as a major DC population residing in 
the lung mucosa (Sung et al., 2006). CD103
+ DCs in the lung do not express the 
typical plasmacytoid DC (B220, Gr-1) or lymphoid markers (CD8α), but express 
high amounts of CD11c, MHCII, and low levels of CD11b (Sung et al., 2006). 
Antigen-carrying CD103
+ bronchial LN DCs are specialised in cross-presenting 
innocuous inhaled antigen (Sung et al., 2006) and might also be responsible for 
subsequent down-regulation of lung immune responses, as previously demonstrated 
in the gut (Annacker et al., 2005).  
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1.3. CYSTIC FIBROSIS (CF) 
 
  Second only to sickle-cell anaemia, CF is the most common genetic disease, 
occurring once in every 3600 children born alive, causing early death (Grosse et al., 
2005). Although pulmonary disease causes most of the morbidity and mortality 
associated with CF, the lungs are thought to be anatomically normal at birth (Chow 
et al., 1982). The first detectable evidence of lung disease in patients with CF is 
infection and/or inflammation in BAL fluid, denoted by elevated concentrations of 
IL-8 and neutrophils and the presence of microorganisams (Khan et al., 1995; 
Armstrong et al., 2005). Sufferers have an average life expectancy of 37 years, and 
current therapies treat the disease’s symptoms rather than its cause. The defective 
gene was identified in 1989 and appeared to be located on chromosome 7. It encodes 
the CF transmembrane conductance regulator (CFTR), which acts as a chloride 
channel. The most common frequent mutation of this gene is the deletion of 
phenylalanine at position 508 (∆508) (Renders et al., 2001). Since that early 
discovery, more than 700 additional CFTR mutations related to CF have been 
identified (Schwiebert et al., 1998). The gene defect results in a combination of low 
or absent chloride secretion and increased sodium absorption in the airways. 
Consequently, the disease is characterised by the production of abnormally viscid 
bronchopulmonary secretions interfering with mucociliary clearance of bacteria. The 
recognition that CF lung disease reflects the failure of airways innate defence has 
focused much attention on normal defence mechanisms that protect this region from 
inhaled bacteria. The reason for the high prevalence of bacteria in the early stage of 
CF is currently unclear. However, a number of hypotheses have been postulated to 
account for innate airways defence, including those based on bacterial binding to 
airway epithelial surfaces (Imundo et al., 1995), or clearance of locally deposited 
bacteria by CFTR attachment-site mediated epithelial phagocytosis (Pier et al., 1996). 
Mutations of CFTR are also hypothesised to reduce airway surface liquid (ASL) 
glutathione levels, which may enhance oxidant injury (Noah et al., 1997; Hiatt et al., 
1999). On the other hand, various components of the innate and adaptive immune 
system might be adversely affected in CF lungs leading to their 
immunocompromised status. Although this field has not been exploited in detail yet, Chapter 1: Introduction 
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a very limited number of studies published to date are encouraging and indicate the 
need for more research in this area. For instance, an interesting study by Knight et al. 
(1997) demonstrated that APCs isolated from BAL fluid of CF patients were unable 
to present antigen and stimulate the allogeneic normal circulating lymphocytes. This 
was despite the fact that blood monocytes taken from the same patients were 
functional in both assays (Knight et al., 1997). Regardless of the mechanisms leading 
to airway infection, once the airways are colonised, a vicious cycle of infection, 
inflammation, and airway damage begins. Figure 1.6 summarises the pathways of CF 
lung disease pathogenesis supported by various in vivo and in vitro studies. 
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Figure 1.6. Pathogenesis of lung disease in patients with CF 
 
Regardless of the initial inflammatory insult or defective process, once this cycle is 
started, it will lead to all elements being increasingly perturbed. Several 
interconnected cycles perpetuate and further impair host defence, leading to a 
persistent bacterial infections and progressive lung disease. ASL, airway surface 
liquid. Adapted from a review by Starner and colleagues (2005). 
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1.3.1. CF Pathogens 
 
  To date, the source of most pathogens in CF patients remain unknown. 
Potential reservoirs include the natural environment (e.g., soil and water), the 
environment in health care settings (e.g., sinks), contaminated equipment (e.g., 
nebulisers), other contaminated objects, and other CF patients.  
 
  Staphylococcus aureus ( S.a.) is often the first pathogen to infect the 
respiratory
  tract of CF patients. In the preantibiotic era, S.a. and non-typeable 
Haemophilus influenzae (NTHI) caused substantial morbidity and mortality in
 infants 
with CF, but with the advent of antibiotic therapy
 effective against these pathogens, 
the life expectancy of infants
 with CF has increased. Colonisation of the anterior 
nares with S.a. is an important
 risk factor for subsequent disease with the same 
genotype in
 CF and non-CF patients (Perl et al., 1995; Goerke et al., 2000;  von Eiff 
et al., 2001). CF patients without
 recent treatment with antibiotics had a higher 
prevalence of
  nasal colonisation with S.a. than did CF patients receiving
  recent 
treatment or healthy controls (Goerke et al., 2000). S.a. strains
 spread within families, 
but loss or replacement of a strain
 was frequently observed in families with and 
without a family
 member with CF. In contrast, CF patients may be infected or
 
colonised with the same strain of S.a. for at least 1 to
 2 years (Branger et al., 1996).
  
 
Pseudomonas aeruginosa ( P.a.) is considered the major pathogen in later 
stages of the disease. Eighty-two percent of patients have colonisation with S.a. and 
NTHI before they have colonisation with P.a. (Abman et al., 1991). Studies of BAL 
fluid of single-pathogen infections with P.a., S.a., and NTHI in CF patients did not 
reveal clinically significant differences in IL-8 or neutrophil levels (Muhlebach et al., 
1999), indicating that all of these early pathogens are associated with high levels of 
inflammation. Other studies of BAL fluid found similarly increased inflammatory 
cells and cytokines regardless of the pathogen (Rosenfeld et al., 2001).  
 
Most of the patient-to-patient transmission studies performed
 to date have 
focused on Burkholderia cepacia (B.c.) complex. B.c. complex was first described as Chapter 1: Introduction 
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a pathogen in CF patients
 in the late 1970s and early 1980s. Initial descriptions 
documented
 the marked virulence of this multidrug-resistant pathogen, the
 so-called 
‘cepacia syndrome’, i.e., high fever, bacteraemia,
 and rapid pulmonary deterioration 
that led to the death of 62
 to nearly 100% of patients (Isles et al., 1984; Tablan et al., 
1987). Thus, infection with B.c. complex can cause a decline in lung function and a 
shortened
 median survival (Whiteford et al., 1995; Liou et al., 2001; Navarro et al., 
2001). Different species
 of the B.c. complex appear to occupy different niches
 in the 
natural environment. B. cenocepacia strains have been found in agricultural
 soil 
(Balandreau et al., 2001), the maize rhizosphere (Bevivino et al., 2002), onion fields 
(LiPuma et al., 2002),
 and occasionally soil in urban settings (Miller et al, 2000). To 
date, B. multivorans
 has only rarely been recovered from soil samples. The risk posed
 
by strains in the natural environment remains uncertain.
  
 
Fungi and molds can also be detected in the lungs of CF patients. The annual 
prevalence of Aspergillus as reported in 2001 was
 10.6%. Most isolates reported are 
A. fumigatus, although some CF
 patients harbour other Aspergillus spp. and, rarely, 
other
 molds (Brown et al., 1999). 
 
In addition to bacteria, fungi and molds, respiratory viruses are important 
pathogens in patients with
 CF. Viruses such as respiratory syncytial virus (RSV), 
influenza
  virus, parainfluenza virus, Ad, and rhinoviruses have
  relatively short 
incubation periods (less than 1 week), and
 transmission occurs primarily via direct 
contact with infected
  persons or indirect contact by touching items handled by 
infected
 persons. Droplet transmission of infectious respiratory secretions
 occurs with 
influenza virus and Ad. As with non-CF
 patients, viral particles enter the mucous 
membranes of the
  eyes and nose of susceptible patients and multiply in the 
respiratory
  epithelium, subsequently decreasing ciliary movement and increasing
 
mucous production (Garner et al., 1996). Viral respiratory infections may predispose 
CF patients
 to bacterial infection (Smyth et al., 1995; Armstrong et al., 1998). Ad
 
infection has been shown to lead to worsening lung function and increased airway
 
obstruction after the acute phase of illness (Hiatt et al., 1999). 
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1.4. CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) 
 
  COPD is a major global health problem. Epidemiological studies by Murray 
and Lopez (1997a and 1997b) in late 90’s found that that COPD was the sixth 
commonest cause of death worldwide in 1990, but made the alarming prediction that 
it would become the third commonest cause of death by 2020 irrespective of public 
health interventions. Furthermore, COPD was recognised as being the twelfth 
greatest cause of chronic morbidity, with a predicted increase to become the fourth 
most important disability-producing illness by 2020. Data from WHO are in 
agreement with these predictions and state that by the turn of the last century COPD 
had become the fourth leading cause of mortality worldwide (Murray et al., 2001). 
COPD is rare before the age of 40, but after that age symptoms of hypersecretion 
occur with increasing frequency. Persistent airflow obstruction becomes more 
common at around age 60. The prevalence of COPD then increases progressively 
until 60-70 year of age when, in large part due to mortality, it becomes more stable. 
The greater prevalence of COPD in men has diminished recently because of 
increased smoking by women (Feinleib et al., 1989). Smoking cessation early in the 
natural history of COPD not only returns the subsequent rate of declining function 
towards normal, but also reduces future mortality (Calverley and Walker, 2003). 
 
COPD, like CF, is characterised by persistent inflammation throughout the 
airways and lung parenchyma, the intensity and cellular characteristics of which vary 
as disease progresses. The inflammation involves a multitude of cells, mediators, and 
inflammatory effectors. Activated inflammatory cells release mediators that are 
capable of damaging lung structures. These mediators include a spectrum of potent 
proteases, oxidants, and toxic peptides. The damage induced by these moieties may 
further potentiate inflammation by releasing chemotactic factors from the extra-
cellular matrix (Shapiro and Ingenito, 2005). Assessment of forced expiratory 
volume1 (FEV1) / forced vital capacity (FVC) is considered as the most sensitive 
indicator for early airway obstruction, and an accelerated decline in pulmonary 
function can be readily detected from repeated yearly measurements. 
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There are several risk factors as to how and why COPD progresses which 
include  α1-protease inhibitor (α1-PI) deficiency, recurrent bronchopulmonary 
infection, air pollution, socioeconomic status, lower birth weight, and a history of 
severe childhood respiratory infections (Edelman et al., 1992; Snider, 1989). 
However, the most striking relationship is between cigarette smoking and COPD. 
Nearly 90% of all COPD patients are either current or ex-smokers (Snider, 1989; 
Peto et al., 1992). Figure 1.7 summarises the pathways by which cigarette smoke (CS) 
components both directly and indirectly could lead to the development of COPD in 
smokers and passive smokers. However, it should be acknowledged that, there is 
great variability in lung function among smokers, with only a minority (only about 
20%) of smokers developing COPD.  
 
In healthy non-smokers, macrophages comprise the major host defence cell in 
the lower airspace. Cigarette smoking is associated with more than 5 fold increase in 
total cells recovered by BAL, with macrophages comprising 95-90% (Shapiro, 1999). 
The inflammatory response in the airways and lung parenchyma in COPD is 
characterised by an increase in macrophages, T lymphocytes (predominantly CD8
+ T 
cells), and neutrophils. There may also be an increase in eosonophils in some patients, 
particularly during exacerbations. Many studies have revealed a correlation between 
the number of inflammatory cells of various types in the lung and the severity of 
COPD (Finkelstein et al., 1995; O’Shaughnessy et al., 1997; Di Stefano et al., 1998; 
Keatings et al., 1996). The role of neutrophils in COPD is shown by the fact that 
neutrophils, but not macrophages, are increased in the BAL fluid of COPD patients 
who have never smoked (Lusuardi et al., 1994). However, the role of neutrophils in 
COPD is not yet clear to date. Neutrophils have the capacity to induce tissue damage 
through
  the release of serine proteases and oxidants (Figure 1.8). Priming is a 
prerequisite
  for degranulation and superoxide anion generation in neutrophils
 
(Condliffe et al., 1998). Neutrophils in the peripheral circulation show evidence
 of 
priming in COPD (Noguera et al., 2001), but this may result from, rather than
 
contribute to, lung pathophysiology. There are several chemotactic
 signals that have 
the potential for neutrophil recruitment in
 COPD, including leukotrine B4 (LTB4), 
IL-8 and related CXC chemokines, including growth-related oncoprotein-α and Chapter 1: Introduction 
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epithelial neutrophil
  activating protein of 78kDa which are increased in COPD
 
airways (Traves et al., 2002; Tanino et al., 2002). These mediators may be derived 
from AMs and epithelial cells, but the neutrophil itself
 may be a major source of IL-8 
(Bazzoni et al., 1991).  
 
There are two central hypotheses as to why and how COPD could develop in 
individuals affected, which are briefly outlined below: 
 
1-  The oxidant:antioxidant imbalance hypothesis- Pulmonary 
antioxidant defences are widely distributed and include both 
enzymatic and non-enzymatic systems (Halliwell, 1996). The 
major enzymatic antioxidants are superoxide dismutase (SOD), 
which degrades O2
.- and catalase, and the glutathione (GSH) redox 
system, which inactivates H2O2 and hydroperoxidases. Vitamin E, 
β-carotene, vitamin C, uric acid, flavonoids, and billirubin are 
some of the non-enzymatic factors that may function as 
antioxidants (Halliwell, 1996). There is compelling evidence for 
increased oxidative stress in patients with COPD as a number of 
studies have shown an increased oxidant burden and consequently 
increased markers of oxidative stress in the airspaces, breath, blood, 
and urine in smokers and patients with COPD (Repine et al., 1997). 
The lungs are exposed to oxidants generated either endogenously 
or exogenously. Cigarette smoke (see below) and inflammatory 
cells have the capacity to produce reactive oxygen species, and 
they have been postulated to play a variety of roles in the 
pathogenesis of emphysema and COPD (Rahman, 2005). Oxidants 
cannot degrade extra-cellular matrix but might modify elastin, 
making it more susceptible to proteolytic cleavage. Moreover, 
Drost and co-workers (2006) recently demonstrated that inhibitor 
of NF-κB-α (IκBα) levels were significantly decreased in healthy 
smokers and current and ex-smoking patients with COPD when 
compared with non-smokers, with an associated increase in NF-κB Chapter 1: Introduction 
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DNA binding in current smokers, resulting in transcription of pro-
inflammatory genes such as IL-8 and TNF-α. Finally, reactive 
oxygen species may also promote apoptosis or necrosis of 
structural cells, a recent concept for imitation of emphysema.   
 
2-  The elastase:antielastase imbalance hypothesis- Just over 40 years 
ago, two lines of evidence, one experimental and one clinical, 
suggested that emphysema is caused by destruction of elastic fibres 
by elastase. This concept started with the observation by Laurell 
and Eriksson (1963) that showed individuals deficient in the serum 
protein α1-PI are at risk of developing emphysema. The second 
evidence was produced by Gross and co-workers (1965) which 
demonstrated papain instillation into the lungs of rodents induced 
emphysema. Subsequently, to further prove the truth in this 
hypothesis, investigators
 instilled a variety of proteases into animal 
lungs. Kuhn
 and colleagues (1976), Senior and co-workers (1977), 
Janoff and associates
 (1977), and Snider and colleagues (1984) 
were among the group of
  investigators who subsequently 
demonstrated that only elastolytic
 proteases, including pancreatic 
elastase and the more
  relevant human NE-caused emphysema.
 
Hoidal's group showed that proteinase 3 (1988) also caused 
destructive
 lung disease. More recently, Shapiro and colleagues 
(2003) generated an NE
-/- mouse line, and to address the role of NE 
in pulmonary emphysema they exposed NE-deficient mice and 
wild-type (WT) littermate controls to long-term cigarette smoke. 
They found that compared to WT littermates, mice that were 
deficient in NE were significantly protected (59%) from the 
development of emphysema. It has become clear that the 
elastase:antielastase imbalance can have several causes including 
inflammation, genetic factors (e.g., α1-PI gene mutation, the most 
common of which is the Z mutation that converts 342Glu to Lys; 
see below), and oxidative stress, and also by direct cigarette Chapter 1: Introduction 
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smoking. To this day, the elastase:antielastase hypthesis remains a 
prevailing concept in emphysema, although as one can 
acknowledge, the real is picture is far more complex. 
 
 
 
 
 
 
 
 
 
Figure 1.7.   Cigarette smoke, oxidative stress, proteolytic activity of enzymes 
and emphysema/COPD 
 
Numerous processes increase lung oxidative stress and protease:antiprotease 
imbalance and contribute to a variety
 of abnormalities that contribute to COPD. 
Adapted from Repine et al. (1997). Red arrows are indicative of direct effects of the 
danger, and the orange arrows are indicative of the indirect consequence of the 
danger signals present in the tissues. 
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1.4.1. Infections in COPD 
 
It is well known that the lower airways of healthy individuals are not 
colonised by microorganisams (van Alphen et al., 1995), whereas patients with 
COPD are frequently infected for many known and unknown reasons, one obvious 
reason being the possible impairment of the mucociliary system to prevent 
infection/colonisation (Wilson et al., 1996). Microorganisams that eventually enter 
respiratory airways, via inhaled air or following micro-aspiration of the pharyngeal 
contents, impact with mucous of the airways, and then are trapped by mucin 
macromolecules. Consequently, the mucociliary drainage is able to carry these 
microorganisams up to the oropharynx, which can last up to 6 hours (Knowles and 
Boucher, 2002). Some patients with COPD are prone to frequent exacerbations 
which are a major cause of morbidity and mortality and an important determinant of 
health related quality of life (Seemungal et al., 1998). COPD exacerbations have 
been associated with a number of etiological factors, including infection and 
pollution episodes. COPD exacerbations are frequently triggered by upper 
respiratory tract infections, and these are commoner in the winter months, when there 
are more respiratory viral infections in the community (Donaldson et al., 1999). 
 
Respiratory viral infections occurring during
 COPD exacerbations are more 
likely to lead to hospitalisation.
 Viral infections are an important trigger for COPD 
exacerbations. Recent studies have shown that around half of COPD exacerbations 
are associated with viral infections that the majority of these were due to rhinovirus 
(Wedzicha, 2004). The major viruses that cause upper and lower respiratory tract
 
infections and that are thus associated with exacerbations are
 listed in Table 1.3. 
 
Between 25 and 100% of stable COPD patients have been shown to have 
lower respiratory colonisation by bacteria including NTHI,  Streptococcus 
pneumoniae, and Branhamella catarrhalis (Palmer, 1987; Elborn and Shale; 1992). 
The presence of bacteria in the lower airways of COPD patients implies a breach of 
host defence mechanisms, which set up a vicious cycle of epithelial damage, 
impaired mucociliary clearance, mucous hypersecretion, increased submucosal Chapter 1: Introduction 
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vascular leakage, and inflammatory cell infiltration. The airway bacterial load in the 
stable state is associated with airway markers, and thus, airway inflammation (Hill et 
al., 2000). Several recent studies by Wedzicha and co-workers (2005) have shown 
higher sputum IL-8 levels are associated with higher bacterial load and faster decline 
in FEV1 and thus, the bacteria increase airway inflammation in the stable state and 
this in turn may increase disease progression.  
 
However, despite all these observations confirming the immunocompromised 
COPD lungs, the role of DCs in COPD has not been thoroughly investigated and still 
awaits further more in-depth studies (see Section 1.5.2 for details). 
 
 
 
 
 
Table 1.3. Respiratory viruses associated with COPD exacerbations 
 
Table taken from a review by Wedzicha (2004). 
 
 
Viruses  Rhinovirus (common cold) 
 Coronavirus 
  Influenza A and B 
 Parainfluenza 
 Adenovirus  (Ad) 
  Respiratory syncytial virus (RSV) 
Atypical organisms  Chlamydia pneumoniae 
  Mycoplasma pneumoniae 
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To summarise, five potential pathways by which bacteria could contribute to 
the course and pathogenesis of COPD are as follows: (i) childhood
 lower respiratory 
tract infection impairs lung growth, reflected
 in smaller lung volumes in adulthood, 
(ii) bacteria cause a substantial
  proportion of acute exacerbations of chronic 
bronchitis which
  cause considerable morbidity and mortality, (iii) chronic 
colonisation
  of the lower respiratory tract by bacterial pathogens amplifies
  the 
chronic inflammatory response present in COPD and leads to
 progressive airway 
obstruction (vicious circle hypothesis), (iv) bacterial pathogens invade and persist in 
the respiratory tissues,
 alter the host response to cigarette smoke, or induce a chronic
 
inflammatory response and thus contribute to the pathogenesis
 of COPD, and (v) 
bacterial antigens in the lower airway induce hypersensitivity
 that enhances airway 
hyperreactivity and induces eosinophilic
 inflammation. 
 
 
1.5. CIGARETTE SMOKE (CS) 
 
As described earlier, CS and other risk factors induce tissue destruction in the 
lung leading to emphysema and COPD in individuals. Cigarette smoking is a 
worldwide epidemic, and it is one of the main preventive causes of death and 
disability worldwide (Table 1.4). CS can be separated into two phases, a gas phase 
that passes through a filter and a tar that collects on the filter. Both phases of CS 
contain very high concentrations of free radicals and other chemical compounds. 
Cigarette tar contains about 10
17 free radicals per gram and gas-phase CS contains 
more than 10
17 free radicals per puff (Church and Pryor, 1985). The gas phase 
contains more than 4500 compounds which comprise of five known human 
carcinogens and many toxic agents, including carbon monoxide, ammonia, acrolein, 
acetone, nicotine, benzopyrenes, hydroquinone and nitrogen oxides. Therefore, it 
would not be surprising to see that chronic inhalation of CS alters a wide range of 
immunological functions, including innate and adaptive immune responses. Indeed it 
has been speculated that many of the health consequences of chronic inhalation of 
CS might be due to its adverse effects on the immune system (Sopori, 2002). Many 
studies have linked smoking to higher incidence of infections, in particular those Chapter 1: Introduction 
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infections of the respiratory system (see above). All in all, as explained above, these 
findings indicate that CS, at least in part, is directly responsible for the chronic 
infections in smokers and patients suffering from emphysema and COPD.  In this 
section, the known effects of CS on various components of the immune system, with 
a special emphasis on DCs and antigen presentation, will be reviewed. 
 
 
 
 
Table 1.4. World Health Organisation (WHO) Smoke Statistics 
 
Taken from the WHO website (http://www.who.int), data published on 28 May 2002. 
 
 
 
Adults 
•  About a third of the male adult global population smokes.  
•  Smoking related-diseases kill one in 10 adults globally, or cause four 
million deaths. By 2030, if current trends continue, smoking will kill 
one in six people.  
•  Every eight seconds, someone dies from tobacco use.  
•  Smoking is on the rise in the developing world but falling in developed 
nations. Among Americans, smoking rates shrunk by nearly half in 
three decades (from the mid-1960s to mid-1990s), falling to 23% of 
adults by 1997. In the developing world, tobacco consumption is rising 
by 3.4% per year.  
•  About 15 billion cigarettes are sold daily - or 10 million every minute.  
•  About 12 times more British people have died from smoking than from 
World War II.  
•  Cigarettes cause more than one in five American deaths.  
•  Among WHO Regions, the Western Pacific Region - which covers East 
Asia and the Pacific - has the highest smoking rate, with nearly two-
thirds of men smoking.  
•  The tobacco market is controlled by just a few corporations - namely 
American, British and Japanese multinational conglomerates. 
 
 
Youths  
•  Among young teens (aged 13 to 15), about one in five smokes 
worldwide.  
•  Between 80,000 and 100,000 children worldwide start smoking every 
day - roughly half of whom live in Asia.  
•  Evidence shows that around 50% of those who start smoking in 
adolescent years go on to smoke for 15 to 20 years.  
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1.5.1. CS and the innate immune system 
 
There is an endless body of evidence in the literature describing the adverse 
effects of CS in both humans and experimental animals as well as cell/tissue culture 
experiments in vitro and ex vivo. AMs and monocytes are the most important part of 
the innate immune system in the lungs. CS increases the number of AMs by several 
folds, and these express increased levels of lysosomal enzymes and secrete elastase 
(Barnes, 2004). In addition, AMs from smokers produce significantly higher levels 
of oxygen radicals and have higher myeloperoxidase activity. However, despite this 
the AMs from smokers have a reduced ability to phagocytose and/or kill bacteria. 
King and colleagues (1988) tested whether AMs from normal non-smokers versus 
normal smokers differed in their ability to phagocytose and to kill the facultative 
intra-cellular bacterium Listeria monocytogenes. Although they found no differences 
in phagocytosis, the AMs from non-smokers, however, killed Listeria, whereas those 
from smokers had no bactericidal or bacteriostatic activity. Further, McCrea and 
colleagues (1994) showed that even in young healthy smokers the pulmonary 
microenvironment is markedly abnormal, characterised by depressed levels of IL-6, 
macrophages that have a markedly depressed capacity for LPS-induced cytokine 
release and, in some smokers, increased concentrations of IL-8. These cytokines are 
crucial for early responses to pathogens and the up-regulation of local host defences. 
This defect in bacterial clearance has also been shown in animal models of infection 
following chronic exposure to CS. The most recent study on this was performed by 
Drannik and co-workers (2004) in which they observed a delayed rate of P.a. 
clearance in smoke-exposed compared
 with sham-exposed mice. 
 
In addition to AMs, other cells involved in innate immunity are affected by 
CS. Because CS is associated with increased risk of various cancers, several 
investigators have evaluated its effects on the function of NK cells. Ferson and 
colleagues (1979) showed that activity of NK cells against melanomas and other 
cancer cells was reduced significantly in smokers compared to non-smokers. These 
data have also been confirmed and extended in animal models, in which resistance to 
the growth of implanted tumour cells was significantly lower in smoke-exposed mice Chapter 1: Introduction 
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(Holt, 1997). Further, a more recent study has shown that male smokers have a 
decreased NK-cells absolute number compared to their control group (Moszczynski 
et al., 2001). 
 
In addition to the cells described above, CS components are also able to 
directly influence the epithelial cells of the oral cavity and the respiratory tract, as 
well as endothelial cells and fibroblasts. In the presence of LPS, CS has been shown 
to inhibit IL-8 mRNA expression and release of all chemokines by primary human 
alveolar epithelial type II cells (Witherden et al., 2004). Glutathione protected the 
cells against the effects of CS, suggesting involvement of the oxidative mechanisms. 
In a similar study by Laan and co-workers (2004), it was demonstrated that the pre-
treatment with CS extract concentration dependently inhibited the
 LPS-induced GM-
CSF and IL-8 protein release, which was accompanied
 by decreased expression of 
mRNA in a human bronchial epithelial
  cell line (Beas-2B). The increase of 
neutrophil chemotaxis induced
 by conditioned medium from LPS-treated Beas-2B 
cells was also
 suppressed by CS. In addition, they demonstrated that the activity of 
LPS-induced
 transcription factor activating protein-1, but not NF-κB, was down-
regulated
 by CS. 
 
Wickenden and colleagues (2003) showed that higher concentrations of CS 
condensate induced necrosis in alveolar epithelial cells and human umbilical vein 
endothelial cells and that CS was able to inhibit apoptosis induced by staurosporine 
or Fas ligation, with both effects prevented by the antioxidants glutathione and 
dithiothreitol. However, these observations are contradictory to the previous data in 
the literature suggesting that in fact CS could induce cell death via activating the 
apoptotic pathways (Tithof et al., 2002). CS extract has also been shown to induce 
oxidative stress and apoptosis in human lung fibroblasts which could be protected by 
N-acetylserine which is a potent antioxidant agent (Carnevali et al., 2003). 
 
1.5.1.1. CS and antiproteases/antimicrobial proteins 
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Apart from its direct effects on cells involved in the innate immune response 
and the epithelial cells, CS has also been shown to inactivate antiproteases secreted 
in the lung. Many amino acid residues of proteins are susceptible to oxidation by 
reactive oxygen specious. Methionine, the most sensitive of amino acids to oxidation, 
is readily transformed into methionine sulfoxide.  Of the three major NE inhibitors in 
lung, α1-PI was the first antiprotease described to be affected in late 1970s and early 
1980s. Gadek et al. (1979) reported that α1-PI activity is decreased in cigarette 
smokers’ lung fluid in comparison to similar fluid obtained from non-smokers. α1-PI 
was shown to be inactivated by both reactive oxygen specious (e.g., hydrogen 
peroxide, superoxide anion, and hydroxyl radicals) derived from smoke-activated 
neutrophils, that accumulate in the lung following smoking, as well as exposure  to 
direct CS (Carp and Janoff, 1979; Carp et al., 1982).  The inactivation of α1-PI is 
believed to involve the oxidation of a critical methionine residue. Further to this, 
secretory leukocyte protease inhibitor (SLPI) was also shown to loose its anti-NE 
activity following exposure to a variety of oxidants in vitro (Vogelmeier et al., 1997), 
and by direct CS exposure in an in vivo system (Cavarra et al., 2001). More recent 
data shows that, exposure of full length and C-terminus recombinant elafin 
molecules to oxidants also results in its poor protease inhibitory activity in vitro. At 
their physiological concentration, fully oxidised elafin and C-terminus elafin did not 
inhibit more than 30% of an equimolar concentration of NE or proteinase 3 (Nobar et 
al., 2005). 
 
1.5.2. CS and the adaptive immune system 
 
A well-documented effect of CS in humans is leukocytosis, however the 
function of these cells (predominantly macrophages and neutrophils) is greatly 
reduced. Smoking has been shown to predispose individuals to more incidents of 
infections. In similar animal models, mice chronically exposed to CS were more 
susceptible to influenza and murine sarcom virus (Sopori, 2002; Razani-Boroujerdi 
et al., 2004). This might result, in part, from lower titers and a decreased half-life of 
the antigen-specific Abs in smokers. On the other hand, a deficiency in DC function 
might explain these observations. Although to this date there are no comprehensive Chapter 1: Introduction 
  47
studies on pulmonary DCs in healthy smokers or past/current COPD patients, this 
issue has been recently studied to an extent using both in vitro models and in vivo 
animal systems. Nevertheless, as will be discussed below, these data are very 
contradictory to each other and as yet do not give a clear picture of the effects of CS 
on DCs. In one of the first studies to address this issue, Zeid and Muller (1995) 
documented an increase in pulmonary Langerhans-like cells on tissue sections of CS-
exposed mice compared to their controlled group. In line with these observations, 
D’hulst  et al. (2005) documented a similar relentless increase in lung DCs in a 
murine model of CS-induced pulmonary emphysema. They showed that after 6 
months of CS inhalation, DC numbers in the BAL fluid were 10-fold greater than 
those observed in control animals. In contrast, Robbins and co-workers (2004) 
reported a decrease in pulmonary DC numbers with dramatically reduced levels of 
CD86 CSM after CS inhalation (2-4 months). Furthermore, CS-smoked mice 
challenged with three consecutive doses (2×10
8 plaque-forming units [pfu]) of 
replication-deficient Ad had reduced expansion and maximal activation of CD4 and 
CD8 T-cells, as well as significantly decreased serum Ad-specific IgG1 and IgG2a 
levels (Robbins et al., 2004). In the most recent published study examining the 
effects of CS on pulmonary DCs, Tsoumakidou and co-wrokers (2007) demonstrated 
that the number (per square millimeter) of CD83
+ mDCs was significantly lower in 
smoker patients with asthma in comparison with never-smoker steroid-naïve and 
steroid-treated patients with asthma or control subjects. Moreover, they showed that 
B cells were fewer in smoker versus never-smoker steroid-naive and steroid-treated 
patients with asthma and in smoker steroid-naïve patients with asthma versus control 
subjects (Tsoumakidou et al., 2007). Relatedly, in agreement with these studies, 
unpublished data from Shapiro’s group (Franco et al., personal communication) 
demonstrate that in vivo smoke-exposed lung DCs have impaired maturation and 
ability to present antigen to CD4
+ T cells in the LNs as compared to DCs in control 
mice. The reasons for these divergent observations could be attributed in part to the 
methodology used for exposure regiments (e.g., different brands of cigarette, 
different doses of CS and experimental time points) and the cohort of patients used in 
the study. Similarly, the in vitro studies available are somehow contradictory. 
Recently, Vassallo and colleagues (2005) demonstrated that CS extract inhibited Chapter 1: Introduction 
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human DC-mediated priming of T cells. CS also significantly inhibited IL-12p70 
release by LPS-matured DCs, in contrast IL-10 secretion was increased by these cells. 
Conditioning of DCs with CS extract also suppressed LPS-mediated induction of 
CD40, CD80, and CD86, and suppressed maturation-associated CCR7 expression. 
These data provided evidence that soluble components extracted from CS suppress 
key DC functions and favour the development of Th2 immunity. Also, human 
monocyte-derived DCs cultured in the presence of nicotine have also been shown to 
manifest lower endocytic and phagocytic activities, and in the presence of LPS 
produced lower levels of pro-inflammatory cytokines, notably IL-12. Nicotine-
treated DCs also revealed a reduced ability to stimulate DC-dependent T cell Th1 
response, as evidenced by a decreased frequency of IFN-γ-producing effector cells 
(Nouri-Shirzai and Guint, 2003). In a follow up study, the same group showed that in 
a nicotinic environment, while human monocytes differentiate into DCs with a 
typical morphology, they display unique phenotype and cytokine profile that 
adversely affect their function. Furthermore, nicotinic DCs expressed lower levels of 
CD40, CD80 and CD86 CSMs and displayed profoundly reduced Th1 promoting 
capacity (Guinet at al., 2004). On the other hand, oxidative stress and reactive 
oxygen species have been shown to activate human DCs and up-regulate IL-8 and 
TNF-α synthesis (Rutault et al., 1999; Verhasselt et al., 1998; Kantengwa et al., 
2002). 
 
CS has also been shown to suppress T cell proliferation. Chang and co-
workers (1990) documented that chronic inhalation of CS in mice preferentially 
inhibited the antigen-specific T cell proliferative response of lung-associated LNs 
compared to anatomically distant LNs. These authors believe that T cell function in 
lung-associated lymphoid tissue may be inhibited in smokers, leading to a localised 
predisposition to respiratory tract infections. The effect of CS might be partly due to 
the direct effects of nicotine on T cells (Geng Y et al., 1996; Razani-Broujerdi et al., 
2004). To determine the mechanism of CS-induced immunosuppression and to 
compare it with chronic nicotine exposure, Karla et al. (1999) presented evidence 
suggesting that T cells from long-term CS-exposed rats exhibited decreased antigen-
mediated proliferation and constitutive activation of protein tyrosine kinase and Chapter 1: Introduction 
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phospholipase C-γ1 activities. Moreover, spleen cells from CS-exposed and nicotine-
treated animals had depleted inositol-1, 4,5-trisphosphate-sensitive Ca
2+ stores and a 
decreased ability to raise intra-cellular Ca
2+ levels in response to T cell antigen 
receptor ligation. These results suggested that chronic smoking causes T cell anergy 
by impairing the antigen receptor-mediated signal transduction pathways and 
depleting the inositol-1,4,5-trisphosphate-sensitive Ca
2+ stores. 
 
 
1.6. NEUTROPHIL ELASTASE (NE) 
 
 Polymorphonuclear  leukocytes  (PMN/neutrophils) play a crucial role in the 
first line of defence against invading bacteria, fungi and protozoa. Neutrophil 
infiltration is a common pathological feature in acute inflammatory disorders. The 
primary function of neutrophils is the phagocytosis and eradication of 
microorganisams. After being generated in the BM the neutrophils circulate in the 
blood stream. Upon infection/inflammation, they adhere to the endothelium and 
migrate to the infected site where they release oxygen radicals and their internal 
constituents, which are stored in different granules (Faurschou and Borregaard, 
2003). Neutrophils contain at least four types of granules: azurophil granules, 
specific granules, gelatinase granules and secretory granules (Faurschou and 
Borregaard, 2003). The various subsets of granules contained within the neutrophil 
constitute an important reservoir not only of antimicrobial proteins, proteases, and 
components of the respiratory burst oxidase, but also of a wide range of membrane-
bound receptors for endothelial adhesion molecules, extra-cellular matrix proteins, 
bacterial products, and soluble mediators of inflammation. It is the controlled 
mobilisation of these cytoplasmic organelles that permits transformation of the 
neutrophil from a passively circulating cell to a potent effector cell of innate 
immunity.  
  
Human NE is a serine protease found in the azurophil granules of the 
neutrophil. The gene for NE, ELA 2, is located within a 50-kilobase segment in the 
terminal region of the short arm of chromosome 19  (Zimmer et al., 1992). The Chapter 1: Introduction 
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glycoprotein
 product contains 218 amino acids and four disulfide bridges, and
 is a 
member of the serine protease family (Bode et al., 1989). Neutrophils can be 
stimulated to release NE upon exposure to various cytokines and chemoattractants, 
including TNF-α, IL-8, C5a, LPS, and a tripeptide derived
 from bacterial wall (N-
formyl-methionyl-leucyl-phenylalanine [fMLP]) (Lee and Downey, 2001).  
 
The concentration of NE in neutrophils exceeds 5mM (Belaaouaj et al., 1998); 
each neutrophil contains approximately 400  NE-positive granules,
  and the total 
cellular concentration of NE has been estimated
 at 1 to 2 picograms (Vender et al., 
1996). Although NE is most abundant in neutrophils,
 small amounts are expressed by 
monocytes and T cells (Ariel et al., 1998; Shapiro 1994). Other cells, including 
epithelial, endothelial,
 and fibroblasts, also synthesise proteases (Barnes et al., 2003).  
When neutrophils are
 activated, NE is rapidly released from cytoplasmic granules 
into
 the extra-cellular space, although some remains bound to the neutrophil
 plasma 
membrane (Owen et al., 1995). 
 
Passively released or actively secreted NE from neutrophils has been linked 
to the pathologic processes of a variety of inflammatory diseases. Neutrophils which 
normally pass through the lung relatively unimpeded, are sequestered and activated 
in the pulmonary microvasculature during the genesis of an inflammatory response, 
such as the chronic inflammatory situations that exist in CF or COPD lungs (see 
previous sections). Neutrophils accumulating in the airways of patients with CF and 
COPD, as a response to chronic infection/inflammation, release high concentrations 
of NE (~ 0.5-5 µM) (Fujita et al., 1990; Doring et al., 1995). In the lung, NE 
functions either intra-cellularly or after
 secretion into the extra-cellular environment. 
Under normal circumstances, the extra-cellular NE activity is inhibited by NE 
inhibitors, such as the endogenous serine protease inhibitors (serpin) that form 
complexes with the NE.
 The major NE inhibitors in the extra-cellular milieu of the 
lung
 are elafin, SLPI, and α1-PI (also called α1-antitrypsin; see next section for 
details).
 In the normal lung, natural NE inhibitors prevent the deleterious effects
 of 
proteases, because they are present in higher concentrations
  than the proteases, 
providing a protective ‘barrier’. However,
 when the protease concentration in the Chapter 1: Introduction 
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local milieu overwhelms
  the local antiprotease protective barrier, such as the 
situation that occurs in
 chronic/infective lung disease, e.g., CF/COPD, this results in 
excessive extra-cellular activity, leading to degradation of lung tissue (Figure 1.8).  
 
 
 
 
 
Figure 1.8. Proteolytic destruction of airway epithelium and bacterial 
colonisation 
 
Neutrophils accumulate in lung inflammatory tissues (e.g., COPD or CF lungs) and upon activation 
release high concentrations of oxidants and proteases such as NE in the microenvironment which in 
addition to killing bacteria overwhelms the natural local antiprotease barrier and damages the lung 
tissue by its potent proteolytic activity. Adapted from Takai et al. (2004). 
 
 
 
1.6.1. NE proteolytic modification of proteins 
 
Many biological molecules like cytokines and their receptors contain putative 
cleavage sites for neutrophil serine proteases. It is therefore not surprising that many 
receptors, cytokines and other molecules have been found to be natural substrates for 
NE (Table 1.5). For instance, free active NE is able to degrade the extra-cellular 
matrix molecules such as collagen, fibronectin, laminin, proteoglycans, and more 
importantly elastin, an abundant component of lung parenchyma. NE also affects the 
epithelium and endothelium by degrading vascular endothelial (VE)-cadherin 
(Ginzberg et al., 2001), and increasing cellular permeability (Peterson et al., 1995), 
and more dramatically, by inducing cell lysis (Nahori et al., 1992; Simpson et al., 
2001b). More recently it has been shown to induce epithelial cell apoptosis 
(Ginzberg et al., 2004). In addition, NE may potentially be involved in modulating 
IL-8 
Exposure to  
Bacteria  Neutrophils
Normal airway epithelium  Damage of epithelium by 
proteases 
‘Overwhelming’ inflammatory 
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inflammation through cleavage of a number of cell surface molecules. For instance, 
NE has been shown to reduce the surface expression of different receptors such as 
CD2, CD4 and CD8 on lymphocytes (Doring et al., 1995), CD16 (Tosi et al., 1992), 
CD43 (Remold-O’Donnell et al., 1995), and the 75-kDa from of the TNF-α receptor 
(Porteu et al., 1991) on neutrophils. 
 
The regulation of an intense inflammatory response in the lung depends
 on 
the rapid removal by phagocytosis of dying (apoptotic) inflammatory
 cells prior to 
their necrotic degeneration. The recognition
 mechanisms involved in apoptotic cell 
removal include CD36 and
  other scavenger receptors, CD14, integrins, the 
phosphatidylserine
 receptor (PSR), and soluble tethering proteins such as collectins
 
and thrombospondin. NE has recently been demonstrated to impair the apoptotic cell 
recognition by cleaving various receptors involved in the removal process of 
apoptotic cells. These include CD14 and PSR expressed on surface of macrophages 
(Le-Barillec et al., 1999; Vandivier et al., 2002; Henriksen et al., 2004). Hence, it is 
speculated that severe and
 sustained inflammation in the airways of CF and COPD 
patients may, due to the proteolytic activity of NE, in
 part, be enhanced by the 
defective clearance of dying inflammatory cells. 
 
  Chemokines and cytokines have also been reported to be processed and 
cleaved by NE. For instance, Valenzuela-Fernandez and colleagues (2002) recently 
demonstrated that limited degradation by NE,
  restricted to the amino-terminal 
domains of both SDF-1α and CXCR4,
 abrogates their interaction and
 function. Last 
but not least, a number of cytokines including IL-2 (Ariel et al., 1998), G-CSF 
(Hunter et al., 2003) and TNF-α (van Kessel et al., 1991) are also proteolytically 
processed and degraded by NE, leading to their inactivation. 
 
1.6.2. NE activation of cellular receptors 
 
NE might not only regulate the activity of chemokines and cytokines by 
proteolysis, but might also modulate host immune responses through cellular 
activation. NE appears to be the most important
  factor present in the CF lung Chapter 1: Introduction 
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responsible
 for IL-8 expression because inhibition of NE activity in CF
 BAL fluid 
almost completely prevents IL-8
 message in bronchial epithelium (Nakamura et al., 
1992). Interestingly, NE has
 been shown to act at least in part via an IL-1 receptor-
associated
 kinase-1/MyD88/NF-κB-dependent
 pathway in bronchial epithelial cells; 
this can be inhibited
 by a dominant negative variant of MyD88
 (Walsh et al., 2001). 
More recent data by the same group suggests that the up-regulation of IL-8 by NE 
occurs in part through the cell surface membrane bound TLR4, which can be readily 
abrogated by using a TLR4 neutralising Ab (Devaney et al., 2003). Clearly, as 
discussed in the previous sections, expression of IL-8 and LTB4 has repercussions for 
neutrophil migration to the lung, and
 given the high neutrophil and NE burden 
present in the CF/COPD lungs
 this has lead to the ‘vicious cycle’ hypothesis whereby 
NE is
  the driving force behind IL-8 production and neutrophil influx
  into the 
CF/COPD lung.  
 
Studies also indicate that NE contributes to the chronic inflammatory airway 
disease by inducing mucin production in airway epithelial cells. Mucins are involved 
in binding and removing bacteria via the
 mucociliary ladder, a process by which 
bacteria are transported
 along the respiratory tract and then ingested (Rose et al., 
2001). For instance, NE increases the mRNA expression of a
 major respiratory tract 
mucin, MUC5AC, by enhancing mRNA stability (Zheng et al., 2006). In normal 
human bronchial epithelial cells, NE also increased MUC4 mRNA levels in both a 
concentration- and time-dependent manner (Fischer et al., 2003). The role of NE in 
mucin production is also most relevant in CF patients where there
 is an NE burden 
and mucus hypersecretion but may also be important
 in other chronic lung diseases, 
such as COPD and asthma, where mucus hypersecretion is
 also a common feature.  
 
In addition, NE has been shown to increase the secretion of elafin and SLPI 
by lung epithelial cell lines in vitro (Sallenave et al., 1994). NE is also able to up-
regulate human beta-defensin-2 (HBD-2, a small cationic peptide with a broad range 
of antimicrobial activity) gene expression in bronchial epithelial cells (Griffin et al., 
2003). However, the mechanisms of elafin, SLPI and HBD-2 up-regulation by NE 
are currently unknown. Chapter 1: Introduction 
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Table 1.5. Overview of different targets of NE 
 
 
 
Target 
 
Hypothetical biological function 
 
Reference 
 
         Receptors 
 
PAR-1  Inactivation, modulation of response  Loew et al., 2000 
PAR-2  Inactivation, modulation of response  Loew et al., 2000 
PAR-3  Inactivation, modulation of response  Cumashi et al., 2001 
IL-2Rα  Inhibiting cellular response and 
prolongation of cytokine half-life time 
Bank et al., 1999b 
TNF-RII  Inhibiting cellular response and 
prolongation of cytokine half-life time 
Porteu et al., 1991 
C5aR (CD88)  Inhibition of chemotaxis, feedback 
mechanism 
Tralau et al., 2004 
C3b/C4b R (CD35)  Inhibition of complement signalling  Sadallah et al., 1999 
urokinase R (CD87)  Regulation of cell migration  Beaufort et al., 2004 
G-CSF-R Growth  inhibition  Hunter  et al., 2003 
CD43 (sialophorin)  Regulation of adhesion  Hunter et al., 2003 
CD16 (low-affinity IgG 
Fc receptor) 
 Galon  et al., 1998 
CD14  Inhibition of LPS-mediated cell 
activation / apoptotic cell recognition 
Le-Barillec et al., 1999 
CD2, CD4 and CD8  Impairment of T lymphocytes  Doring et al., 1995 
 
Cytokines/Chemokines 
 
TNF-α  Regulation of inflammation  van Kessel et al., 1991 
IL-2  Regulation of inflammation  Ariel et al., 1998 
IL-6  Regulation of inflammation  Bank et al., 1999b 
IL-8  Regulation of inflammation  Leavell et al., 1997 
G-CSF Growth  inhibition  Hunter  et al., 2003 
 
    Integrins/others 
 
Intercellular adhesion 
molecule-1 
Regulation of adhesion  Champagne et al., 1998 
Robledo et al., 2003 
Vascular endothelium 
cadherin 
Regulation of adhesion  Hermant et al., 2003 
Proepithelin Wound  healing  Zhu  et al., 2002 
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1.6.3. Therapeutic interventions to inhibit NE 
  As neutrophils are often involved in inflammatory diseases (see above), it is 
temping to speculate that inhibitors of serine proteses, in particular NE, may provide 
a logical therapeutic approach in these diseases. Indeed, animal experiments have 
shown that elafin efficiently reduces posthypoxic damage in the lung (Zaidi et al., 
2002), the heart (Cowan et al., 1996; Ohta et al., 2004) and a vein graft model 
(O'Blenes et al., 2000). Ad augmentation of elafin has also been demonstrated to 
protect murine lungs against acute injury mediated by activated neutrophils and 
bacterial infection (Simpson et al., 2001b; McMichael et al., 2001). Antiprotease 
clinical trials have been performed using α1-PI and SLPI, both of which have 
successfully inhibited NE activity in vivo in CF and α1-PI deficiency (Hubbard et al., 
1989; McElvaney et al. 1991; McElvaney et al., 1992).  
A small molecular weight synthetic NE inhibitor called ‘sivelestat’ has been 
shown to be effective in multiple animal models of acute lung injury (ALI) by the 
same investigators (Zeiher et al., 2002). In a similar setting, a phase 3 study in 
patients with ALI associated with systemic inflammatory response syndrome, 
demonstrated that sivelestat improved pulmonary function and slightly reduced the 
duration of intensive care unit stay (Tamakuma et al., 2004). In a more recent clinical 
trial Inoue and colleagues (2006) evaluated whether sivelestat improves leukocyte 
deformability and pulmonary function in patients with ALI, and concluded that 
sivelestat is able to reduce NE concentration and neutrophil stiffness and improves 
pulmonary oxygenation in patients with ALI. Similarly, sivelestat as well as the 
specific NE inhibitor EPI-hNE-4 have been shown to have beneficial effects on 
belomycin-induced lung fibrosis (Taooka et al., 1997; Honore et al., 2004). Three 
major naturally produced respiratory NE inhibitors (elafin, SLPI and α1-PI) are 
discussed in more details in the following section. 
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1.7. LUNG NE INHIBITORS 
 
The natural inhibitors of NE constitute a pleiotropic group of molecules that 
are capable of limiting the function of potentially injurious pathogen and host-
derived proteases. These molecules can be broadly classified into two groups, the 
alarm and the systemic antiproteases. Although some epithelial surfaces and cells of 
the immune system may produce small quantities of systemic protease inhibitors, 
such as α1-PI (Sallenave et al., 1997; Paakko et al., 1996), they are produced 
primarily by hepatocytes and constitute a circulatory source of antiprotease activity 
which acts as a protective shield against protease-induced injury. However, during 
infection and/or heightened NE release, this protective shield can be overcome and is 
supplemented by the activity of the alarm protease inhibitors such as elafin and SLPI. 
Produced by epithelial cells and cells of the immune system, alarm protease 
inhibitors are generated locally in areas of infection or neutrophil infiltration and are 
up-regulated by pathogen- and inflammation-associated factors, including  NE itself 
(Sallenave et al., 1994). In addition to their antiprotease properties, and because of 
their biochemical characteristics (low molecular mass cationic peptides, heavily 
disulphide-bonded, present at mucosal sites), elafin and SLPI have recently been 
proposed to possess ‘defensin
1/cathelicidin
2-like’ properties. This section will 
describe the characteristics of the alarm protease inhibitors, elafin and SLPI, and the 
systemic protease inhibitor α1-PI, and discuss the evidence pertaining to their 
pleiotropic functions in inflammation and immunity. 
 
 
 
                                                 
1 Defensins are 3- to 5-kDa peptide members of a widely distributed family with characteristic three-
dimensional folding with six cysteine-three disulfide patterns. Defensins have broad cytotoxic activity 
against bacteria, fungi, parasites, viruses and even host cells (Bals and Hiemstra, 2004; Williams et al., 
2006). 
 
2 Cathelicidins are a family of antimicrobial proteins found in neutrophil specific granules of which 
LL-37 is the only human member identified to date. LL-37 was identified based on its broad-spectrum 
antimicrobial activity and ability to neutralise LPS. Subsequent studies revealed other activities, such 
as chemotaxis of neutrophils, eosinophils, T cells and mast cells, modulation of DC function, 
induction of chemokine and cytokine synthesis in epithelial cells and monocytes, induction of 
angiogenesis and epithelial wound healing in vitro (Hiemstra, 2006). 
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1.7.1. Alarm protease inhibitors 
 
1.7.1.1. Elafin 
 
Elafin (previously known as elastase specific inhibitor [ESI], skin-derived 
antilukoprotease [SKALP] or trappin-2) was first isolated from the skin of psoriatic 
patients (Wiedow et al., 1991) and simultaneously from sputum of normal subjects 
and those with farmer's lung (Sallenave et al., 1991; Tremblay et al., 1996). The 
gene encoding elafin was cloned and sequenced by Saheki et al. in 1992 and 
subsequently by Sallenave and Silva in 1993, and shown to code for a 117 amino 
acids protein, of which the first 22 amino acids represent a hydrophobic signal 
peptide. Elafin is produced as a 9.9-kDa full-length non-glycosylated cationic protein 
composed of an N-terminal ‘cementoin’ domain which facilitates transglutaminase-
mediated cross-linkage on to polymers or extra-cellular matrix components (Nara et 
al., 1994) and a globular C-terminus, containing the protease inhibitor moiety, the 
primary substrate of which is NE (Simpson et al., 1999). The C-terminus has also 
been identified separately in human lung secretions (Sallenave et al., 1991 and 1992), 
possibly generated from the full-length molecule by tryptase-mediated cleavage 
(Guyot et al., 2005). The C-terminal domain of elafin is often termed the whey acid 
protein (WAP) domain
3, leading Schalkwijk et al. (1999) to classify elafin as a 
member of the ‘trappin’ family, hence the name trappin-2. Elafin molecule shares 
~40% homology with SLPI, although the scissile bond forming the active inhibitory 
site of elafin has been shown to be Ala-Met (compared with Leu-Met in SLPI), and 
this difference is thought to be important for the disparity in protease inhibitory 
spectra of these molecules (Sallenave and Ryle, 1991).  Elafin has been shown to be 
a more specific inhibitor of proteases than SLPI (see below), since it inhibits NE, 
porcine pancreatic enzyme, and proteinase 3 (Wiedow et al., 1990; Sallenave and 
Ryle, 1991; Ying and Simon, 2001), but does not inhibit cathepsin G, trypsin or 
chymotrypsin (Wiedow et al., 1990; Sallenave et al., 1991). 
                                                 
3 The 50-amino acid whey acidic protein (WAP) motif has 8 cysteines at defined positions that form 4 
intra-cellular disulfide bonds. WAP motif-containing proteins, such as WFDC12, have antibacterial 
and/or antiprotease activities (Hagiwara et al., 2003). Elafin and SLPI are the WAP motif proteins 
with both ‘antibacterial’ activity and ‘antiprotease’ activity. 
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Elafin is produced in a variety of epithelial and mucosal sites, such as the skin, 
the oral cavity, the small intestine, and the lung (Molhuizen et al., 1993, Sallenave et 
al., 1993; Nara et al., 1994;  Pfundt et al., 1996). Lung expression of elafin may be 
associated with alveolar epithelium, Clara (bronchial) cells, or tracheal epithelium 
(Sallenave et al., 1993; Nara et al., 1994; Suzuki et al., 2000). In-vivo, it is suggested 
that elafin contributes up to 20% of the antielastase capacity of the lung (Tremblay et 
al., 1996). Moreover, elafin production has also been described in inflammatory cells 
such as neutrophils and macrophages (Sallenave et al., 1997a; Mihaila and Tremblay, 
2001; Simpson et al., 2001a). The regulation of elafin expression during 
inflammation has received much attention. In vitro bronchial and alveolar epithelial 
cells produce little elafin protein, but the quantity of elafin recovered from the 
supernatant can be greatly increased by addition of the inflammatory cytokines IL-1 
and TNF-α (Sallenave et al., 1994). These cytokines produce similar increases of 
expression of elafin from keratinocytes in vitro (Tanaka et al., 2000). The c-jun, p38 
MAP kinase and NF-κB pathways are thought to be implicated in the elafin response 
to inflammatory cytokines (Pfundt et al., 2000; Pfundt et al., 2001; Bingle et al., 
2000). Of note, the cytokine-mediated increase in elafin production by epithelial cells 
is greater than the increase in SLPI production (Sallenave et al., 1994). Hence 
whereas SLPI has been described as providing a baseline antiprotease shield and can 
be isolated from bronchial lavage samples from healthy individuals (van Seuningen 
et al., 1995), elafin might be of greater significance during an inflammatory 
challenge to the lungs. In keeping with this notion, elafin mRNA expression in 
bronchial epithelial cells is increased by free NE, which is in abundance at times of 
inflammation (Reid et al., 1999; van Wetering et al., 2000). 
 
Although inhibition of proteolytic activity has historically been considered to 
be the primary role of elafin, recent work has highlighted further properties of this 
cationic molecule which propose it as ‘defensin/cathelicidin-like’ entity. Simpson 
and colleagues (1999) in our laboratory demonstrated that elafin has antibacterial 
activity against Gram-negative P.a. and Gram-positive S.a., and further established 
that, while antiprotease activity resides exclusively in the C-terminus, the majority of 
antimicrobial activity of elafin resides in its N-terminal domain (Simpson et al., Chapter 1: Introduction 
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1999). To confirm this, investigators from Wiedow’s laboratory showed that 
supernatants of P.a. could induce elafin production in human keratinocytes, and that 
elafin was able to inhibit the growth of P.a., but not E.coli in vitro (Meyer-Hoffert et 
al., 2003). Further, Simpson et al. (2001b) demonstrated that Ad augmentation of 
human elafin in murine lungs was able to protect the lungs against injury mediated 
by P.a., and also reduced bacterial numbers. Similarly, McMichael et al. (2005a) 
using an Ad-mediated gene transfer strategy, showed that over-expression of elafin 
dramatically improved the clearance of S.a. in vitro. In addition, they demonstrated 
that intra-tracheal (i.t.) instillation of Ad-elafin significantly reduced the lung 
bacterial (S.a.) load and demonstrated concomitant anti-inflammatory activity by 
reducing neutrophil numbers and markers of lung inflammation, such as BAL levels 
of TNF and myeloperoxidase. 
 
Elafin has also been demonstrated to possess immunomodulatory activities 
during inflammation/infection in various in vitro and in vivo experiments carried out 
both in our laboratory and elsewhere. Work carried out using transgenic mice 
expressing human elafin (eTg) has demonstrated that these mice exhibit lower 
serum-to-BAL fluid ratios of pro-inflammatory cytokines (TNF-α, MIP-2 and MCP-
1) than WT mice, following LPS administration to the lungs, which was also 
associated with an increase in neutrophil and macrophage influx, suggesting priming 
of innate responses in the lung (Sallenave at al., 2003). Conversely, when LPS was 
given systematically, eTg mice had lower levels of serum TNF-α than WT mice, 
while peritoneal macrophages from eTg mice were hypo-responsive to LPS 
(Sallenave  at al., 2003). In this eTg mouse model, elafin appears to function to 
promote local immunity, but reduces systemic inflammation. Relatedly, recent in 
vitro data by our group demonstrated that elafin is indeed able to bind both smooth 
and rough forms of LPS (McMicheal et al., 2005b). Moreover, the interaction of 
elafin with LPS resulted in an augmentation of the LPS-induced TNF-α response in a 
murine macrophage cell line (RAW 264.7) in serum-free conditions, whereas it 
caused a significant decrease in TNF-α in serum-positive conditions (McMicheal et 
al., 2005b). Furthermore, similar to other antimicrobial peptides, e.g., defensins and 
LL-37 (Yang et al., 1999; Yang et al., 2000; Oppenheim and Yang, 2005; Tjabringa Chapter 1: Introduction 
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et al., 2006), elafin may exhibit chemotactic activity for leukocytes. Ad-mediated 
expression of elafin enhanced neutrophil migration in vitro, which could be inhibited 
by neutralising Ab to elafin (Simpson et al., 2001a). In addition, infection of murine 
airways with Ad-elafin significantly augmented LPS-mediated neutrophil migration 
in vivo, and was shown to enhance LPS-induced levels of TNF-α and MIP-2 in BAL 
fluid (Simpson et al., 2001a). It is believed that elafin in this model provides local 
antimicrobial protection and enhances neutrophil influx, while protecting host tissues 
from subsequent NE-mediated damage (Simpson et al., 2001a). However, this is in 
contrast to the findings reported by Vachon et al. (2002) who showed that 
recombinant elafin could reduce influx of neutrophils, gelatinase activity, and levels 
of MIP-2 and TNF-α in lung following intranasal LPS administration. Another in 
vivo model has further indicated that exogenous human elafin can play an anti-
inflammatory role in inhibiting NE-induced ALI in hamsters (Tremblay et al., 2002). 
These findings would suggest that elafin may play a role as a potent anti-
inflammatory mediator in the lung. The discrepancies between this study and those 
described above may reflect differences in elafin concentration, dose of LPS 
administered, route of delivery, and duration of experiment. On the other hand, while 
viral-derived elafin gains access to intra-cellular compartments, administration of 
recombinant elafin is, at least originally, likely to be limited to extra-cellular contact 
with the cell membrane. In addition, studies using Ad to deliver elafin must also 
consider the ‘danger signals’ provided by the Ad vector.  
 
In summary the alarm antiprotease elafin has been shown to have multiple 
bioactive functions including inhibition of proteolytic enzymes at times of 
inflammation, suppression of harmful inflammation and stimulation of innate 
immune defences. In this context further examination of the functions of elafin in 
innate and adaptive immunity is required.  
 
1.7.1.2. Secretory leukocytes protease inhibitor (SLPI) 
 
SLPI is an 11.7-kDa protein that was first isolated from human parotid gland 
secretions (Thompson and Ohlsson, 1986). SLPI orthologs have also been Chapter 1: Introduction 
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demonstrated in mice, rats, pigs and sheep (Zitnik et al., 1997; Song et al., 1999; 
Brown et al., 2005). It is a non-glycosylated, highly basic, acid-stable, cysteine-rich, 
107-amino acid, single-chain polypeptide (Thompson and Ohlsson, 1986). The 
tertiary structure of the SPLI molecule resembles a boomerang, with each arm 
carrying one domain (Grutter et al., 1988). The four-in-each-domain disulfide 
bridges formed between the cysteine residues, as well as the two-domain interaction, 
contribute to the conformation and efficacy of the molecule (Hiemstra et al., 1996). 
SLPI provides a significant component of the human antiprotease shield within the 
lung. Through its C-terminal domain SLPI is a serine protease inhibitor and provides 
significant protection against NE. Importantly, unlike α1-PI (see below) the 
interaction between SLPI and NE is reversible. SLPI also inhibits the serine protease 
cathepsin G as part of its antiprotease effects in the lung (Gauthier et al., 1982). Its 
N-terminal domain has no such properties, but it may aid in stabilising the 
protease:antiprotease complex (Grutter et al., 1988). SLPI is constitutively expressed 
at most of mucosal sites by a variety of epithelial cells. In the lung it is produced in 
the central airways by serous glandular cells and in the lower respiratory tract by 
Clara cells and goblet cells (Hiemstra et al., 1996). It has also been shown to be 
produced by various inflammatory cells, such as neutrophils (Sallenave et al., 1997a), 
mast cells (Westin et al., 1999), and macrophages (Mihaila and Tremblay, 2001). It 
is estimated that SLPI is present at concentrations of 0.1-2 µg/ml in airway lavage 
fluid (Vogelmeier et al., 1991; Kouchi et al., 1993) and 2.5µg/ml in nasal secretions 
(Lee et al., 1993).  
 
It is believed that SLPI also shields the tissues against inflammatory products 
by down-regulating the macrophage responses against bacterial LPS. Patients with 
sepsis have been shown to have elevated circulating SLPI levels and LPS is the key 
mediator in bacterial endotoxic shock (Grobmyer et al., 2000; Duits et al., 2003). 
LPS seems to induce SLPI production by macrophages directly or by way of IL-1β, 
TNF-α, IL-6, and IL-10 (Jin et al., 1997; Gipson et al., 1999). SLPI in turn inhibits 
the downstream components of the NF-κΒ pathway by protecting I-κβ from 
degradation by the ubiquitin-proteosome pathway. Indeed SLPI has recently been 
shown to enter cells, becoming rapidly localised to the cytoplasm and nucleus where Chapter 1: Introduction 
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it affects NF-κΒ activation by binding directly to NF-κΒ binding sites in a site-
specific manner (Taggart et al., 2005). Thus, SLPI renders macrophages unable to 
release pro-inflammatory cytokines and nitric oxide (Jin et al., 1997). These data are 
also confirmed by in vivo studies demonstrating that SLPI knockout (SLPI
-/-) mice 
show increased susceptibility to endotoxic shock and macrophages and B 
lymphocytes from the same mice show increased activation after administration of 
LPS when compared to control (SLPI
+/+) mice (Nakamura et al., 2003). Ding et al. 
(1999) point out that the inhibitory effect of SLPI on macrophage responses may be 
due to its blockade of LPS transfer to soluble CD14 and its interference with the 
uptake of LPS from LPS-soluble CD14 complexes by macrophages. In contrast, 
Sano and co-workers (2003) recently found that SLPI may up-regulate the LPS-
induced activation of NF-κB in terms of transcriptional function. 
 
In addition to its NE inhibitory and immunomodulatory activities, SLPI has 
broad-spectrum antibiotic activity that includes bactericidal, antiviral and antifungal 
properties. Fahey and Wira (2002) examined the production of antibacterial factor(s) 
by uterine epithelial cells from pre- and postmenopausal women. Apical rinse fluids 
from polarised epithelial cells recovered from women at the proliferative and 
secretory stages of the menstrual cycle were equally effective in killing S.a. and E. 
coli, but those from postmenopausal women were not. SLPI production correlated 
with bactericidal activity with respect to menstrual status and culture time. Anti-SLPI 
significantly decreased bactericidal activity of premenopausal epithelial cell rinse 
fluids. It seems that the N-terminal domain is responsible for the dose-dependent 
bactericidal properties of SLPI against both Gram-positive (S.a.) and Gram-negative 
(E. coli) bacteria. The antimicrobial actions of SLPI are likely to be particularly 
important in the protection of uterus from infection during implantation and early 
pregnancy. Hiemstra et al. (1996) showed that the activity of this domain is not as 
efficient as the one of the intact molecule. Hence, they speculated that a 
conformational change in the N-terminal domain is induced by the cleavage of the 
native protein. In addition, Miller and colleagues (1989) suggested that the 
mechanism of the SLPI-mediated bactericidal activity may include binding of the Chapter 1: Introduction 
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protease inhibitor to the bacterial mRNA and DNA, but Hiemstra et al.'s findings 
proved that this binding is not significant to explain the antibacterial activity of SLPI. 
 
Tomee and co-workers (1997) showed that SLPI has activity (50% fungicidal 
activity) against human isolates of the pathogenic fungi A. fumigatus and Candida 
albicans. They also found partial inhibition of fungal protease activity by 
recombinant SLPI, a putative virulence factor of A. fumigatus, and subsequent 
inhibition of the inductive pro-inflammatory cytokine response in cultured human 
airway epithelial cell lines. In a recent study, Chattopadhyay and co-workers (2004) 
showed that the increase of salivary SLPI levels (to >2.1 µg/ml) along with other 
factors, such as low levels of CD4, antiretroviral monotherapy, and smoking, is a key 
predictor of oral candidiasis in human immunodeficiency virus type 1 (HIV-1)-
infected persons. A possible biological explanation for this association is that SLPI is 
up-regulated in response to the infection in order to kill the pathogen and resolve the 
disease. An individual threshold limit to SLPI production and secretion may be 
reached. As with the antibacterial-bactericidal activity, the antifungal activity was 
mainly localised in the N-terminal domain. It is believed that killing of fungus 
protects the epithelia from the fungal proteases (Tomee et al., 1997). Probably the 
antibacterial and antifungal activities are related to the cationic nature of SLPI 
(Tomee et al., 1998). In addition, SLPI is likely to be a major deterrent of HIV-1 
transmission through oral secretions (Chattopadhyay et al., 2004). SLPI was found to 
be the most potent anti-HIV-1 factor among several innate inhibitory molecules, 
namely, virus-specific Abs, mucins, and thrombospondins, identified and purified 
from saliva (Tomee et al., 1998). In 1995, McNeely and co-workers showed that 
infection of adherent primary monocytes with HIV-1 was significantly suppressed in 
the presence of human saliva. Of the proteins present in the saliva, only SLPI was 
found to have antiretroviral activity at physiological concentrations (0.1-10 µg/ml) 
(McNeely et al., 1995). To further confirm these findings Jana et al. (2005) recently 
demonstrated
 that brief exposure
 of keratinocytes to HIV-1 leads to a significant dose 
and time dependent increase in SLPI mRNA
 and protein secretion that occurs
 rapidly 
after virus contact, and does not require productive cellular
  infection, which is 
elicited specifically by the external envelope
  glycoproteins of HIV-1. The Chapter 1: Introduction 
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mechanism by which SLPI inhibits HIV-1 infection is still elusive, but it appears to 
involve the host cell target rather than binding to the virus (McNeely et al., 1995;  
Hocini et al., 2002). Moreover, the antiviral activity of SLPI appears to be distinct 
from its known antiprotease activity (McNeely et al., 1997). Evidence suggests that 
SLPI blocks HIV-1 internalisation in a dose-dependent manner rather than binding to 
CD4 (McNeely et al., 1997). McNeely et al. (1997) found that SLPI most likely 
inhibits a step of viral infection that occurs after virus binding but before reverse 
transcription. They also succeeded in preventing HIV infection of macrophages after 
pre-treatment with SLPI. Moderate activity is also exerted against HIV-2 strains, but 
only when the concentration of SLPI exceeds the norm. Saliva is rich in SLPI and it 
is felt that this accounts for the low viral transmission rates via saliva (Wahl et al., 
1997; McNeely et al., 1997). 
 
Last but not least, SLPI and elafin expression have also been noted in 
response to cutaneous injury in humans (van Bergen et al., 1996;  Wingens et al., 
1998). Further, Ashcroft et al. (2000) generated mice null for the gene encoding 
SLPI, which showed impaired cutaneous wound healing with increased inflammation 
and NE activity. This altered inflammatory profile was shown to involve enhanced 
activation of local TGF-β in SLPI
-/- mice. Therefore, in addition to their roles in 
innate immunity, these low molecular mass NE inhibitors seem to be involved in 
resolution and subsequent tissue regeneration.  
 
1.7.2. The systemic proteases inhibitor α1-PI 
 
  α1-PI is a 52-kDa secreted glycoprotein and is the prototypic member of 
serpin superfamily of proteins, which have a major role in inactivating NE and other 
proteases to maintain protease:antiprotease balance. α1-PI is predominantly produced 
in the liver and reaches the lungs by diffusion from the circulation and by local 
production in macrophages and bronchial epithelial cell (Lomas and Mahadeva, 2002;  
Stecenko and Brigham, 2003). Normal serum concentrations of α1-PI range from 20-
53 µM, and levels in the lung are about 2-6.5 µM. Despite its early name (α1-
antitrypsin), it actually reacts with NE much more readily than with trypsin (Beatty Chapter 1: Introduction 
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et al., 1980), and represents a major defence against the elastolytic burden in the 
lower airways posed by NE, which is produced by neutrophils (see previous section, 
1.6).  
 
  Serpins have been likened to mousetraps complete with bait, a loaded high-
energy but unstable state, and a swinging arm. In the case of α1-PI (Figure 1.9), the 
bait is a methionine amine acid side chain in the reactive centre of the serpin. 
Docking of the NE on the residue cleaves the reactive centre, releases α1-PI from its 
metastable high energy state, and allows the cleaved reactive loop to snap back, with 
the protease in tow (Huntington et al., 2000). While this process is mutually suicidal 
and ensures the destruction of both molecules, there is normally an excess of α1-PI in 
the lung, thereby providing an adequate protective screen against the elastolytic 
burden of NE (Eriksson, 1999). 
 
Quantitative studies show that α1-PI is the predominant NE inhibitor in CF 
sputum (Suter et al., 1986). However, the majority of endogenous α1-PI in the 
sputum of COPD and CF patients is in an inactive form. This suggests the existence 
of a mechanism for inactivating α1-PI within COPD and CF lungs. It is believed that 
excess concentrations of proteases and/or oxidants, such as CS and myeloperoxidase 
released from primed neutrophils, may be responsible for this inactivation of α1-PI. 
Indeed, as mentioned above, a critical methionine residue at position 358, which 
determines its specificity toward NE, is very sensitive to inactivation by oxidants or 
matrix metalloproteases released from primed activated neutrophils (Ossanna et al., 
1986; Vissers et al, 1988). 
 
α1-PI deficiency is a genetic disorder that affects about 1 in 2000-5000 
individuals. The most frequent mutation that causes α1-PI deficiency gives rise to the 
Z allele. α1-PI deficiency is characterised by a decrease in levels of α1-PI, which 
results in early-onset of emphysema in affected individuals. It was originally 
believed that this emphysema was caused by decreased α1-PI in the respiratory tract, 
leading to unopposed and prolonged NE activity (Campbell et al., 1999). However, 
recent evidence suggests that the Z variant of α1-PI, when polymerised, may be pro-Chapter 1: Introduction 
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inflammatory, acting as an important chemoattractant for neutrophils in the α1-PI –
deficient lung and adding to the excessive neutrophil and NE burden (Parmar et al., 
2002). Indeed, a substitution of lysine for glutamic acid at position 342 in the Z 
protein widens β-sheet A and allows polymerisation in an irreversible process 
(Figure 1.9; Lomas and Mahadeva, 2002). Polymerisation, and retention of polymers 
in the endoplasmic reticulum of liver cells, causes a decrease in the amount of 
plasma α1-PI that is available to protect the lung against proteolytic cleavage.  
 
  In addition to its role as an antiprotease, α1-PI has important anti-
inflammatory properties (Stockley et al., 2002). These effects are independent of the 
protease inhibition and include blocking of the pro-inflammatory effects of human 
NE (Spencer et al., 2004), and regulating expression of pro-inflammatory cytokines 
such as TNF-α, IL-6, IL-8, MCP-1, and IL-1β by monocytes (Aldonyte et al., 2004;  
Janciauskiene et al., 2004). In a recent study Petrache et al. (2006b) noted that α1-PI 
could also inhibit alveolar cell apoptosis in vivo. A follow-up study by the same 
group suggested that direct inhibition of active caspase-3 by α1-PI may represent a 
novel anti-apoptotic mechanism relevant to disease processes characterised by 
excessive structural cell apoptosis, oxidative stress, and inflammation, such as 
pulmonary emphysema (Petrache et al., 2006a). 
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Figure 1.9. Mechanism of inhibition of proteases by α1-PI and polymerisation of 
α1-PI 
 
A) Docking of protease to the reactive centre loop of α1-PI (upper). The protease has cleaved the 
reactive loop, releasing it from its metastable high energy state. This process distorts and alters the 
structure of the protease. B) Mutation of serpins, e.g., α1-PI, can result in several diseases such as 
emphysema. Adapted from Lomas and Mahadeva, 2002. 
B. 
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1.8. CENTRAL HYPOTHESES AND AIMS 
 
  This introduction has outlined the adverse effects of high NE concentration in 
the lungs, its involvement in CF and COPD pathologies and increased disease 
severity and acute exacerbation in these patients. The colonisation of 
microorganisams in lower airways of CF and COPD patients implies a breach of the 
host defence mechanisms. Since DCs are the most potent APCs and bridge the innate 
and adaptive arms of the immune system in the respiratory system, the following 
hypotheses were investigated: 
 
1-  Cigarette smoke (CS) and lung inflammatory secretions from COPD 
and CF patients adversely affect the DC phenotype and function, 
hence making patients immunocompromised to frequent 
opportunistic respiratory infections. 
 
2-  NE inhibitors are able to interact with DCs and the local 
augmentation of these NE inhibitors is able to activate DCs and 
increase their numbers in the lung tissue. 
 
 
The following experimental aims were developed to address these hypotheses. These 
form the basis of subsequent results chapters and as such, give a brief insight into the 
basis of the work presented herein. 
 
 
AIMS 
 
Inhibition of DC maturation and function by CS and NE-containing 
inflammatory lung secretions/purified NE (Chapter 3) 
 
•  Culture murine BM cells in the presence of GM-CSF to generate a 
highly pure and dense iDC population Chapter 1: Introduction 
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•  Expose DCs to fresh CS condensate (CSC) and assess their phenotype  
•  Collect sputum samples from CF and COPD patients and measure 
their active NE concentrations 
•  Expose DCs to sputum supernatants collected from CF and COPD 
patients as well as purified human NE and analyse following 
treatment 
•  Co-culture treated DCs with ovalbumin (OVA) specific D011.10 
transgenic lymphocytes to assess their antigen presenting function 
•  Characterise the cytokine profile of lymphocytes stimulated with 
treated DCs 
 
 
Characterisation of lung DCs following in vivo augmentation of elafin 
(Chapter 4) 
 
•  Develop protocols for isolation of murine lung APCs  
•  Analyse WT and elafin transgenic (eTg) lung APCs following Ad 
infection by flow cytometry and related techniques 
•  Analyse the inflammatory cell differentials and profile of cytokines in 
BAL fluid of Ad treated mice 
•  Develop vaccination strategies by means of NE inhibitor gene therapy 
 
 
In vitro effects of NE inhibitors on DC maturation, function and 
chemotaxis (Chapter 5) 
 
•  Develop protocols for efficient infection of DCs by Ad constructs in 
vitro 
•  Examine the effects of lung natural NE inhibitors, namely elafin, 
SLPI and α1-PI, on DC phenotype and maturation in in vitro systems  
•  Investigate the chemotactic activity of elafin on DCs 
   Chapter 2: Materials and Methods 
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CHAPTER 2 
MATERIALS AND METHODS 
 
2.1. MATERIALS 
 
2.1.1. Source of chemicals and reagents 
 
  Unless stated, chemicals and reagents were obtained from Sigma (Poole, 
Dorset, UK). 
 
2.1.2. Polyclonal rabbit anti-human elafin antibody (Ab) 
 
  The polyclonal rabbit anti-human elafin IgG, prepared from antiserum raised 
against COOH-terminal 2.5-kDa fraction of human elafin (Sallenave et al., 1992), 
was available in-house from the outset of this work. Biotinylated rabbit anti-human 
elafin IgG was also available in-house. 
 
2.1.3. Adenoviral (Ad) constructs 
 
  Five E1-, partially E3-deleted Ad vector constructs of serotype 5 were used, 
and these vectors were available in-house from the outset of this work. The vectors 
used were: Ad-elafin, encoding the cDNA for human elafin; Ad-SLPI/GFP, encoding 
the cDNA for murine SLPI; Ad-null, an empty vector encoding no transgene; Ad-
α1PI, encoding murine α1-PI 2; Ad-GFP, encoding the cDNA for green fluorescent 
protein, Ad-eotaxin, encoding the cDNA for murine CC chemokine eotaxin, and Ad-
GMCSF, encoding the cDNA for murine GM-CSF, which is a member of the 
heamapoetic cytokine family. The techniques used to generate these Ad vectors have 
been described in detail elsewhere (Hitt et al., 1995; Addison et al., 1997; Jobin et al., 
1998; Sallenave et al., 1998; Wang and Huang, 2000). The transgene in each vector 
is located downstream of a fragment of the murine cytomegalovirus (CMV) 
immediate early promoter (Dorsch-Hasler et al., 1985). While the Ad-elafin, Ad-  Chapter 2: Materials and Methods 
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α1PI, and Ad-eotaxin vectors encode a single transgene driven by a 1.4-kb fraction 
of the murine CMV promoter, Ad-SLPI/GFP is a bicisteronic vector encoding both 
murine SLPI (followed by an internal ribosomal entry site) and green fluorescent 
protein (GFP), under the control of a 531 base pair fraction of the murine CMV 
promoter. 
  
The Ad-elafin vector was originally constructed by Professor Jean-Michel 
Sallenave in Professor Jack Gauldie’s laboratory at McMaster University, Hamilton, 
Ontario, Canada (Sallenave et al., 1998). Ad-SLPI/GFP was constructed in-house in 
our laboratory by other investigators. Ad-null was a kind gift from Professor Jack 
Gauldie and Dr Mary Hitt (McMaster University). Ad-α1PI, Ad-eotaxin and Ad-
GMCSF were a kind gift from Professor Zhou Xing (McMaster University). I, Ali 
Roghanian, have not been involved in the constructions or amplification of any Ad 
vectors mentioned herein. 
 
2.1.4. Mice 
 
  Female BALB/c and C57BL/6J mice aged between 4 and 8 weeks were 
obtained from Charles River UK, Margate, UK.  
 
Human elafin transgenic (eTg) mice were previously derived from C57BL/6J 
× CBA mice in our laboratory and were bread in-house (Sallenave et al., 2003). They 
express the elafin gene under the murine CMV promoter, which has previously been 
shown to be inducible by inflammatory mediators by our group (Simpson et al., 
2001). DO11.10 CD4-T cell receptor (TCR) transgenic mice were maintained as an 
in-house breeding colony, housed in isolators.  
 
All mice were housed in the animal facilities of the University of Edinburgh 
and all animal experiments were conducted in accordance with the specifications of 
the local regulatory committee (The University of Edinburgh) and the Home Office 
guidelines. 
   Chapter 2: Materials and Methods 
 
  72
2.2. METHODS 
 
2.2.1. Cell culture 
 
2.2.1.1. GM-CSF secreting cell line 
 
  Murine GM-CSF secreting cells were a gift from Professor David Gray, The 
University of Edinburgh (Svensson et al., 1997). The cells were grown in a selection 
medium containing RPMI 1640, 5% foetal calf serum (FCS; heat-inactivated at 56°C 
for 1 hour prior to use), 2-mercaptoethanol (ME) (50µM), 1mg/ml G418/Geneticin 
(Invitrogen, Paisley, UK) and 1% L-glutamate until they reached a stage of 
confluency. The cells were then cultured in a medium without G418/Geneticin for 2-
4 days after which they were harvested and the GM-CSF concentration was 
estimated by titration and/or murine GM-CSF ELISA kit (R&D Systems, Oxon, UK).  
Normally the optimum concentrations of GM-CSF for generating BM-derived DCs 
(BM-DC) cultures were 5-10% v/v depending on the preparation.  
 
2.2.1.2. Raw 264.7 cells 
 
  The RAW 264.7 murine macrophage cell line was obtained from the 
American Type Culture Collection (Manassas, VA, USA). Cells were cultured in 
Dulbecco’s Modified Easgle’s Medium (DMEM) supplemented with 0-10% (v/v) 
FCS (Labtech, Ringmer, UK), 100 U/ml penicillin, 100µg/ml streptomycin, 4mM L-
glutaminutese, 4.5g/l glucose and 1.5g/l sodium bicarbonate. For simplicity 
throughout this thesis ‘DMEM’ is used to describe this culture medium, unless 
otherwise indicated. 
 
  In experiments where RAW 264.7 cells were used to assess possible 
contaminating endotoxin presence in Ad constructs, the cells were plated at a density 
of ~2×10
5 cells/ml in DMEM and incubated overnight at 37°C to settle down. They 
were then stimulated with increasing concentrations of LPS (Escherichia coli   Chapter 2: Materials and Methods 
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serotype 026:B6) as well as Ad constructs for 4 hours. The supernatants were then 
analysed for TNF-α as described below. 
 
2.2.1.3. Clara cells 
 
  The murine Clara (bronchial epithelial) cell line DJS2-2 was a kind gift from 
Dr. Franco DeMayo (Baylor College of Medicine, Houston, TX, USA). Cells were 
cultured in DMEM supplemented with 0-10% (v/v) FCS, 100 U/ml penicillin, 100 
µg/ml streptomycin, and 4 mM L-glutamine. 
  
All cells were maintained at 37°C in a humidified incubator containing 5% 
CO2, and used for assays at the lowest possible passage number. Estimation of the 
number of cells in each monolayer was performed by washing cells with phosphate 
buffer saline (PBS), and counting of cells using a haemocytometer. Cell viability was 
assessed by staining with trypan blue, with exclusion indicating viability.   
 
2.2.1.4. Bone marrow-derived DC culture and maturation 
 
BM-DCs were generated in two ways as described previously (Inaba et al., 
1992; Lutz et al., 1999). The first method (method 1) was based on the ‘Inaba 
method’. BM from BALB/c mice was extracted from cleaned femurs and tibiae 
(surrounding tissue was removed by rubbing with antibacterial disinfectant wipes). 
Intact bones were rinsed in 70% ethanol and washed with PBS. The bone ends were 
then cut using a disposable scalpel and the marrow flushed through with DC 
complete medium (RPMI 1640 supplemented with 2mM L-glutamine, 100U/ml 
penicillin, 100µg/ml streptomycin, 10% heat-inactivated FCS), containing ~10% of 
conditioned supernatant from an hybridoma expressing GM-CSF (at a final 
concentration
 of 20–30ng/ml), using a syringe with 0.45mm (26-gauge) diameter 
needle. Cells were centrifuged for 5 minutes, 300 g. The pellet was then resuspended 
in red blood cell (RBC) lysis buffer (1mM NH4HCO3 and 114mM NH4Cl; 1ml per 
mouse) and incubated on ice for 2 minutes. Cells were then washed in DC complete 
medium and resuspended in 10ml for counting. Cells were seeded at 3.75×10
5   Chapter 2: Materials and Methods 
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cells/well of a 24-well plate in 1ml DC complete medium and incubated at 37°C, 5% 
CO2. Culture medium was aspirated after 3 and 6 days of culture. This involved 
gently swirling the plate before aspiration so as to remove non-adherent granulocytes 
and B cells without dislodging loosely adherent clusters of developing DCs. Medium 
was replaced with fresh DC complete medium. On day 7, loose DC aggregates were 
removed by pipetting, washed and counted. On day 7, the cells were heterogeneous, 
with 60-85% having a morphology and a cell surface receptor phenotype 
characteristics of iDC (see Chapter 3). Where matured DCs were required, day 7 
cells were stimulated with LPS (E. coli serotype 026:B6) for 24 hours. 
 
In method 2, adopted from the ‘Lutz method’, briefly, femurs
 from BALB/c 
mice were removed, dipped in 70% ethanol for 1-2 minutes, and then placed in DC 
complete medium, and ~5% of conditioned supernatant from a hybridoma expressing 
GM-CSF (at a final concentration
 of 10-20ng/ml). After flushing of the femur’s 
content, 10ml of a single-cell suspension (2×10
5/ml) was plated in non-tissue culture 
grade 100mm Petri
 dishes. On day 3 an additional 10 ml of fresh medium was added
 
to the cultures. On days 6 and 8, half of the medium was removed, and 10 ml fresh 
medium was added to the Petri dishes. On day 10 of the culture, non-adherent cells 
were removed,
  leaving strongly adherent macrophages on the plate. The non-
adherent cells
 were centrifuged (300×g, 5 minutes), resuspended in DC medium, and 
counted before use. On day 10, the cells were heterogeneous, with 85-95% having a 
morphology and a cell surface receptor phenotype characteristics of iDC (see 
Chapter 3). 
 
Unless otherwise stated, mature DCs (mDCs) were obtained after a further 
incubation of iDCs with 100ng/ml LPS (E. coli serotype 026:B6) in 10% heat-
inactivated FCS for 24 hours. When maturation was performed in serum-free 
medium, LPS was used at a concentration of 2µg/ml for 4 hours. 
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2.2.2. Flow cytometry 
 
2.2.2.1. Fluorescence-activated cell sorter (FACS) analysis of DC surface 
markers  
 
Cells were immediately washed post each treatment with PBS without 
Ca
2+/Mg
2+ (PBS w/o) containing 0.1% bovine serum albumin (BSA) (FACS wash).
 
Blocking was performed using 10% mouse serum (Serotec, Oxford, UK) for 15 
minutes; subsequently, cells
 were stained with relevant monoclonal Abs (mAb) at 
4°C in the dark for 30
 minutes. Cells were then washed and resuspended in 200µl
 of 
FACS wash and analysed using FACSCalibur and Cellquest softwares (BD 
Biosciences, CA).
  All stained samples were compared with appropriate isotype 
controls. Unless otherwise stated, the expression of molecules on DCs was either 
expressed as percentage or geometric mean fluorescence intensity (MFI) and was 
compared to that of cells treated with isotype-matched
  controls. The MFI of a 
population of cells labelled with a fluorochrome conjugated to a ligand or mAb is 
linearly related to the mean number of receptors/cell or mean number of mAb biding 
sites/cell. 
 
2.2.2.2. Assessing cell viability by FACS 
 
  To assess the viability of DCs in the experiments performed in this project, 
DCs were immediately stained with propidium iodide (PI; Invitrogen Ltd., Paisley, 
UK) and FITC-annexin V (Caltag Laboratories, CA) after each specific treatment. 
Staining cells simultaneously with FITC-annexin V (green fluorescence) and the 
non-vital dye PI (red fluorescence) allows (bivariate analysis) the discrimination of 
intact cells (annexin V
- PI
-), early apoptotic (annexin V
+ PI
-) and late apoptotic or 
necrotic cells (annexin V
+ PI
+). Hence cells were suspended in 10mM HEPES buffer 
contacting 4mM CaCl4, and were stained with FITC-annexin V according to the 
manufacturer’s protocol for 15 minutes in the dark at room temperature. Immediately 
prior to running the samples on FACS, PI was added and cells were analysed by flow 
cytometry.    Chapter 2: Materials and Methods 
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2.2.3. CSC/CF/COPD/NE studies 
 
2.2.3.1. Preparation of CSC 
 
Cigarette smoke condensate (CSC) was produced fresh by exposing PBS to 
whole cigarette smoke obtained from ‘Regal king-size’ cigarettes containing 0.9mg 
nicotine, 10mg tar and 10mg carbon monoxide per cigarette (Figure 2.1). One ml of 
PBS w/o per cigarette was pipetted into a tonometer and the smoke from the cigarette 
was drawn up into a glass syringe and passed into a tonometer agitating PBS 
(Rahman  et al., 1995). Each puff consists of ~35ml of CS, with 20 puffs being 
achieved from each cigarette. The condensate obtained was filtered thorough a 
0.2µM Minutesisart
®  microfilter (Sartorius, Goettingen, Germany) and used at 
pathophysiological concentrations of 10% or less. 
 
 
 
 
Figure 2.1. Smoke machine 
 
The apparatus shown above was manufactured at the University of Edinburgh and 
was used to generate fresh samples of CSC for in vitro and in vivo experiments. CSC 
was prepared by drawing
 35 ml of cigarette smoke into the syringe and then slowly 
bubbling
 the smoke into sterile PBS w/o. The cigarette was smoked up to 1-cm
 butt 
length. One cigarette was smoked per 1ml of PBS. Following
 preparation of CSC, the 
solution was filtered through 0.2-µm
 filters and used immediately.   Chapter 2: Materials and Methods 
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2.2.3.2. Exposing DCs to CSC 
 
Immature DCs (iDC) as well as LPS (100ng/ml)-matured DCs (mDC) were 
seeded in 6 well cell culture plates (Corning Incorporated, Corning, NY) at a density 
of 2×10
6 cells/well supplemented with 2ml of serum
+ve or serum
-ve RPMI medium.  
Freshly prepared CSC was added at different doses of 1%, 5% and 10%, and PBS 
w/o was also added to the control wells. Cells were incubated for 4 hours, after 
which, their co-stimulatory molecules (CSMs) and MHC class II (MHCII) 
expression levels as well as their viability were assessed by FACS. 
 
2.2.3.3. Sputum samples from COPD patients 
 
COPD sputum samples were obtained from patients attending a COPD clinic 
in the Edinburgh Royal Infirmary. A total of 27 COPD patients (11 F and 16 M, see 
subjects’ demographics in Chapter 3, Appendix I) with an average age of 69 ± 8.29 
(SD) (SEM=1.6) were studied. FEV1 % was 39 ± 12.9 (SEM=2.6) predicted and 
FEV1/FVC % was 47 ± 12.9 (SEM=2.6) predicted. Pack year history was 55 ± 17 
(SEM=3.4). All the sputum samples were processed within 2 hours of production as 
described by Popov et al. (1994). CF sputum samples were collected from a total of 
18 CF patients (9 F and 9 M, see subjects’ demographics in Chapter 3, Appendix II) 
with an average age of 31.5 ± 12.44 (SD) attending a CF clinic at the Western 
General Hospital (Edinburgh). Subsequently, the samples were re-suspended in 
Sputolysin reagent (Calbiochem, San Diego, USA) at a ratio of 1:1 (v/v) and were 
treated as for COPD samples. The sputum samples were either induced or 
spontaneous, but most were induced as described by Drost et al. (2005). All subjects 
were informed of the nature and purpose of the study and gave their consent. The 
study had the approval of the Lothian Ethics Committee. 
 
2.2.3.4. Neutrophil elastase (NE) assay 
 
The concentration of NE in COPD and CF sputum samples was determined 
as described before (Sallenave et al., 1998). Briefly, samples were diluted in NE   Chapter 2: Materials and Methods 
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reagent buffer (50mM Tris, 0.5M NaCl, 0.1% Triton X-100, pH 8) and NE activity 
was measured by adding the NE substrate MeOsucc-Ala-Ala-Pro-Val-p-nitroanilide 
(0.2mg/ml) and measuring the optical density of the released product at 450 nm on a 
microplate spectrophotometer (Dynax Technologies, West Sussex, UK). Serial 
dilutions of purified NE (Elastin products, Missouri) were performed, adding 
dithiothreitol (DTT)/Sputolysin to the same final concentration as previously added 
to patient’s samples, and were used as standards in the assay.  
 
2.2.3.5. Treatment of DCs with either NE or sputum samples from patients with 
COPD/CF 
 
LPS-matured DCs (mDCs) were washed with PBS and checked for viability 
by Trypan blue staining. Cells were resuspended in 300µl PBS containing 0.1% (w/v) 
BSA, with active NE (0.5-3µM) or with sputum and incubated at 37°C for 90 
minutes on a shaker, as described previously (Nemoto et al., 2002). The percentage 
reduction in CSMs expression was determined by flow cytometry and calculated as: 
 
100 – [(MFI NE/sputum-treated cells) / (MFI PBS-treated cells) × 100] 
 
, and plotted against the concentration of active NE in sputa. When NE inhibition 
was assessed, purified active NE (2µM) or a pool of COPD or CF sputa (containing 
0.2µM and 3.39µM active NE respectively) were pre-incubated at 37°C for 90 
minutes on a shaker either with excess concentrations (8µM) of recombinant murine 
secretory leukocyte protease inhibitor (SLPI, a kind gift from Dr C. Wright, Amgen, 
CA, USA) or with a 1:25 dilution of an EDTA-containing broad spectrum protease 
inhibitor cocktail tablet (PIT), inhibiting serine, cysteine, metalloproteases as well as 
calpains (Roche Diagnostics GmbH, Mannheim, Germany). 
 
2.2.3.6. Assessment of CSMs re-expression by DC post-NE treatment 
 
In some experiments, mDCs (10
6/ml) were incubated at 37
oC in 24-well 
Costar plates in serum-free medium with or without 2µM purified active NE for 90   Chapter 2: Materials and Methods 
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minutes. FCS, which is a rich source of antiproteases, was then added (final 
concentration of 15%) to inhibit the NE activity. Cells were then taken at various 
time-points (2, 4, 6 and 8 hours post NE inhibition) and tested for expression of 
surface markers by FACS (all done in triplicates). 
 
2.2.3.7. Stimulation of iDC ± NE and ± LPS 
 
  Immature DC were seeded at a density of 1×10
6 cells/well in a 12 well plate 
in serum-free medium. They were either stimulated with PBS, 2µg/ml LPS, 2µM NE, 
or 2µg/ml LPS and 2µM NE simultaneously.  The cells were incubated for 5 hours 
and then the DCs were collected for FACS analysis and their supernatant was frozen 
at -20°C for cytokine analysis. 
 
2.2.3.8. Effects of NE on recombinant IL-12p40 subunit protein 
 
  One microgram/ml of recombinant IL-12p40 protein (R&D Systems, Oxon, 
UK) was incubated with 2µM NE at 37°C for 5 hours. The samples were treated with 
excess concentrations of SLPI (~4µM) to inhibit remaining NE activity and samples 
were run on IL-12p40 ELISA plates (see 2.2.3.11). 
 
2.2.3.9. Murine CD86 Western blot analysis 
 
a) mDC cell culture supernatants  
Post NE treatment, mDC culture supernatants were concentrated 10 times (with cold 
methanol); pellets were resuspended in reducing sample buffer and were 
immediately heat-denatured at 70°C for 10 minutes prior to electrophoresis on a 
NuPAGE 4-12% Bis-Tris polyacrylamide gel (NuPAGE Invitrogen Ltd., Paisley, 
UK) at 200 Volts (constant voltage) for 35 minutes. 
 
b) mDC lysates 
mDCs were washed with PBS and lysed (10
6 cells/ml ) in 1:1 ratio of PBS:RIPA 
buffer (150mM NaCl, 50mM Tris-HCl, 0.5% DOC, 0.1% SDS and 1% NP40) .The   Chapter 2: Materials and Methods 
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cell lysate was heated at 95°C for 10 minutes and centrifuged at 10000 × g at room 
temperature for 5 minutes. Supernatants were concentrated by methanol precipitation 
as described above; pellets were resuspended in PBS and frozen at -20
oC until further 
use. For CD86 digestion assays, the mDC lysate was incubated with various 
concentrations of purified NE on a shaker at 37°C for various times. For NE 
inhibition studies, SLPI was pre-incubated with NE at 37°C for 30 minutes. mDC 
lysates were added to electrophoresis reducing sample buffer and SDS-PAGE gels 
run as above.  
 
c) Western blotting 
Samples were prepared and run on 4-12% Bis-Tris NuPAGE SDS-PAGE gels as 
described above. Transfer to Hybond ECL nitrocellulose membranes (in a X Cell II 
Blot module) was performed according to the manufacturer’s (InVitrogen Ltd, 
Paisley, UK) instructions. Membranes were then blocked in Tris buffered saline 
containing 0.05% Tween-20 (TBS-T) and 5% dry skimmed milk for 2 hours. After 
blocking, membranes were probed overnight at 4°C with 0.1µg/ml goat polyclonal 
anti-CD86 (B7-2) (R&D Systems, Oxon, UK) in TBS-T. Membranes were washed 
trice for 5 minutes with TBS-T and incubated with rabbit anti-goat IgG horse radish 
peroxidase (HRP)-conjugated secondary Ab (1:50,000; DAKO, Cambridgeshire, UK) 
for 1 hour at room temperature. Membranes were incubated with Hybond ECL Plus 
reagent and exposed to Hyperfilm ECL (Amersham Biosciences, Buckinghamshire, 
UK).
 
 
2.2.3.10. Lymphocyte proliferation assays 
 
Single cell splenocyte suspensions were made from spleens of 6-8 week old 
female ovalbumin (OVA) CD4-T cell TCR transgenic DO11.10 mice (BALB/c 
background, 2-4 animals per experiment) by passing
 the spleen through a 40-µm pore 
size cell strainer (BD Biosciences, San Jose, USA). Debris and
  red cells were 
removed by density gradient sedimentation through Lympholyte-M
  (Cedarlane 
Laboratories, Ontario, Canada) according to the manufacturer’s
 instructions. Day 10 
WT BALB/c BM-DCs were matured with 100ng/ml LPS overnight, washed with   Chapter 2: Materials and Methods 
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PBS and incubated with or without 3µM NE for 90 minutes as described above. The 
treated mDCs were then pulsed with 0.1µM OVA peptide
 (OVA323–339; Peptides 
International, Kentucky, USA) for 90 minutes at 37
oC and washed thoroughly. 10
4 
OVA-pulsed mDCs were added to 10
5  DO11.10 lymphocytes in 96-well tissue 
culture plates in a final volume of 200µl and incubated in a humidified 5% CO2 
incubator. Activation of the transgenic DO11.10 CD4 T cells was assessed after 48 
hours by removing 100µl of the supernatants (for cytokine analysis) and proliferation 
was determined by adding AlamarBlue™ (Serotec, Oxford, UK) to the cells, to yield 
a final concentration of 20% in the incubation mixture. AlamarBlue™ is soluble, 
stable in culture medium and is non-toxic. As with tetrazolium salts, AlamarBlue™ 
monitors the reducing environment of the proliferating cell and allows continuous 
monitoring of cells in culture. Proliferation measurements with AlamarBlue™ may 
be made either spectrophotometrically by monitoring the absorption of 
AlamarBlue™ supplemented cell culture media at two wavelengths. Here, cell 
proliferation was measured by fluorimetry at 545nm excitation wavelength and 
590nm emission wavelength, using a plate reader (Fluoroskan Ascent FL, 
LabSystems, Minnesota, USA).  
 
2.2.3.11. Cytokine analysis 
 
Cytokine secretion was assessed either by using the mouse Th1/Th2 Cytometric 
Bead Array (CBA) kit, (BD Biosciences, San Jose, USA) or by use of ELISA kits 
(R&D Systems, Oxon, UK) in accordance
 with the manufacturers’ instructions. The 
detection limit for CBA kit cytokines was 20pg/ml; the detection limits for IL-12p40 
and TNF-α were 15pg/ml for in the ELISA kits. 
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2.2.4. In vitro and in vivo Ad infection assays and DC analysis 
 
2.2.4.1. In vivo analytical methods 
 
2.2.4.1.1. Intra-tracheal (i.t.) Ad administration 
 
C57BL/J6 mice received i.t. instillations of either PBS, Ad-null (2.5×10
8 pfu), 
or Ad-elafin (2.5×10
8 pfu). Elafin transgenic (eTg) and their WT control litter mates 
received either PBS, Ad-null (2.5×10
8 pfu).  Jean-Michel Sallenave kindly performed 
the i.t. procedures in these experiments. On day 10, animals were anaesthetised and 
blood collected by cardiac puncture and sera and BAL fluid were kindly prepared by 
Lesley A. Farrell and stored at -30°C until use. Spleens were collected, and lungs, 
hearts and tracheae were removed en bloc.  
 
The experiments described in the rest of the paragraph 2.2.4.1.1 were part of 
an ‘honours project’ for Mr. Steven Williams. They were propagated and put by 
Jean-Michel Sallenave, Steven Williams and Tara A. Sheldrake. My contribution 
was limited to the histological analysis of the lung sections to examine lung CD11c
+ 
cell numbers following Ad vaccination (see Roghanian et al. [2006b] for details). In 
experiments to assess the secondary anti-Ad immune response and study further the 
potential of Ad-elafin, 4 groups of mice were used: at day 0, the first group received 
PBS alone; the second group received 2.5×10
8 pfu Ad-null (8.8×10
9  total virus 
particles); the third group received 0.3×10
8 pfu Ad-elafin and 2.2×10
8 pfu Ad-null 
(8.2×10
9 total virus particles). On day 14, all mice received Ad-LacZ (2.5×10
8 pfu; 
2.04×10
10 particles) i.t. and they were culled 3 days later. Sera, BAL fluid, lungs and 
spleens were obtained as explained elsewhere. For determination of Ad-derived β-
galactosidase expression, lungs were snap-frozen in liquid nitrogen and stored at             
-80°C.  
 
2.2.4.1.2. Retrieval of BAL fluid and lungs and flow cytometry 
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Tracheae were intubated and BAL fluid was obtained by instillation of 2 × 
0.4 ml of sterile PBS. Typically, 0.4 to 0.6 ml was retrieved per animal. The cell 
pellet was used for cell differential analysis (performed after centrifugation of BAL 
fluid at 2000 × g for 5 minutes). Cytospinning (100 × g for 3 minutes at room 
temperature) was performed and slides were stained with Diff-Quick (Dade 
Diagnostika, GmbH, Germany). Supernatants were used for elafin and cytokine 
ELISA analysis (see below). In an experimental subset, mice were sacrificed, right 
heart catherization was performed and the pulmonary circulation was perfused with 
PBS. After carefully dissecting the thymus and all thoracic lymph nodes, the lungs 
were removed and collected in ice-cold PBS. They were minced using fine scissors 
and a scalpel and incubated in PBS containing 0.7 mg/ml collagenase A (Roche 
Diagnostics, GmbH, Germany) and 30 µg/ml DNase I in a humidified incubator at 
37°C and 5% CO2 for 45 minutes. These combinational doses of collagenase A and 
DNase I were chosen because they were found to yield the maximum number of 
APCs from perfused lung tissues by previous investigators in our centre (documented 
in Sharon Ahmed’s PhD thesis, CIR; 2003). Subsequently, the digested tissue was 
mechanically disrupted and passed thorough a 40-µm cell strainer (Falcon). Finally 
cells were subjected to RBC lysis buffer, washed in complete medium (RPMI 1640 
supplemented with 10% FCS, L-glutamine, penicillin/streptomycin [P/S]), and kept 
on ice for immunofluorescent labelling.  
 
mAbs used to identify mouse DC populations were APC-CD11c (N418, 
eBiocience), and FITC-MHCII (2G9; BD Biosciences Pharminutesgen). Additional 
markers used for phenotyping were: PE-conjugated anti-CD11b/Mac-1α (M1/70), 
CD3, CD40 (1C10), CD80/B7-1 (16-10A1), CD86/B7-2 (GL1), Gr1, B220/CD45R 
(RA3-6B2) (all from eBiocience, CA) and F4/80 (CI-A3-1; Caltag, CA). Isotype-
matched control Abs to each mAb were used.  
 
All staining reactions were performed on ice in FACS buffer (PBS containing 
0.2% BSA). Cells were pre-incubated with mouse serum (Serotec, Oxford, UK) to 
reduce non-specific binding of mAb. Cells were stained with mAbs for 30 minutes 
on ice and washed with FACS buffer before being analysed. Flow cytometry data   Chapter 2: Materials and Methods 
 
  84
acquisition was performed on FACSVantage SE flow cytometer (Becton Dickinson, 
CA) and around 1×10
5 events were collected per sample. CellQuest™ software was 
used for data analysis (BD Biosciences, CA). 
 
2.2.4.1.3. Sorting of lung antigen presenting cells (APC) 
  
  Mouse lungs were perfused and digested as described above and the lung 
single cell suspension from 2-4 mice were pooled and stained with mAbs to CD11c 
and MHCII (see above). The cells were then washed with FACS wash and 
resuspended in FACS wash buffer at a density of ~5×10
6 cells/ml. They were then 
passed thorough the FACSVantage SE flow cytometer (Becton Dickinson, Franklin 
Lakes, NJ) and the CD11c
+MHCII
+ and CD11c
+MHCII
- cells were collected in two 
separate tubes. The sorted cells were further stained with mAbs to CSMs and their 
isotype control and were analysed by FACS. CellQuest™ software was used for data 
analysis (BD Biosciences). 
 
2.2.4.1.4. Magnetic separation of lung CD11c
+ cells 
 
  Mouse lung single cells were prepared as described above. They were then 
incubated with mouse serum for 10 minutes in the fridge (4-6°C) and were 
resuspended in 400µl of buffer (PBS w/o supplemented with 0.5% BSA, pH 7.2). 
The cells were stained with 100µl of monoclonal hamster anti-mouse CD11c 
MicroBeads (N418; Miltenyi Biotec Ltd., Bergisch Gladbach, Germany) and 
incubated for 15 minutes at 4-6°C (fridge). At this stage APC-conjugated CD11c 
mAb was also added to the cells for another 10 minutes in the fridge (4-6°C). 
Following staining, cells were washed by adding 10-20× volume of buffer and 
centrifuged at 200 × g for 10 minutes and the cell pellet was resuspended in 500µl of 
buffer in a 50-ml Falcon tube. 
 
  A positive selection column type MS
+/RS
+ was chosen on the magnetic cell 
separator MACS (Miltenyi Biotec Ltd.) and the column was washed with buffer. 
Cells labelled with CD11c MicroBeads were collected in a new 50ml Falcon tube in   Chapter 2: Materials and Methods 
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the positive column, and the negative cells were flushed to thorough the negative 
column. CD11c
+ cells were further stained with MHCII mAbs and were analysed by 
FACS.
 
 
2.2.4.1.5. CD11c immunohistochemistry 
 
Sections (15µm) were cut from OCT-inflated lungs using a microtome with a 
cabinet temperature of -30°C, mounted on polylysine-coated slides and fixed with 
100% methanol. Sections were washed twice with PBS and incubated for 2 hours 
with either PE-conjugated hamster anti-mouse CD11c (clone N418) or isotype 
control (BD Biosciences, CA), diluted 1:20 in ChemMate™ Antidody Diluent 
(DakoCytomation, UK). Slides were washed with PBS and briefly counterstained 
with TO-PRO-3 (Molecular Probes Invitrogen, UK). Digital images were acquired 
with a confocal microscope (Leica TCSNT; Leica Microsystems, Germany). Cells 
stained with CD11c Ab were counted from three independent confocal fields taken at 
magnifications of 10× and 83×. 
 
2.2.4.1.6. Enzyme-linked immunosorbent assays (ELISA) 
 
ELISA analyses to detect murine GM-CSF, IL-12p40, IFN-γ and TNF-α were 
performed by using commercially available ELISA kits (R&D Systems, Oxon, UK) 
in accordance
 with the manufacturer's instructions. Human elafin was measured
 by 
using an ELISA developed in-house (Reid et al., 1999). IL-12p40 ELISA was 
performed on BAL fluid using paired mAb and cytokine standards (BD Biosciences, 
CA) as described (MacDonald et al., 2001). 
 
 
2.2.4.2. In vitro analytical methods 
 
2.2.4.2.1. Ad infection of BM-DCs in vitro 
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Immature DCs (2×10
5 cells/condition) were washed, checked for viability by 
Trypan blue staining, and suspended in fresh complete RPMI medium in 2ml 
Eppendorf tubes or 12-well Costar plates. Two infections methods were applied. In 
the first protocol, Ad was applied to cells cultured in plates at various multiplicity of 
infection (MOI) in a total volume of 500µl for 45-90 minutes at 37°C. Medium was 
carefully removed and DC were reconstituted with 2ml complete or serum-free 
RPMI and incubated overnight at 37°C. 
 
In the second method, Ad was applied to cells suspended in Eppendorf tubes 
at various MOIs in a total volume of 500µl and the cells were spun at a speed of 2000 
× g for 70 minutes at room temperature (Nishimura et al., 2001). Following 
centrifugation the infection medium was removed and cells were washed with PBS × 
2 and DC were resuspended in 2ml fresh complete or serum-free RPMI medium and 
cultured in 12-well plates and incubated overnight at 37°C. Then, cells were either 
treated with other reagents or were further analysed by FACS. The supernatants of 
treated DCs and their corresponding controls were kept at -20°C for further analysis. 
 
2.2.4.2.2. Ultraviolet (U.V.) light-inactivation of Ad vectors 
  
  Ad vectors were exposed to direct U.V. light for a period of 45 minutes for 
complete inactivation and then incubated with DCs. To test the protocol of 
inactivation, DCs were infected with active and U.V.-inactivated Ad-GFP and GFP 
expression was assessed by flow cytometry 24 hours post infection.  
 
2.2.4.2.5. DC trans-migration assay 
 
Murine Clara cells were seeded at a density of 1x10
6 in 1ml serum
+ve DMEM 
medium in a 24-well culture plates (Costar, UK). After reaching confluency, the 
Clara cells were washed with PBS and infected with either Ad-elafin or Ad-null at an 
MOI of 100, for ~1 hour at 37°C, 5% CO2. The infected Clara cells were then 
washed with PBS 3× to remove all FCS residues (as they contain chemotactic 
proteins that greatly interfere with the trans-migration assay), and were incubated for   Chapter 2: Materials and Methods 
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a further period of 48 hours enabling them to produce and secrete the transgene into 
the medium. Supernatants were collected and centrifuged to remove the floating cells 
and debris and stored at -20°C. 
 
On the day of the experiment, day 7 iDCs were harvested and washed with 
PBS, resuspended in serum
-ve DMEM medium and counted. At the same time, 600µl 
of the infected Clara cell supernatant (source of elafin) were pipetted into the lower 
chamber of the trans-well Costar plates (Costar, UK) and pre-incubated at 37°C. 
Supernatants taken from uninfected Clara cells and Clara supernatants containing 
100ng/ml MIP-3α (Peprotech Ltd., London, UK) were also used as negative and 
positive controls, respectively. Next, 1×10
5 iDCs in 100µl were added to the top 
chamber and incubated for 90 minutes at 37°C. After the incubation period, the 
medium in both top and bottom chambers were collected and examined 
microscopically for the presence of iDCs.  
 
Furthermore, the remaining media was removed from the upper side of the 
trans-well membranes with cotton buds, and they were submerged into absolute 
methanol for 10 minutes and air dried. They were then placed in Diff-Quick II (Dade, 
Germany), to fix the cells stuck onto the trans-well membranes, for 20 minutes at 
room temperature and cleaned thoroughly with cotton buds. Finally using an inverted 
microscope cells that migrated to the lower side of the trans-well membrane were 
counted, 5-10 fields were chosen systematically and the average number of iDCs 
stuck onto the membranes were calculated. 
 
2.2.4.2.4. Western blotting for detection of murine α1-PI  
 
  To detect murine α1-PI in cell supernatants, it was first deemed necessary to 
optimise the system. Recombinant human α1-PI and rabbit anti-human α1-PI Ab 
(Sigma) were both available in house and hence used in the following experiments. 
Rabbit anti-human α1-PI Ab was shown to recognise the murine α1-PI protein too.  
Preliminary experiments were performed to choose the optimum concentrations of 
rabbit anti-human α1-PI Ab (with a stock concentration of 42mg/ml) which was   Chapter 2: Materials and Methods 
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found to be 1:1000. Cells were infected with Ad-α1PI for 48 hours and supernatants 
were collected and concentrated in methanol as described above. Pellets were 
resuspended in reducing sample buffer and were immediately heat-denatured at 70°C 
for 10 minutes prior to electrophoresis on a NuPAGE 4-12% Bis-Tris 
polyacrylamide gel (NuPAGE Invitrogen Ltd., Paisley, UK) at 200 Volts (constant 
voltage) for 35 minutes. The blotted membranes were blocked in 8% milk-Tween 
solution for 1 hour, washed and incubated with rabbit anti-human α1-PI Ab diluted in 
8% milk-Tween for 1 hour at room temperature. Goat anti-rabbit-HRP (DAKO, 
Cambridgeshire, UK) was used as a secondary Ab which was diluted in 8% milk-
Tween at a final concentration of 1:4000, for 1 hour at room temperature. 
Membranes were incubated with Hybond ECL Plus reagent as recommended by the 
manufacturers and exposed to Hyperfilm ECL (Amersham Biosciences, 
Buckinghamshire, UK). 
 
2.2.6. Statistical analysis 
 
  Results are reported either (i) as pooled data from a series of n separate 
experiments, and presented as mean ± S.D., or (ii) as individual experiments, carried 
out in duplicate or triplicate, or (iii) single experiment using pooled cells from 2-4 
mice.  
 
Statistical significance was analysed by Student’s unpaired t-test using the 
GraphPad Prism 4 statistical software (San Diego, CA). Statistical significance was 
assigned to data returning a ‘P value’ of less than 0.05. 
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CHAPTER 3 
 
THE EFFECTS OF CIGARETTE SMOKE CONDENSATE AND 
LUNG INFLAMMATORY MEDIATORS ON DENDRITIC CELL 
PHENOTYPE AND FUNCTION 
 
3.1. AIMS 
 
The upper and lower airways are repeatedly exposed to a multitude of 
airborne particles and microorganisams. However, due to the presence of a tight 
defence network comprising various components of the innate and immune systems, 
the airways are usually sterile and non-inflamed in healthy individuals (Zalacain et 
al., 1999). On the other hand, lungs of chronic obstructive pulmonary disease (COPD) 
and cystic fibrosis (CF) patients are frequently infected and colonised by 
microorganisms. The latter is associated with chronic infections with Staphylococcus 
aureus (S.a.), Pseudomonas aeruginosa (P.a.), and often in the worst cases with 
Burkholderia cepacia (B.c.). Although cigarette smoking is the accepted aetiologic 
factor in the pathogenesis of COPD in the huge majority of cases, recent evidence 
suggests that respiratory tract of COPD patients is often colonised in 50-100% of 
cases (Zalacain et al., 1999; Sethi et al., 2006; Tumkaya et al., 2006) and that 
infections with viruses and bacterial pathogens such as non-typeable Haemophilus 
influenzae ( NTHI),  Streptococcus pneumoniae, and Branhamella  catarrhalis are 
instrumental in the generation of disease exacerbations (Patel et al., 2002; Sethi et al., 
2006). COPD and CF are characterized by intense neutrophilic inflammation and the 
release of high levels of cytotoxic molecules such as NE that overwhelm and 
inactivate antiprotease and innate immune defences (Suter, 1989; Fujita et al., 1990; 
Birrer  et al., 1994; Tumkaya et al., 2006; Sethi et al., 2006). NE is capable of 
modifying many cytokines and cell surface receptors through its proteolytic activity 
(see Table 1.5). For instance, it is able to cleave important receptors from the surface 
of macrophages which could potentially impair the clearing of apoptotic cells and 
perpetuate a pro-inflammatory phenotype (Le-Barillec et al., 1999; Vandivier et al., Chapter 3: The effects of cigarette smoke condensate and lung inflammatory mediators on dendritic cell phenotype and function 
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2002; Henriksen et al., 2004). On the other hand cigarette smoke (CS) has been 
shown to modulate immune responses (see section 1.5). As DCs are one of the first 
lines of defence to be present in the tracheobronchial tree (see Figure 1.5), it was 
hypothesised that CS and COPD/CF lung inflammatory secretions containing high 
concentrations of NE are able to influence the behaviour or phenotype of DCs in 
such a way as to inhibit their ability to present antigens and, thus, initiate protective 
immunity to pathogens. Therefore, the principal aim of the work described in this 
chapter was to investigate whether cigarette smoke condensate (CSC) and sputum 
secretions (containing NE) from COPD and CF patients as well as purified human 
NE are able to ‘deactivate’ DCs and impair their functional activity, thereby 
providing a mechanism by which microbes may escape immune surveillance. Hence, 
the effects of CSC and human lung secretions/purified human NE on the function of 
murine BM-DCs were investigated using a variety of parameters, namely the 
expression of DC CSMs ‘CD40, CD80, and CD86’, and pro-inflammatory cytokine 
such as IL-12p40 and TNF-α. BM-DCs, and not lung DCs, were used in this study 
because they could be generated at high numbers in vitro, thereby reducing the 
number of animals used. Nonetheless, progenitors of lung DCs also originate from 
CD34
+ BM stem cells. 
 
In the event that upon treatment, DC phenotype and activation state was 
affected, a further aim was to investigate how this could influence the maturation of 
iDCs in the presence of LPS and to test functional activity of DCs, using 
lymphocytes derived from DO11.10 transgenic mice and OVA-induced mediated T 
cell proliferation as a read-out of effective antigen presentation. 
 
Since the OVA transgenic mice used here were derived from a BALB/c 
background, the source of DCs used throughout this chapter was from BALB/c mice 
BM cells. The CSC was freshly produced for each experiment as described in 
Chapter 2 (section 2.2.3.1), chromotographically purified human NE from purulent 
sputum was purchased from Elastin Products (Missouri, USA); COPD and CF 
sputum samples were prepared as described in Chapter 2 (section 2.2.3.3). 
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3.2. RESULTS 
 
3.2.1. Preliminary experiments to generate and optimise yields of BM-DCs in 
vitro  
 
  As DCs are rare populations in all organs, their generation from 
haematopoietic precursors in large quantities has proven critical to study their 
biology and their use in modulating the immune response in in vivo studies. The 
principal source of DCs used through out this project was murine BM-DC that as 
their name suggests were generated from murine haematopoietic BM cells, under the 
influence of GM-CSF over a period of several days (see Chapter 2 for more details). 
Given that this was the first project in the laboratory to use DCs, it was first essential 
to optimise an efficient protocol which could provide a ready supply of iDCs for 
routine in vitro studies. Currently, there are two widely used standard protocols of 
producing BM-DCs in vitro (Inaba et al., 1992; Lutz et al., 1999). At the start of this 
project, protocols derived from these two sources (referred to as method 1 and 
method 2 respectively) were applied to determine which is the most efficient method 
(both in terms of the final yield and DC purity) for generating BM-DCs, for day to 
day use in the laboratory. Each of these methods has advantages and disadvantages; 
Table 3.1 summarises and compares the conditions used in methods 1 and 2. As 
shown in Figure 3.1, microscopic analysis of cells revealed that method 1, generated 
cells with typical DC morphology as well as neutrophils, whereas method 2 
contained an almost homogenous population of cells having DC morphology; the 
FACS data (Gr1 and F4/80 staining) were also in agreement with these observations 
(not shown). In general, when cells were stained with FACS mAbs to CD11c and 
MHCII (markers used to identify DCs), method 2 generated a more heterogeneous 
population of cells (which could be separated into iDCs and semi-mDCs) than 
method 1 (Figure 3.2 A, bottom dot plots). When compared like for like, cells 
generated by method 1 expressed slightly higher levels of the activation markers, 
CD40, CD80 and CD86 (Figure 3.2 B).  
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  Since method 2 resulted in significantly higher number of cells and a far 
higher BM-DC purity than method 1 (despite its longer culture period) it was decided 
to use this method for the rest of this project. In the rest of this thesis, BM-DCs 
would be referred to as DCs for simplicity. 
 
 
 
 
 
 
 
 
Table 3.1. Comparison of DC culture techniques  
Adapted from Lutz et al., 1999. 
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Figure 3.1. DC culture phenotypic assessments 
 
On day 7 (method 1) or day 10 (method 2) of the DC cultures, loosely adherent cells 
were removed by pipetting and washed. A) Day 10 DC cultures were analysed by 
light microscopy. White arrow indicating GM-CSF-induced DC colonies in culture. 
B & C) Cytospinning (100 × g for 3 minutes at room temperature) of method 1 and 
method 2 DC cultures was performed and slides were stained with Diff-quick (Dade 
Diagnostika, GmbH, Germany) and fixed. Representative pictures are shown (n=6). 
White arrow head showing contaminant neutrophils in culture. 
B. Method 1-generated DCs  C. Method 2-generated DCs 
A. BM-DC culture  Chapter 3: The effects of cigarette smoke condensate and lung inflammatory mediators on dendritic cell phenotype and function 
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Figure 3.2 (Part A). Comparison of method 1- and method 2-derived DC 
phenotype and activation 
 
BM-DC were generated using two widely methods for generating murine iDC in vitro; referred to as 
Method 1 (Inaba et al., 1992) or Method 2 (Lutz et al., 1999) (see Chapter 2, section 2.2.1.4). On day 
7 or 10 of the cultures, respectively, cells were washed and stained with FACS Abs to assess final DC 
purity (n=3). A) Forward/side scatter plots of DCs, B) Unstained profiles of DCs, C) profiles of DCs 
stained with isotype-matched control Abs (Armenian hamster IgG-APC and Rat IgG2aκ-FITC, 
respectively), and D) profiles of DCs stained with CD11c-APC and MHCII-FITC Abs. 
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Figure 3.2 (Part B, continued). Comparison of method 1- and method 2-derived 
DC phenotype and activation 
 
BM-DCs generated by Method 1 and Method 2 were stained with mAbs to CSMs 
(CD40, CD80 and CD86), MHCII and Gr1 and analysed by flow cytometry. Dotted 
lines indicate isotype-matched controls. Blue histograms (right) represent method 1-
generated DCs and the green histograms represent method 2-generated DCs. Data 
shown is representative of three independent experiments, MFI and % positive cells 
shown for each marker. To enable direct comparisons, similar DC purity cultures 
from each method were chosen here. 
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3.2.2. Stimulation of immature DCs with lypopolysaccharides (LPS) 
 
  As explained in Chapter 1 (section 1.2), DCs exist in two main maturation 
states, referred to as immature DC (iDC) and mature DC (mDC). When DCs 
generated from BM are harvested at the end of the culture period, they 
predominantly have an immature phenotype which is indicated by very low 
expression levels of CD40, and moderate levels of CD80, CD86 and MHCII (Figure 
3.2 B). A common way of inducing DC maturation is by stimulating them with 
Gram-negative bacterial outer surface antigenic components such as LPS. iDCs are 
strongly activated by LPS which signals via the conserved TLR2 and TLR4 receptors 
highly expressed on DCs and other phagocytic cells (Takeuchi et al., 1999). The 
engagement of TLR2/TLR4 induces nuclear translocation of the NF-κB transcription 
factor via activation of an adaptor protein (MyD88) and a serine/threonine kinase 
(IRAK) (Medzhitov et al., 1997; Sweet and Schorey, 2006). Also, microbial 
activation might lead to the transcription of the IFN-inducible genes via IRF-3 
(Trottein et al., 2004). On day 10 of culture, iDCs were initially stimulated with LPS 
or 0.02% (w/v) S.a. (Cowan strain) (SAC) to assess cell activations by morphology 
and TNF-α secretion (Figure 3.3). An LPS titration of iDCs over a 24 hour period 
was also performed in serum
+ve (10% v/v) complete medium in order to optimise the 
LPS concentration for the experiments undertaken throughout this project (Figure 
3.4). These experiments indicated that 100ng/ml LPS was the optimum concentration 
to use in serum
+ve medium over this period and further addition of LPS did not make 
a significant impact on DC maturation. Representative FACS data presented in 
Figure 3.5 compare the cell surface phenotypes of iDCs and LPS-matured DCs. 
Following LPS stimulation the CD40 levels are increased from just a few percent of 
CD40-expressing iDCs to more than 60% CD40-expressing mDCs. Whereas, ~40% 
of iDC express CD80 and CD86 molecules which increased upon stimulation to 
~80%. On the other hand, the majority of iDCs express MHCII (~85%) which is 
slightly increased (~90%) upon LPS-stimulation. However, it should be 
acknowledged that the expression levels of MHCII on individual DCs was 
dramatically increased as assessed by MFI (iDC vs mDC; ~440 and ~934, Chapter 3: The effects of cigarette smoke condensate and lung inflammatory mediators on dendritic cell phenotype and function 
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respectively. This is also the case for the other DC surface markers examined here 
(CD40, CD80 and CD86) (Figure 3.5 B). 
                             
 
Figure 3.3 (Part A). Stimulation of DCs 
 
iDCs were generated as described above. On day 10 of the culture, fully differentiated DCs were 
removed, washed and replated in 12-well Costar plates at a density of 1×10
6 cells/ml in complete 
RPMI medium. They were then stimulated with 100ng/ml LPS or SAC (0.02% w/v) and analysed by 
light microscopy 24 hours later. A) White arrowhead showing iDC colonies, B) white arrows 
indicating LPS-matured mDCs, and C) SAC-matured mDCs. Representative pictures are shown (n=5). 
A.  DC ctrl 
C. DC+SAC 
B.  DC+LPS Chapter 3: The effects of cigarette smoke condensate and lung inflammatory mediators on dendritic cell phenotype and function 
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Figure 3.3 (Part B, continued) Stimulation of DCs 
 
Immature DCs were generated and stimulated as described above. TNF-α output by 
activated DCs (24 hours post-stimulation) was analysed by ELISA. * indicates 
significance iDC vs LPS (100ng/ml)-matured DCs and ** indicates significance 
between matured cells; LPS (100ng/ml) vs LPS (500ng/ml)/SAC (0.02% w/v); 
p<0.05, n=5 independent experiments.  
 
 
 
 
 
 
 
 
 
 
* 
**
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Figure 3.4. LPS titration of DC maturation 
 
To optimise the concentration of LPS used in experiments where DC maturation was 
required, DCs were generated as described above (see legend of Figure 3.3) and 
stimulated with increasing concentrations of E.coli LPS for 24 hours in complete 
medium (serum
+ve). The cells were then washed and stained with mAbs to CSMs and 
MHCII and analysed by flow cytometry. A)  Graph showing percentage of cells 
expressing CSMs and MHCII following LPS-stimulations. B) Graph showing mean 
fluorescence intensity (MFI) of CSMs and MHCII levels on DCs following LPS-
stimulations; n=3 independent experiments. 
B. 
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Figure 3.5. Comparison of surface expression levels of CSMs on iDCs versus 
mDCs  
 
DCs were generated as described above and stimulated with 100ng/ml E.coli LPS for 24 
hours in complete medium. They were then washed and analysed by flow cytometry for 
expression of CSMs and MHCII. A) Dot plots of iDCs and mDCs are shown, and B) 
histograms showing expression levels of CSMs and MHCII molecules on iDCs (filled blue) 
compared to LPS-matured DCs (mDCs; open red lines). Unstained cells, isotype-matched 
controls and gates are not shown for simplicity; n=10 independent experiments. 
iDC: 3.67 / 4.23% 
mDC: 54.82 / 64.45% 
MFI / % of positive cells
iDC: 46.83 / 30.12% 
mDC: 389 / 87.65% 
iDC: 27.38 / 43.07% 
mDC: 321 / 75.87% 
iDC: 439.79 / 84.57% 
mDC: 934.17 / 88.97% 
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3.2.3. Effects of cigarette smoke condensate (CSC) on DCs 
 
In order to investigate the effects of CSC on mDCs, iDCs were matured with 
100ng/ml E.coli LPS for 24 hours, as described above, prior to the addition of freshly 
produced CSC. mDCs (as well as iDCs, not shown) were exposed to CSC (1%, 5% 
and 10%) or PBS (control) for 4 hours in complete medium. The cells were 
subsequently stained for CSMs as well as MHCII and analysed by flow cytometry. 
As Figure 3.6 demonstrates, CSC at higher doses (5% and 10%) caused a decrease in 
CSMs and MHCII expression on mDCs as indicated by a dose-dependent peak shift 
to the left. The reduction was more profound in the case of CD80 and CD86 as 
compared to CD40. This could be explained by the fact that iDCs hardly express 
CD40 and when stimulated to mature not all the cells are responsive, as shown in 
Figure 3.5 B. 
 
3.2.3.1. CSC induces DC death in dose-dependent manner 
 
  Cells undergoing apoptosis break up the phospholipid asymmetry of their 
plasma membrane and expose phosphatidylserine (PS) due to its translocation to the 
outer layer of the membrane. This occurs in the early phases of apoptotic cell death 
during which the cell membrane remains intact. This PS exposure may represent a 
hallmark (early and widespread) for the detection of dying cells. Annexin V belongs 
to a recently discovered family of proteins, the annexins, which could be used as a 
useful marker for detection of apoptotic cells. This is because annexin V 
preferentially binds to negatively charged phospholipids like PS on apoptotic cells in 
the presence of Ca
2+. Changes in PS asymmetry, which is analyzed by measuring 
annexin V binding to the cell membrane, could be detected before morphological 
changes associated with apoptosis have occurred and before membrane integrity has 
been lost. By conjugating a fluorochrome such as FITC to annexin V it is possible to 
identify and quantify apoptotic cells on a single-cell basis by flow cytometry. 
Staining cells simultaneously with FITC-annexin V (green fluorescence) and the 
non-vital dye propidium iodide (PI; red fluorescence) allows the discrimination of Chapter 3: The effects of cigarette smoke condensate and lung inflammatory mediators on dendritic cell phenotype and function 
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intact cells (annexin V
- PI
-), early apoptotic (annexin V
+ PI
-) and late apoptotic or 
necrotic cells (annexin V
+ PI
+). 
 
To investigate the reason for the down-regulation of DC CSMs by CSC and 
to assess cell viability post CSC exposure (Figure 3.6), DCs treated with either PBS 
or 1%, 5% or 10% fresh CSC for 4 hours were stained with PI and annexin V and 
analysed by flow cytometry immediately after treatment. CSC caused a dose-
dependent death in of DCs as demonstrated in Figure 3.7.  This seemed to be mainly 
due to cell necrosis and little apoptosis, as majority of the cells were positive for PI.  
 
 
 
Figure 3.6. CSC causes down-regulation of DC surface molecules 
 
DCs were generated as described above and stimulated with 100ng/ml E.coli LPS for 24 hours in 
complete medium. The cells were then exposed to either PBS or 1-10% freshly prepared CSC) and 
incubated for 4 hours at 37°C. They were then washed and analysed by flow cytometry for expression 
of CSMs and MHCII. Blue histograms represent untreated mDCs and coloured lins (overlays) 
represent expression levels of DC markers following PBS/CSC treatments. Representative data of at 
least three independent experiments are shown. Unstained cells, isotype-matched controls and gates 
are not shown for simplicity. 
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Figure 3.7. CSC exposure induces DC death in culture 
 
DCs were generated as described above and stimulated with 100ng/ml E.coli LPS for 
24 hours in complete medium. The cells were then exposed to either PBS or 1-10% 
freshly prepared CSC) and incubated for 4 hours at 37°C. They were then washed 
and analysed by flow cytometry for annexin V and propidium iodide (PI) positivity. 
Gates were chosen using unstained cells which fell in the bottom right quadrant (not 
shown), as before. Representative data of three independent experiments are shown. 
 
 
 
 
Annexin V
PI 
37.15% 
11.39% 
43.36% 
19.38% 
10.96% 
9.74%  18.17%
9.74% 
8.85% 
22.21% 
19.71%
22.17% 
Ctrl mDCs    mDCs+1% CSC 
 mDCs+10% CSC    mDCs+5% Chapter 3: The effects of cigarette smoke condensate and lung inflammatory mediators on dendritic cell phenotype and function 
  104
3.2.4. Comparison of COPD and CF patients’ sputum samples 
 
  NE concentrations in solubilised sputum samples prepared from samples 
collected from COPD/CF patients were measured as described in Chapter 2. As 
Figure 3.8 shows, the mean NE concentration in COPD sputum samples was 
0.1143µM ± 0.04850 (n=27, 11 F and 16 M), whereas the mean NE concentration in 
CF sputum samples was more than 20 times higher (2.3245µM ± 1.5069; n=18, 9 F 
and 9 M) (COPD [NE] vs CF [NE], p<0.0001). Microbiological analyses showed 
that the majority of the COPD and all of the CF sputum samples contained one or 
more kind of pathogens. See Appendix (Tables A3.1 and A3.2) for comprehensive 
demographics of the COPD/CF subjects used in these experiments. 
 
3.2.4.1. Effects of COPD and CF sputum samples on DC CSMs 
  
  Upon DC maturation by LPS (100ng/ml), the levels of the CSMs, CD40, 
CD80 and CD86, were typically increased 3-4 folds in an overnight culture (Figure 
3.5 B). To examine the effects of sputum on DC morphology and phenotype, mDCs 
were incubated with COPD and CF sputum samples in 1.5ml Eppendorf tubes on a 
shaker for 90 minutes at 37°C. In preliminary experiments, using 7 of the COPD 
sputum samples and all of the 18 CF sputum samples, with the last marker (CD86) as 
shown in Figure 3.9, the levels of mDCs CD86 CSM were lower after treatment with 
CF sputum samples (mean NE concentration: 4.7µM ± 0.73, n=18, p<0.0001) than 
after treatment with COPD sputum samples (mean NE concentration: 0.11µM ± 0.05, 
n=7, p=0.0015). In addition, for each type of sputum, there was a strong, statistically 
significant correlation between the NE concentration in individual sputum samples 
and reduction of CD86 levels (CF: r=0.94 and COPD: r=0.76). A more 
comprehensive experiment using pooled sputum samples showed that mDCs 
incubated with the COPD/CF sputa expressed lower levels of CD80 and CD86, 
whereas the expression levels (expressed as MFI) of CD40 were increased (Figure 
3.10), with no or very little change in expression levels of MHCII (not shown). Of 
note, even though mDCs were chosen because of their higher starting initial levels of 
CSMs expression, sputa had a similar effect on the expression of CSMs on iDCs (see Chapter 3: The effects of cigarette smoke condensate and lung inflammatory mediators on dendritic cell phenotype and function 
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below, Figure 3.19 A). In parallel control experiments mDCs were incubated with 
the same concentrations of the Sputolysin reagent as in sputum samples; mDC CSMs 
were shown to be unaffected in the presence of Sputolysin reagent alone (data not 
shown).  
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Figure 3.8. NE levels in COPD and CF sputum samples 
 
COPD and CF sputum samples were prepared, and NE concentrations were 
measured as described in Chapter 2. Graph showing the concentrations of NE in 
COPD (n=27) and CF (n=18) sputum samples (* indicates statistical significance, 
p<0.0001).  
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Figure 3.9. Reduction of CD86 by sputum samples 
 
mDCs (matured with LPS in serum-containing medium for 24 hours) were washed to remove serum 
and incubated with individual sputa from COPD (n=7; Patients 1, 5, 6, 8, 12, 13 and 14) and CF 
patients (n=18; Patients 1-18) or an equivalent volume of PBS for 90 minutes on a shaker at 37°C, and 
cells were stained with CD86 mAbs and analysed by FACS. R=equation of straight line. 
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Figure 3.10. Effects of COPD and CF sputum samples on mDC CSMs 
 
mDCs were washed to remove serum and incubated with either purified human NE (2µM), individual 
pooled sputa samples from COPD and CF patients or an equivalent volume of PBS for 90 minutes on 
a shaker at 37°C. Graph pooled from 2 independent experiments (triplicate wells). * indicates 
significant difference (p<0.05) compared to uninhibited PBS-treated mDCs (control). 
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3.2.5. Effects of purified human NE on DC CSMs 
 
  The data presented above indicate that patients’ sputum samples are able to 
induce down-regulation of the CSMs (CD80 and CD86), and that the down-
regulation of CD86 positively correlates with the concentration of NE in sputum 
samples. To test whether NE in isolation was also able to affect the levels of DC 
CSMs expression, mDCs were incubated with increasing pathophysiological 
concentrations of purified human NE (0.5-3 µM) and the levels of CSMs and MHCII 
expression were assessed by flow cytomerty. Purified NE caused a dose-dependent 
down-regulation in all CSMs under investigation (CD40, CD80 and CD86), but no or 
very little change in MHCII levels on mDCs (Figure 3.11; also see Figure 3.19 A). 
Importantly, the reduction in expression of CSMs on mDCs was not due to cell 
apoptosis and/or necrosis (measured by annexin V and propidium iodide staining) 
NE treatment (Figure 3.12). 
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Figure 3.11. Reduction of CD40, CD80 and CD86 CSMs but not MHCII by 
purified NE 
 
A) mDCs were washed, resuspended in PBS containing 0.1% BSA and exposed to 
NE (2µM) for 90 minutes at 37°C. Treated mDCs were then washed, stained with 
antibodies to CD40, CD80, CD86 and MHCII and analyzed by flow cytometry 
(green line: mDCs; dark line: NE-treated mDCs, filled grey line: isotype control). B) 
mDCs were exposed to a range of NE concentrations (0.5-3 µM) and expression of 
CD40, CD80, CD86 was analyzed. The % reduction was calculated as follows: 
 
 
 
 
Values were pooled from 3-6 independent experiments and represent mean ± SD 
compared to untreated controls. R=equation of straight line. 
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Figure 3.12. NE does not induce DC death 
 
mDCs were washed, resuspended in PBS containing 0.1% BSA and exposed to NE (1 and 3 µM) on a 
shaker for 90 minutes at 37°C. Treated mDCs were then washed and resuspended in HEPES 
containing 4mM CaCl4 buffer and stained with PI and annexin V and examined by FACS. 
Representative dot blot analysis of 3 independent experiments shown. 
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3.2.6. NE inhibitors prevent NE-induced reduction of CSMs 
 
To prove that the reduction in CSMs levels was due to the proteolytic activity 
of NE in the sputum samples, recombinant murine SLPI (8µM), a well characterized 
inhibitor of both murine and human NE (Wiersner et al., 2005; Junger et al., 1992), 
and a 1:25 dilution of protease inhibitors tablet (PIT; Roche Diagnostics Ltd., East 
Sussex, UK) were incubated with either purified NE (2µM) or with pooled COPD 
(18 samples) or CF (9 samples) sputum samples (containing 0.2µM and 3.39µM NE 
respectively), prior to treatment of mDCs. Although SLPI and PIT significantly 
rescued the reduction of mDCs CD86 by purified NE (74% and 83% expression, 
respectively) or COPD sputa (100% and 85% expression, respectively), the rescue 
was more modest (but significant) after treatment with CF sputum samples (36% 
expression in both cases) (Figure 3.13). To investigate this effect, cells were assessed 
for viability by PI and annexin V assessments using FACS, following treatment of 
mDCs with NE and sputum samples ± inhibitors. Figure 3.14 shows data from a 
single representative experiment of four. As demonstrated, when SLPI and PIT were 
used to inhibit the free proteases (NE and sputa), despite full/partial rescuing of 
CD86 reduction, surprisingly there was increased cell death (PI
+) following the 
treatments. Necrotic cell death was more apparent when protease-inhibited mDCs 
were incubated with CF sputum samples. 
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Figure 3.13. The reduction of mDC CD86 by purified NE is prevented by SLPI 
and PIT 
 
Purified NE (2µM) and pooled COPD (n=18) and CF (n=9) sputa (containing 0.2µM and 3.39µM 
active NE respectively) were pre-incubated with either SLPI (8µM) or a cocktail of protease inhibitors 
tablet (PIT), before incubation with mDCs for 90 minutes at 37°C. A) Representative flow cytometry 
histograms shown. B) Pooled data from 3 experiments ± inhibitors presented. Values represent mean 
± SD [* indicates significant difference (p<0.001) compared to uninhibited NE/sputa-treated mDCs]. 
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Figure 3.14. NE inhibition induces DC necrosis 
 
Purified NE (2µM) and pooled COPD (n=18) and CF (n=9) sputa (containing 0.2µM and 3.39µM NE 
respectively) were pre-incubated with either SLPI (8µM) or a cocktail of protease inhibitors tablet 
(PIT), before incubation with mDCs for 90 minutes at 37°C. Subsequently the cells were analysed by 
flow cytometry. A) Representative treated-mDCs CD86 expression data from one of 3 experiments 
shown. B) A sample of treated mDCs in each group was also stained with PI and annexin V and 
analysed by flow cytometry. As annexin V was negative in all cases, only PI data is shown. 
A. 
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3.2.7. Western blot analysis confirmation of enzymatic cleavage of murine CD86 
by NE 
 
Following the observations that NE and sputa were able to affect the 
expression of CSMs and that protease inhibitors were able to alleviate this effect, it 
was deemed necessary to determine whether NE enzymatic activity was responsible 
for their shedding. For practical reasons (commercially available/reliable polyclonal 
Ab for Western blot analysis) CD86 was chosen for this part of the study. The Ab to 
CD86 had been raised in goat (R and D Systems, Oxon, UK) and hence a rabbit anti-
goat immunoglobulin (Ig) G secondary Ab (DAKO, Cambridgeshire, UK) was used 
to detect it.  
 
The CD86 cDNA is comprised of 1183 nucleotides, and exhibits a single 
large open reading frame of 927 nucleotides. The encoded polypeptide is 309 amino 
acids (aa) long and exhibits many features common to type I Ig superfamily 
membrane proteins. The mature protein consists of an approximately 222 aa extra-
cellular region, and a hydrophobic trans-membrane domain of about 20 aa, and a 
cytoplasmic tail of approximately 44 aa (Freeman et al., 1993). The CD86 is heavily 
glycosylated and its extra-cellular domain contains 9 potential N-linked 
glycosylation sites. The CD86 glycosylated protein has a MW of 60-100 kDa, which 
reduces to 34kDa after N-glucanase treatment (Hathcock et al., 1993). Western Blot 
analysis for CD86 (Figure 3.15 A, lane 1 and 2) showed that mDC lysate solutions 
contained a protein detected by the goat anti-murine CD86 Ab, which had a 
molecular weight consistent with that of the CD86 protein (Freeman et al., 1993; 
Freeman et al., 1993). Indeed, the band around 38kDa may represent the unmodified 
protein while proteins migrating between 38 and 50kDa may represent glycosylation 
intermediates. In addition, mDCs incubated with NE released few proteins in the 
supernatant that cross-reacted with anti-CD86 Ab, the main one having a similar 
molecular weight than the one found in lysates (60kDa), suggesting that indeed this 
is a product of CD86 cleavage by NE. The slight difference between the lysate and 
the supernatant-derived molecule (lanes 1-2 and 4 respectively) likely reflects the 
presence of the intra-cellular portion (7kDa) in the lysate-derived molecule absent in Chapter 3: The effects of cigarette smoke condensate and lung inflammatory mediators on dendritic cell phenotype and function 
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the species cleaved from the cell surface. As expected the supernatant analysed from 
mDCs control group did not contain any CD86 fragments (lane 3). To ensure that the 
secondary rabbit anti-goat Ab does not react with the CD86 protein, a second blot 
prepared in the same way was probed only with the secondary Ab, which when 
developed was blank (Figure 3.15 B). 
 
NE treatment of mDC lysates induced a loss of CD86 immunoreactivity in a 
time- (Figure 3.16 A) and dose-dependent (Figure 3.16 B) manner. The latter is in 
agreement with the FACS data obtained in Figure 3.11 B (bottom graph). The 
finding that few fragments were released (Figure 3.16 A), compared to the almost 
total absence of CD86-reactive material in NE-treated mDC lysates (Figure 3.15 A) 
is probably best explained by the fact that released CD86 is in its ‘native state’ in 
mDCs supernatants whereas the RIPA buffer used for solubilisation of mDCs lysates 
has likely denatured the CD86, hence exposing the NE-sensitive cryptic sites. 
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Figure 3.15. NE cleaves CD86 molecules on mDCs 
 
mDC cell lysate were resuspended in PBS and exposed to 2µM  NE or PBS for 90 minutes at 37°C. 
Supernatants were concentrated 10× and lysates were prepared and ran on a NuPAGE 4-12% Bis-Tris 
polyacrylamide gel, transferred onto a nitrocellulose membrane. A) Membrane was probed with anti-
CD86 polyclonal Ab. Lanes 1 and 2 are samples of the same mDC lysate loaded neat (lane 1) or at 
50% in PBS (lane 2), showing strong staining with the anti-CD86 polyclonal Ab. Lane 3 is 10× 
concentrated supernatant from untreated mDCs showing no evidence of CD86, and lane 4 represents 
supernatant from NE-treated mDCs showing staining with the anti-CD86 Ab. B) A second gel 
prepared as above was only probed with the secondary rabbit anti-goat Ab. Representative (n=2) 
Western blot data are shown. 
A. 
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Figure 3.16. NE cleaves CD86 in mDC lysates 
 
A) mDC cell lysate was incubated with 2µM NE at 37°C for 5-40 minutes. Samples 
were 10× concentrated and ran (10µl) on a NuPAGE 4-12% Bis-Tris polyacrylamide 
gel, transferred onto a nitrocellulose membrane and probed with anti-mCD86 
polyclonal Ab. Lane 1 represents untreated mDC lysates showing CD86 staining, 
lanes 2-6 indicate that majority of the protein is degraded within 5 minutes of NE-
treatment. * denotes non-specific labeling. B) mDC cell lysate (20µl) was incubated 
with 0.5-3µM NE as above for 10 minutes at 37°C. Lane 1 represents untreated mDC 
lysates showing CD86 staining, Lanes 2-5 show a dose dependent degradation of 
CD86 by NE. Representative (n=3) Western blot data are shown. 
 
B. 
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3.2.7.1. SLPI prevents enzymatic cleavage of CD86 by NE in cell lysate 
 
Purified NE (2µM) was pre-incubated with SLPI (8µM) for ~30 minutes prior 
to its addition to the mDC lysate containing the CD86 protein. In agreement with 
data presented in Figure 3.13, the loss of CD86 was largely prevented (Figure 3.17 A, 
lane 2 versus lane 3). However, in lane 3, where SLPI was present in the sample, 
several extra bands were detected which were not previously seen (Figures 3.15 and 
3.16) and were not present in the absence of SLPI in lanes 1 and 2. In addition, the 
strongest band was around 12kDa suggesting that it could be due to cross-reactivity 
of the anti-CD86 Ab with murine SLPI protein in the sample. To test this, the same 
membrane was stripped by submerging it in stripping buffer (100mM 2-
mercaptoethanol, 2% SDS, 62.2M Tris-HCl, pH 6.7) and incubated at 50°C for 30 
minutes with occasional agitation. The membrane was then washed, stripped of the 
Abs and reprobed with primary rabbit Ab to SLPI and secondary goat anti-rabbit 
HRP-conjugated Ab.  As predicted, the extra bands visualized in Figure 3.17 A were 
of SLPI origin and were readily picked up by specific Ab to SLPI (Figure 3.17 B, 
lane 3).  
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Figure 3.17. SLPI prevents NE-cleavage of CD86 
 
mDC cell lysates were resuspended in PBS and exposed to 2µM NE preincubated ± 
SLPI (8µM) for 90 minutes at 37°C. Samples were then run on a NuPAGE 4-12% 
Bis-Tris polyacrylamide gel, transferred onto a nitrocellulose membrane. A) 
Membrane was probed with anti-CD86 polyclonal Ab. Lanes 1 and 2 are samples of 
the same mDC lysate loaded neat (lane 1) or at 50% in PBS (lane 2), showing strong 
staining with the anti-CD86 polyclonal Ab. Lane 3 is lysate treated with SLPI-
inhibited NE, and lane 4 represents lysate treated with NE alone. B) The same 
membrane was stripped and probed with anti-murine SLPI Ab. Representative (n=2) 
Western blot data are shown. 
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3.2.8. Kinetics of CD40, CD80 and CD86 re-expression after NE treatment of 
mDCs 
 
Migration of mDCs towards T cell area of regional LNs is a crucial 
component of DC’s physiology, and hence, of the initiation of an immune response. 
Kinetic experiments using FITC-conjugated molecules to label airway DCs have 
shown that FITC-carrying airway-derived DCs appear in the thoratic LNs as soon as 
6 hours after instillation of FITC-OVA (Vermaelen et al., 2001). To determine 
whether NE treatments induced a durable change in the mDC phenotype, mDCs were 
allowed to recover after 90 minutes of stimulus treatment (2µM NE) by 
supplementing the culture medium with ~15% FCS. FCS is known to contain a rich 
source of protease inhibitors (Johansson et al., 2001) which are able to inactivate NE. 
Cells from duplicate/triplicate wells were washed and stained for FACS at 2 hour 
intervals. Figure 3.18 shows the levels of CSMs re-expression over an 8 hour time 
period.  The expression of CD80 and CD86 on mDCs increased gradually over the 8 
hour period, although their levels did not reach pre-NE levels and were still 
significantly lower 8 hours post NE inhibition by FCS. Interestingly, CD40 levels did 
not recover at all during this period. 
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Figure 3.18. Re-expression of CD40, CD80 and CD86 after NE treatment of 
mDCs 
 
mDCs were plated in serum-free medium and treated with NE (2µM) for 90 minutes 
at 37°C. FCS (15%) was then added to the wells (t 0) to inhibit NE and re-expression 
of CD40, CD80 and CD86 analysed every 2 hours up to 8 hours post inhibition. 
Expression on iDCs is given for comparison. Values represent mean ± SD of three 
independent experiments, each performed in triplicate (* and ** indicate significant 
difference,  p<0.01 and p<0.001 respectively, compared to corresponding control 
mDCs). 
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3.2.9. NE interferes with normal LPS-induced maturation of iDCs 
 
Since iDCs are exposed to bacterial or host-derived maturation signals in the 
context of high NE concentration in inflammatory conditions such as COPD and CF, 
it was decided to expose iDC to LPS (2µg/ml) and NE (2µM) simultaneously for 4 
hours in serum-free conditions. In this way the inflammatory environment of the lung 
could be mimicked in vitro. Figure 3.19 A shows that the iDC + NE treatment 
resulted in lower expression of CSMs, indicating that (as mentioned above) not only 
mDCs, but iDCs are also susceptible to the enzymatic activity of NE, and in addition 
NE interferes with normal DC maturation upon LPS treatment. Even more 
significantly, it was shown that compared to iDCs + LPS alone, iDCs incubated with 
both LPS and NE had reduced levels of CSMs.  
 
Interestingly, in these conditions, LPS- and LPS/NE-stimulated iDCs were 
still able to up-regulate MHCII on their surface compared to PBS-treated iDCs 
(p=0.003 and p=0.01 respectively). iDCs exposed to NE alone had also slightly 
increased levels of MHCII (although not statistically significant). 
 
Concomitantly, the levels of the DC activation cytokines IL-12p40 and TNF-
α were drastically reduced in iDCs simultaneously submitted to LPS and NE, 
compared with iDCs treated with LPS alone (Figure 3.19 B). Previously cytokines 
such as IL-2 (Ariel et al., 1998) and IL-6 (Bank et al., 1999), as well as TNF-α (van 
Kessel et al., 1991) have been shown to be cleaved as a result of NE enzymatic 
activity, although there is no evidence in the literature showing that NE could 
directly affect IL-12. To test this hypothesis, recombinant murine IL-12p40 (1ng/ml) 
was co-incubated with NE (2µM) for 4 hours at 37°C. Then SLPI was immediately 
added to stop the NE activity and the concentration of IL-12p40 was measured by a 
specific ELISA kit (R and D Systems, Oxon, UK). As shown in Figure 3.20, co-
incubation of IL-12p40 protein with active NE resulted in total loss of the protein in 
the mixture, and it could no longer be detected by the ELISA assay. 
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Figure 3.19. iDCs fail to mature normally when simultaneously stimulated with 
LPS and NE 
 
iDCs were plated in serum-free medium and treated with either PBS (ctrl), LPS (2µg/ml) alone, NE 
(2µM) alone or LPS and NE together, for 4 hours at 37°C. Following treatment, supernatants were 
collected and cells were washed, stained and fixed for FACS analysis. A) Flow cytometry data was 
analysed and expressed as % change in MFI relative to iDC + PBS Controls (mean ± SD, n=3). B) 
Supernatants were analysed for pro-inflammatory cytokines IL-12p40 and TNF-α by ELISA. Values 
represent mean ± SD of n=3 independent experiments performed in triplicate wells (* indicates 
statistical significant difference, p<0.01 compared to corresponding controls; ND=non-detected).  
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Figure 3.20. Proteolytic processing of IL-12p40 by human NE 
 
Murine recombinant IL-12p40 (1000pg/ml) protein was incubated ± 2µM NE for 5 
hours at 37°C. The samples were then treated with SLPI to inhibit free NE and were 
analysed by murine IL-12p40 ELISA (n=3 independent experiments, * indicates 
statistical significance compared to control samples (p<0.0001). 
 
 
 
 
 
 
 
 
 
 
* Chapter 3: The effects of cigarette smoke condensate and lung inflammatory mediators on dendritic cell phenotype and function 
  124
3.2.10. NE impairs the function of DCs: reduction in lymphocyte proliferation 
following OVA pulsing of DCs  
 
To assess whether NE impaired the function of DCs, a DC-T cell system was 
adapted to address this issue as will be described below. Firstly, to optimise this 
system the mDCs were pulsed with various concentrations of chicken egg OVA323–
339 peptide (Peptides International, Kentucky, USA) for 90 minutes at 37
oC and co-
cultured with D011.10-derived transgenic spleen lymphocytes. Activation of the 
transgenic DO11.10 CD4
+ T cells was assessed after 48 hours by cytokine analysis 
of 100µl of the supernatants and determining proliferation by adding Alamarblue™ 
(Serotec, Oxford, UK) to the cells. These preliminary experiments indicated that the 
optimum concentration of OVA was 0.1µM, since it allowed measurement of higher 
and lower proliferative responses in culture.  
 
Consequently OVA-pulsed control mDCs or NE-treated mDCs (10
4) were co-
incubated with
 DO11.10 lymphocytes (10
5). Figure 3.21 shows that pulsed DCs 
induced the proliferation of splenocytes to the same extent as Concanavalin A 
(ConA), a non-specific mitogen. By contrast, mDCs pre-treated with NE were less 
effective at inducing splenocyte proliferation (p=0.042), In parallel, when the 
cytokine profile of supernatants was assessed 48 hours post DC:T cell co-culture, 
TNF-α, IFN-γ and IL-2 levels were drastically reduced in supernatants arising from 
NE-treated mDCs. Whether NE affected type 2 cytokines such as IL-4 and IL-5 is 
difficult to ascertain using this protocol as their levels were very low. 
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Figure 3.21. NE-treated mDCs have impaired antigen presenting ability 
 
mDCs (from BALB/c wild-type mice) were treated with PBS or NE (3µM), washed, pulsed with 
OVA peptide (0.1µM) for 90 minutes at 37°C, and washed 3× with PBS. Spleen lymphocytes were 
purified from 2-4 D011.10 transgenic mice and incubated with NE-treated, OVA-pulsed mDCs at a 
ratio of (1:10, mDC [10
4/well] : lymphoctye [10
5/well]) in a 96-well plate and incubated at 37°C. 
ConA was used at a concentration of 2µg/ml as a positive control. Half of the supernatant (100 µl) was 
removed and saved for cytokine analysis after 24 hours and Alamarblue™ solution was added at a 
20% final concentration to each well. A) Shows lymphocyte proliferation measured after 48 hours. 
Values represent mean ± SD of n=3 independent experiments. * indicates statistical significance (p< 
0.05). B)  Cytokine output following the co-culture was analyzed using a Th1/Th2 CBA kit (BD 
Biosciences, San Jose, USA). A representative experiment of two is shown. 
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3.3. DISCUSSION 
 
  The principal novel observations arising from the data in this chapter are that: 
(i) CSC kills DCs by inducing necrosis, (ii) NE-containing lung inflammatory 
secretions from patients with COPD or CF are able to disable DC function by 
reducing their cell surface CSMs, and (iii) purified NE also down-regulates DC 
CSMs, inhibiting their antigen presenting capability.  
 
3.3.1. The effects of cigarette smoke condensate on DCs 
 
  A number of studies have implicated cigarette smoking as harmful to the 
innate and adaptive immune responses (see Chapter 1, section 1.5). Several lines of 
evidence suggest that cigarette smoking alters the respiratory tract’s ability to defend 
itself from infection. Cigarette smoking is established as the main aetiological factor 
for COPD. Even individuals exposed passively to CS have higher rates of respiratory 
illnesses (Marcy and Merrill, 1987). However, the precise pathogenic mechanisms of 
the disease are still relatively poorly understood. APCs are an important component 
in the initiation and maintenance
 of adaptive immune responses. Interestingly, there 
is a paucity
 of data regarding the impact of CS on antigen presentation and the 
current data in the literature are very contradictory.  In a recent study D’hulst and co-
workers (2005) observed an infiltration of activated DCs in airways and lung 
parenchyma of CS-exposed mice. Indeed this observation was in line with two earlier 
studies that concluded cigarette smoking increases the number of human pulmonary 
DCs/LCs (Soler et al., 1989; Casolaro et al., 1988). On the contrary, two elegant 
studies by Robbins et al. (2004 and 2006) established that CS decreased the
 number 
and activation status of DCs in murine lung tissue. They also demonstrated that 
chronic CS exposure impairs the immune response against adenovirus and 
Pseudomonas aeroginosa (P.a.) (Robbins et al., 2004; Drannik et al., 2004). 
Likewise, CSC has been shown to suppress human DC function leading to 
preferential induction of Th2 priming in vitro (Vassallo et al., 2004). Nicotine has 
also been shown to affect the differentiation and functional maturation of human 
DCs in vitro (Nouri-Shirazi and Guinet, 2003; Guinet et al., 2004). Moreover, Chang
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and co-workers (1990) have reported no change in the ability of APCs
 from lung-
associated lymph nodes (LN) of CS-exposed mice to stimulate
 T cell proliferation. 
Overall, whether or not CS impacts APCs remains an unresolved issue. 
 
Exposing animals to direct CS is illegal in UK universities according to 
Home Office guidelines. Therefore to further elucidate the effects of CS on DCs, 
attempts were made to administer fresh CSC into mouse lungs but it was very 
laborious and could not be done routinely due to the repeated anesthetisations and i.t. 
procedures involved in these experiments.  Moreover, preliminary experiments 
showed mice receiving a single dose of 100% or 50% CSC did not have significant 
differences in their BAL fluid cell types/numbers and cytokines compared to control 
group receiving PBS alone, 24 hours post treatment (not shown). Therefore, the 
decision was taken to test the effects of CSC on murine DCs in vitro. Early 
experiments indicated that, as hypothesised, CSC had an adverse effect on the 
phenotype of DCs and was able to down-regulate their CSMs and MHCII in a dose-
dependent fashion (Figure 3.6). However, upon PI/annexin V staining of the CSC-
treated DCs the reduction of the cell surface markers examined was found to be due 
to the induction of necrosis (and partly apoptosis), and did not seem to be as a result 
of CSC-induced intra-cellular signalling (Figure 3.7). The in vitro effects of CSC 
observed here were irrespective of the maturation state of DCs and the presence or 
absence of serum (which contains antioxidants) in the culture media.  
 
Oxidative stress is responsible for many of the effects of cigarette smoking 
seen in biological systems. Oxidants such as hydrogen peroxide have been shown to 
inhibit apoptosis (e.g., via inhibition of caspases) and induce necrosis (Hampton and 
Orrenius, 1997; Samali et al., 1999; Lee and Shacter, 1999). Our preliminary data 
presented here is in agreement with these findings, and with the previous studies 
where CSC was shown to prevent apoptosis (through inhibition of caspase activation) 
and induced necrosis (Wickenden et al., 2003; Piperi et al., 2003). These 
observations may provide a possible mechanism as to why Robbins et al. (2004) 
observed a reduction in lung DCs of CS-exposed mice. Furthermore, antioxidants 
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necrosis, by preventing the inhibitory effect of CSC on caspase activation in an 
alveolar epithelial type II cell line (A549), primary
 human umbilical vein endothelial 
cells (HUVEC) and Jurkat T cells (Wickenden et al., 2003). Although these data 
might be also relevant to the current study, nonetheless as it stands now, better 
controlled in vitro and in vivo systems examining the effects of CS ± antioxidants on 
DCs are required to fully address this issue. 
 
3.3.1. The effects of NE and sputum samples on DCs 
 
COPD and CF affect millions of people worldwide. These conditions are 
characterised by an activation of the innate immune system, involving mostly 
neutrophils in CF and both neutrophils and macrophages in COPD. Because of an 
excessive and maladaptive activation of neutrophils, very high levels of NE are 
released into the lung fluid of patients with COPD and CF (Birrer et al., 1994; Rees 
et al., 1997 and 1999; Suter, 1989), and in combination with the pathogens lead to 
severe exacerbations in affected individuals. As DCs bridge the innate and acquired 
immune systems and because of the abundance of proteases, e.g., NE, in COPD and 
CF patients’ sputa, it was hypothesised that inflammatory lung secretions from these 
patients might interfere with the initiation of acquired immunity by inactivating or 
biasing DC function.  
 
The data presented in the latter part of this chapter, demonstrate the novel 
finding that NE concentration correlated with the ability of sputa to reduce DC CD86 
CSM expression and that CF sputa were more potent than COPD sputum samples 
(Figure 3.9). This difference could be explained by the fact that CF sputum samples 
contained far higher concentrations of active NE than the COPD sputum samples 
(Figure 3.8), which is well documented in the literature (Fujita et al., 1990; Schuster 
et al., 1995; Liu et al., 1999; Sagel et al., 2001; Tumkaya et al., 2006). The reason 
COPD and CF lung secretions contain high concentrations of NE is that although 
natural NE inhibitors are normally found in lung fluids and their levels even increase 
in the COPD and CF lungs, protection is inadequate against the overwhelming 
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inflammation (Khan et al., 1995; Birrer et al., 1994; O’Connor CM et al., 1993). On 
the other hand, as mentioned in Chapter 1 (1.5.1.1.), in chronic inflammatory tissues 
most of the secreted elafin as well as other natural protease inhibitors are inactivated 
by oxidation or proteolytic cleavage, and can not efficiently inhibit the free proteases 
in such pathologies (Nobar et al., 2005; Greene et al., 2003; Vogelmeier et al., 1997; 
Carp et al., 1982; Taggart et al., 2001).  
 
Amongst the three CSMs examined following the brief treatment of DCs with 
the sputum samples (Figure 3.10), despite significant down-regulation of both CD80 
and CD86, CD40 levels were up-regulated (as assessed by total MFI expression on 
cell surface). This observation was quite intriguing since in parallel experiments, 
where purified human NE was used (discussed below) there was a general down-
regulation in all of the three CSMs examined, including CD40, although with 
different kinetics. Several arguments could explain this phenomenon. The most 
relevant argument is that, human NE used here has been chromotographically 
purified and is dissolved in a buffer (50mM Tris, 0.5M NaCl, 0.1% Triton X-100, pH 
8), whereas the sputum samples came from COPD and CF lungs and hence contain 
various human and pathogen-derived molecules such as cytokines, LPS and bacterial 
unmethylated CpG DNA. Therefore it is likely that other factors present in these 
sputum samples could compete with and over-ride the NE-mediated CD40-down-
regulation process, possibly by activating the specific signalling pathways 
responsible for CD40 (but not CD80 and CD86) transcription and/or relocation to the 
cell surface. At least three families of mitogen-activated protein kinases (MAPK), 
that is, extra-cellular signal-regulated kinases (ERK), c-Jun N-terminal kinases 
(JNK) and p38 MAPK, as well as the NF-κB family of transcription factors 
(composed of 5 members; p65 [Rel-A], Rel-B, c-Rel, p50 and p52), are involved in 
the DC maturation process. To support this argument, the general consensus in the 
literature is that CD40 signalling takes place predominantly via the IFN-γ-activated 
signal transducer and activator of transcription 1α (STAT-1α) and NF-κB signalling 
pathways (Qin et al., 2005; Benveniste et al., 2004; Nguyen and Benveniste, 2000), 
but not the MAPKs (Nakahara et al., 2004; Sun and Fernandes, 2003; Ardeshna et al., 
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controlled via the JNK and p38 MAPK signalling pathways (Nakahara et al., 2004; 
Ardeshna et al., 2000). Therefore, as mentioned above, it could be argued that certain 
factors present in the sputum samples at high concentrations, such as oxidants (e.g., 
reactive oxygen species), might be responsible for activating the STAT-1α and NF-
κB signalling pathways leading to rapid replacement of ‘cleaved’ CD40 on treated 
mDCs. Indeed, the number of CD4
+, CD8
+ cells and macrophages expressing NF-κB, 
STAT-4 and IFN-γ proteins is increased in mild/moderate COPD disease (Di Stefano 
et al., 2004). Oxidative stress activates NF-κB-mediated transcription of pro-
inflammatory mediators either through activation of its activating IκB-α kinase or the 
enhanced recruitment and activation of transcriptional co-activators. Enhanced NF-
κB-co-activator complex formation results in targeted increases in histone 
modifications, such as acetylation leading to inflammatory gene (e.g., CD40) 
expression (Rahman, 2005). 
 
The sputum data prompted the need to determine whether NE in isolation 
could also influence mDC CSM expression levels. It was found that NE-treatment of 
mDCs did not affect MHCII expression but significantly reduced CD40, CD80 and 
CD86 expression (Figure 3.11). Comparison of Figures 3.9 and 3.11 B (bottom 
graph) indicate that for the same concentration of NE, sputa were slightly more 
efficient at down-regulating CD86 expression than purified NE, suggesting that other 
factors may also be operative. Most importantly, the reduction in expression of 
CSMs on mDCs was not due to cell apoptosis and/or necrosis following treatment of 
DCs with pathophysiological concentrations of NE (1-3 µM), as measured by 
annexin V and PI staining (Figure 3.12). 
 
Furthermore, the reduction in CD86 caused by the COPD sputum samples 
and NE was abrogated by the use of both the NE inhibitor SLPI, and that of a broad 
spectrum protease inhibitor cocktail (PIT) (Figure 3.13). In contrast, SLPI and PIT 
were not fully effective at reversing the effect of CF sputum samples on CSM 
expression (Figure 3.13, ~36% inhibition in both cases). This may reflect the fact 
that other proteases (not inhibited by SLPI and the protease inhibitors present in the 
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secretions or that the protease inhibitors may be less active in the complex mix of 
inflammatory sputa, or due to possible cell death (see below). Incidentally, Rees et al. 
(1999) found that 90% inhibition of pure NE required half the concentration of a 
natural NE inhibitor (human monocyte/neutrophil elastase inhibitor) required to 
inhibit 90% equivalent NE activity in CF samples. Equally these protease inhibitors 
might partially lose their activities when co-incubated with the CF sputum samples 
prior to mDC treatment. Indeed, as explained above, although present in high 
amounts in lung inflammatory secretions, it has been shown that endogenous SLPI, 
elafin and α1-PI are inactivated in these secretions by proteolytic cleavage and 
oxidation (Nobar et al., 2005; Greene et al., 2003; Vogelmeier et al., 1997; Carp et 
al., 1982; Taggart et al., 2001; Suter, 1989). Possible candidates, explaining the 
partial inhibition of proteases in CF sputum samples by PIT (Figure 3.13), could 
include the degradative enzymes secreted by bacteria frequently colonising the CF 
airways, such as P.a (Doring et al., 1983 and 1984) and Staphylococcus aureus (S.a.) 
(Prokesova et al., 1988 and 1991). P.a. secretes several proteases (e.g., elastase and 
alkaline protease) considered as important virulence factors, which are able to cleave 
cytokines (such as IL-6 and IL-8; Matheson et al., 2006), chemotactic proteins (such 
as RANTES and MCP-1; Leidal et al., 2003) and other secreted (e.g., surfactants) 
and cell surface proteins (e.g., proteinase-activated receptor 2) that have important 
roles in the innate immune responses to P.a. (Mariencheck et al., 2003; Dulon et al., 
2005). Additionally, metalloproteases and serine proteases secreted by S.a. have been 
shown to modulate lymphocyte responses (Prokesova et al., 1988 and 1991), and 
similar to P.a. elastase and metalloproteases, are able to degrade proteins involved in 
host defense such as human Ig (Prokesova et al., 1995) and human LL-37 
(Sieprawska-Lupa et al., 2004). 
 
To our surprise, upon the treatment of mDCs with SLPI/PIT-inactivated-
NE/sputum samples (Figure 3.14 B) there was increased staining with PI (but not 
annexin V) compared to mDCs treated with active NE/sputa. The PI positivity was 
the highest when mDCs were treated with SLPI/PIT-inactivated CF sputum samples 
compared to inactivated COPD sputa/NE (Figure 3.14 B). This is a very intriguing 
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inhibitors. The NE-NE inhibitor complexes appear to be cytotoxic to DCs and lead to 
the destruction of these cells as observed here (Figure 3.14 B). This finding requires 
more in-depth examination in future studies. 
 
In an attempt to investigate the mechanism by which NE was able to down-
regulate the CSMs, a polyclonal Ab to murine CD86 was employed to detect any 
possible cleaved fragments of this CSM in supernatants of NE-treated mDCs and in 
NE-treated mDC lysates.  As hypothesised, NE was able to release the extra-cellular 
portion of CD86 in mDC supernatants (Figure 3.15 A). NE was also able to degrade 
CD86 protein in mDC lysates and this was in a time- and dose-dependent manner 
(Figure 3.16 A and 3.16 B). To further prove that the proteolytic activity of NE was 
responsible for this down-regulation, NE was treated with SLPI prior to addition of 
mDC lysate. The degradation of CD86 in lysate was prevented by SLPI-inactivated 
NE (Figure 3.17 A), which was in agreement with the earlier FACS data (Figure 
3.13). These observations are further strengthened by recent data by Lofdahl and 
colleagues (2006) showing that alveolar macrophages isolated from BAL fluid of 
COPD patients had a lower expression of CD86 molecule compared with ‘healthy’ 
smokers. Similarly, Droemann et al. (2005) have demonstrated that TLR2 expression 
is decreased on alveolar macrophages in cigarette smokers and COPD patients, 
which might also be as a result of increased proteolytic activity of NE in these 
subjects. 
 
The decision was then taken to examine whether the effect of NE on CSMs 
expression was short-lived or whether it may impair the function of mDCs more 
durably. Figure 3.18 shows that up to 8 hours post NE treatment, a time-frame 
relevant to DC activation and migration to local LNs (Vermaelen and Pauwels, 2003), 
CSM re-expression was only partial; in particular, CD40, an essential molecule for 
providing an activation/anti-apoptotic signal to the cells (Bjorck et al., 1997; Koppi 
et al., 1997; Ludewig et al., 1995), did not show any increased level of expression 
over the 8 hour time period. This suggests that chronic NE over-expression in the 
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In addition to reducing mDC CSM expression, NE also prevented the LPS-
induced maturation of iDCs (Figure 3.19 A). In these experiments, NE could 
potentially be acting by either reducing the levels of LPS-induced CSMs or by 
interfering with the LPS signalling pathway, e.g., by cleaving CD14 receptor 
molecules (Henriksen et al., 2004; Le-Barillec et al., 1999). DCs simultaneously 
treated with LPS and NE up-regulated MHCII levels equally which indicates that 
LPS was able to signal intra-cellularly and that NE is unlikely, in this model, to 
interfere with the LPS transduction machinery. The logical explanation is that NE 
acts by cleaving susceptible CSMs when they arrive at the cell surface, out-
competing the LPS-induced transcription of them. The long term (4 hours) effect of 
NE on MHCII expression on DCs is interesting: NE alone slightly up-regulated 
MHCII levels on iDCs, but this did not reach significance (Figure 3.19 A), 
demonstrating that, as shown by our group and others previously in other cell types 
(Sallenave et al., 1994; Devaney et al., 2003; Nakamura et al., 1992), NE can signal 
through receptors at cellular surfaces. Recent data suggests that NE signals via the 
cell surface membrane-bound TLR4 (Devaney et al., 2003), by activating the NF-κB 
signalling pathway (Lee et al., 2006; Walsh et al., 2001). Indeed, the up-regulation of 
MHCII on DCs and macrophages is dependent on NF-κB transcription factor (Sun 
and Fernandes, 2005; Rescigno et al., 1998; Qin et al., 2005), and consequently, 
could explain the observation that MHCII is up-regulated upon NE treatment of iDCs. 
However, whether this differential effect of NE on iDCs (up-regulating MHCII while 
down-regulating CSMs levels) is physiologically important is unclear.  
 
Relatedly, iDCs simultaneously treated with LPS and NE concomitantly 
released significantly lower levels of IL-12p40 and TNF-α in culture (Figure 3.19 B). 
It could be argued that the reduction in these cytokines is also due to the proteolytic 
activity of NE; since NE released from activated neutrophils has been shown to 
cleave recombinant TNF-α (van Kessel et al., 1991). However, to date there is no 
data suggesting that IL-12 is also affected by NE. Therefore to test this, recombinant 
murine IL-12p40 subunit was co-incubated with NE and analysed by ELISA. As 
shown in Figure 3.20, IL-12p40 was fully degraded in the presence of NE and could 
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function and induction of Th1 responses (Romagnani, 1995). These observations 
further confirm the immunomodulatory effects of NE on DC function and maturation. 
 
Ultimately, it was important to demonstrate whether the NE-differential 
effect on CSM levels on DCs had functional consequences on DC-lymphocyte 
interactions. Figure 3.21 shows that indeed, NE treatment of mDCs followed by 
OVA-pulsing significantly reduced lymphocyte proliferation and TNF-α, IFN-γ and 
IL-2 cytokine output. The output of type 2 cytokines (IL-4 and IL-5) by stimulated 
lymphocytes was very low, making it impossible to interpret the effects of NE on 
Th2 responses, if any.  An interesting follow up study to these experiments would be 
to pulse DCs with an antigen (e.g., Ad) and expose them to either PBS or NE in vitro, 
before adoptively transferring them into murine lungs. Consequently, the immune 
responses of mice towards i.t. Ad infection could be analysed as previously described 
by us (Roghanian et al., 2006b). Alternatively, NE/sputum samples (containing high 
NE concentrations) could be instilled into mouse lungs, and the lung DCs could be 
analysed (for expression of CSMs and their antigen-presenting capability to naïve 
lymphocytes) as described above. These experiments would shed further light into 
the effects of these NE-rich samples on DCs phenotype/function and the subsequent 
immune responses in vivo. The observations that NE-treated DCs were less efficient 
at stimulating lymphocytes are supported by earlier limited data published by Abe et 
al. (2002) and Knight et al. (1997). Abe and co-workers showed that patients with 
COPD who had exacerbations due to NTHI  had a decreased lymphocyte 
proliferative response to P6 (a 16-kD lipoprotein that makes up ~1-5% of the total 
outer membrane proteins of the NITH) compared with patients with COPD with no 
exacerbations due to NITH, and compared with healthy control subjects. On the other 
hand, Knight and colleagues (1997) isolated macrophages separated from lavage 
samples obtained from lungs removed at transplantation from patients with CF and 
other lung disease, and compared them with circulating monocytes from the same 
patients for their ability to stimulate allogeneic normal circulating lymphocytes. They 
elegantly demonstrated that, compared to control non-CF patients, macrophages 
separated from CF patients were unable to stimulate allogeneic lymphocytes and to 
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assays. Although the role of NE was not studied by these groups, NE-cleavage of 
CSMs might be responsible for the defect in antigen presentation by lung APCs in 
COPD and CF patients, as demonstrated in the current project (Roghanian et al., 
2006a). 
 
The experiments performed in this part utilised murine DCs in conjunction 
with human NE/sputum samples. However, it should be noted that the murine and 
human CD40, CD80 and CD86 proteins share considerable homologies at protein 
levels (~54%, 46% and 50% identity, respectively; see Appendices III-V). Most 
importantly a recent study by Wiesner et al. (2005) concluded that substrate 
specificity and efficiencies of substrate hydrolysis of murine NE are very similar to 
human NE, thus supporting the validity of conclusions drawn from the data presented 
in this chapter, and similar studies using human proteases and protease inhibitors in 
animal models (Churg et al., 2003; Delacourt et al., 2002; Dhami R et al., 2000; 
Rees et al., 1999; Belaaouaj et al., 1998; Rees and Brain, 1995). 
 
  Although the characteristics and functional properties of lung
  DCs are 
extensively studied in animal models, very few data
  concerning their human 
counterparts are available. This is mainly
  due to the poor availability of tissue 
(especially when compared
  with animal models), the labour-intensive and time-
consuming
 experimental procedures, and the
 lack of specific markers for DCs in the 
past (Vermaelen and Pauwels, 2005). The ability to access and characterise DCs and 
their precursors in COPD and CF is critical to the understanding of immune 
modulation in these pathologies. A recent study by Donnenberg and Donnenberg 
(2003) demonstrated that mDCs and their monocytic and plasmacytoid precursors 
can be sampled in the lung by the minimal invasive procedure of BAL, despite their 
relative scarcity and can be detected by rare event multi-parameter flow cytometry. 
Demedts and colleagues (2005), by using recently developed DC specific surface 
markers, also managed to identify different respiratory DC subsets in
 lung digests of 
patients who underwent lobectomia
 or pneumectomia for various reasons (mostly 
lung cancer). In a more recent study, McCarthy et al. (2007) investigated the 
respiratory tract DC surface markers, which comprised approximately 0.5% of viable Chapter 3: The effects of cigarette smoke condensate and lung inflammatory mediators on dendritic cell phenotype and function 
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sputum cells, in induced sputum samples taken from steroid-naïve, allergen-
challenged and allergen-naïve subjects. Therefore, these newly established 
methodologies could ideally be employed in future studies to elucidate the subtypes 
of DCs and their activation status in COPD and CF lung tissue sections and BAL 
fluids. These studies would further help investigators to confirm the in vitro findings 
(showing the adverse effects of COPD and CF patients on DCs) reported in the 
current study. 
 
  In conclusion, the data presented here show that NE and NE-containing 
secretions from patients with COPD or CF are able to disable DC function by 
interfering both with the ability of iDCs to mature in response to bacterial LPS 
stimulation, and by reducing the antigen presenting capability of mDCs.  However, 
the in vivo effects of these changes still remain to be investigated and also these 
experiments should be further reassessed using human and murine lung DCs. The 
NE-induced inhibition of DC activation and secretion of pro-inflammatory Th1 
cytokines (e.g., IL-12) may be instrumental in the inability of these patients to clear 
semi-facultative intra-cellular pathogens in the lung, such as P.a., B.c. and NTHI, as 
suggested recently by a variety of animal and human studies (King et al., 2003; 
Evans et al., 2002; Moser et al., 2002; Martin and Mohr, 2000; Moser et al., 1997). 
In that context, therapeutic interventions to over-express the NE inhibitors such as 
SLPI and elafin could be dually advantageous (see Chapters 4 and 5; Roghanian et 
al., 2006b), firstly by inhibiting NE, and secondly as shown recently, by providing an 
antibacterial shield in the lungs (Gibbons et al., 2006; Fitch et al., 2006; Williams et 
al., 2006; McMichael et al., 2005a; Hiemstra et al., 2004; Simpson et al., 2001). 
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3.4. SUMMARY 
 
  The work described in this chapter demonstrates that exposure of DCs to 
mainstream soluble components of the CS result in cell death (primarily necrosis). 
On the other hand NE and NE-containing lung inflammatory secretions from patients 
with COPD or CF are able to disable DC function by reducing their cell surface 
CSMs important in antigen presentation. Furthermore, NE could interfere both with 
the ability of iDCs to mature in response to bacterial LPS stimulation and by 
reducing the allostimulatory activity of mDCs when co-cultured with D011.10-
derived OVA transgenic spleen lymphocytes. 
 
  Chronic inhalation of CS and the presence of high concentrations of NE in 
the respiratory tract may each play important roles in pulmonary adaptive immune 
system by modulating host responses (via down-regulating DC activity) to invading 
respiratory pathogens, and specific therapeutic interventions are required to revert 
this immunosuppression state. 
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APPENDIX I 
 
Table A3.1. COPD patients’ characteristics 
 
COPD sputum samples were obtained as described in Chapter 2. Individual patients’ 
characteristics are listed, including FEV1, FEV1/FVC and smoking status. Data 
produced by collaborators at Edinburgh Royal Infirmary. 
 
 
 
PATIENT'S 
NO. SEX  AGE  FEV1 
FEV1 
PRED 
FEV1/FVC 
RATIO 
SMOKER-
CURRENT 
SMOKER-
EX PACK/YEAR 
1 F  76  0.8  57  70  Yes  -  60 
2 F  79  0.6  38  48  -  Yes  42 
3 M  78  0.51  20  35  -  Yes  50 
4 M  72  0.8  25  43  Yes  -  75 
5 M  83  0.9  31  45  -  Yes  64 
6 M  53  1.55  42  57  -  Yes  54 
7 F  78  0.4  29  42  -  Yes  64 
8 M  60  1.3  35  39  Yes  -  38 
9 F  79  0.6  46  44  Yes  -  60 
10 M  59  1.62  46 53  Yes  -  65 
11 M  64  0.95  30 44  Yes  -  55 
12 M  61  2  57 44  Yes  -  60 
13 F  72  0.7  43  45  -  Yes  60 
14 M  61  2.15  61 57  Yes  -  80 
15 F  77  0.45  32  38  Yes  -  50 
16 F  73  0.75  47  48  Yes  -  30 
17 F  56  0.6  32  46  -  Yes  76 
18 M  73  0.8  -  -  -  Yes  76 
19 M  59  0.45  15 32  Yes  -  20 
20 F  73  0.75  38  50  Yes  -  30 
21 M  67  1.3  38 43  -  Yes  60 
22 M  60  2.4  63 73  -  Yes  80 
23 F  70  0.95  53  79  Yes  -  40 
24 F  71  0.7  41  52  -  Yes  50 
25 M  76  -  -  -  -  Yes  20 
26 M  63  0.72  65 33  No  No  - 
27 M  73  0.8  25 29  Yes  -  30 Chapter 3: The effects of cigarette smoke condensate and lung inflammatory mediators on dendritic cell phenotype and function 
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APPENDIX II 
 
 
Table A3.2. CF patients’ microbiological data 
 
CF sputum samples were obtained as described in Chapter 2. Sputum samples were 
assessed for the presence of microorganisams shown in the table. Microbiological 
analyses were kindly performed by Dr. Catherine J. Doherty from the CF laboratory, 
Medical Microbiology, The University of Edinburgh. 
P.a.,  Pseudomonas aeroginosa; B.c., Burkholderia cepacia; S.a., Staphylococcus 
aureus. 
 
Patient’s 
No. 
Age (yr) / 
Sex 
P.a. B.c. S.a. Haemophilus 
parainfluenza
β-hemolytic 
Streptococcus 
Yeasts  [NE] 
  µM 
1  57 / M  +            5.59 
2  31 / F            ++  1.7 
3  21 / M      ++      +  0.69 
4  45 / M      ++  +      1.87 
5  20 / F    +++  ++    +    0.70 
6  19 / F  +  ++  +        3.55 
7  36 / M    +++          0.76 
8  29 / M    ++  +        1.89 
9  38 / F  ++      ++      3.21 
10  40 / M  ++            1.42 
11  21 / F      +++ +      2.54 
12  26 / M  +            3.17 
13  57 / M  +            5.62 
14  23 / F  ++            2.39 
15  21 / F  +++            0.62 
16  21 / M  ++  ++          1.06 
17  22 / F  +    +        2.32 
18  24 / F  +            2.75 
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APPENDIX III 
 
CD40 Protein FASTA (Human vs Murine): 
 
Human CD40 - AAH64518 (151 aa)             
 
mvrlplqcvl wgclltavhp epptacrekq ylinsqccsl cqpgqklvsd cteftetecl pcgesefldt wnrethfhqh kycdpnlglr 
vqqkgtsetd tictceegwh ctseacescv lhrscspgfg vkqidicqph fpkdrglnll m 
 
 
Murine CD40 - AAH29254  (289 aa)             
 
mvslprlcal wgclltavhl gqcvtcsdkq ylhdgqccdl cqpgsrltsh ctalektqch pcdsgefsaq wnreirchqh rhcepnqglr 
vkkegtaesd tvctckegqh ctskdceaca qhtpcipgfg vmematettd tvchpcpvgf fsnqsslfek cypwtscedk 
nlevlqkgts qtnvicglks rmrallvipv vmgilitifg vflyikkvvk kpkdnemlpp aarrqdpqem edypghntaa 
pvqetlhgcq pvtqedgkes risvqerqvt dsialrplv 
 
 
Human CD40 (top sequence) vs Murine CD40 (bottom sequence), 
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APPENDIX IV 
 
CD80 Protein FASTA (Human vs Murine): 
 
Human CD80 (B7-1)- AAH42665 (288 aa)   
 
mghtrrqgts pskcpylnff qllvlaglsh fcsgvihvtk evkevatlsc ghnvsveela qtriywqkek kmvltmmsgd 
mniwpeyknr tifditnnls ivilalrpsd egtyecvvlk yekdafkreh laevtlsvka dfptpsisdf eiptsnirri icstsggfpe 
phlswlenge elnainttvs qdpetelyav sskldfnmtt nhsfmcliky ghlrvnqtfn wnttkqehfp dnllpswait lisvngifvi 
ccltycfapr crerrrnerl rresvrpv 
 
 
Murine CD80 (B7-2) - NP_033985 (306 aa)             
 
macncqlmqd tpllkfpcpr lillfvllir lsqvssdvde qlsksvkdkv llpcrynsph    edesedriyw qkhdkvvlsv 
iagklkvwpe yknrtlydnt tysliilglv lsdrgtyscv    vqkkergtye vkhlalvkls ikadfstpni tesgnpsadt kritcfasgg 
fpkprfswle   ngrelpgint tisqdpesel ytissqldfn ttrnhtikcl ikygdahvse dftwekpped   ppdskntlvl fgagfgavit 
vvvivviikc fckhrscfrr neasretnns ltfgpeeala  eqtvfl 
 
 
Human CD80 (top sequence) vs Murine CD80 (bottom sequence), 
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APPENDIX V 
 
CD86 Protein FASTA (Human vs Murine): 
Human CD86 (B7-2)- CAG46642 (323 aa)             
 
mglsnilfvm afllsgaapl kiqayfneta dlpcqfansq nqslselvvf wqdqenlvln evylgkekfd svhskymgrt 
sfdsdswtlr lhnlqikdkg lyqciihhkk ptgmirihqm nselsvlanf sqpeivpisn itenvyinlt cssihgypep kkmsvllrtk 
nstieydgim qksqdnvtel ydvsislsvs fpdvtsnmti fciletdktr llsspfsiel edpqpppdhi pwitavlptv iicvmvfcli 
lwkwkkkkrp rnsykcgtnt mereeseqtk krekihiper sdeaqrvfks sktsscdksd tcf 
 
Murine CD86 (B7-2) - NP_062261 (309 aa) 
 
mdprctmgla ilifvtvlli sdavsvetqa yfngtaylpc pftkaqnisl selvvfwqdq qklvlyehyl gtekldsvna kylgrtsfdr 
nnwtlrlhnv qikdmgsydc fiqkkpptgs iilqqtltel svianfsepe ikldqnvtgn sginltcmsk qghpkpkkmy flitnstney 
gdnmqisqdn vtelfsisns lslsfpdgvw hmtvvcvlet esmkisskpl nftqefpsaq tywkeitasv tvalllvmll iivchkkpnq 
psrpsntask lerdsnadre tinlkelepq iasakpnae 
 
Human CD86 (top sequence) vs Murine CD86 (bottom sequence), 
 
 
Function used to analyse above sequences was FASTA [version 3.4t26 July 7, 2006]. Source: 
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CHAPTER 4 
 
IN VIVO MODULATION OF DENDRITIC CELLS BY ELASTASE 
SPECIFIC INHIBITOR (ELAFIN) 
 
4.1. AIMS AND BACKGROUND 
 
Having established in the preceding results chapter that NE could potentially 
down-regulate the DC CSMs and adversely affect their allostimulatory function 
(Roghanian et al., 2006a), it also seemed logical to study the effects of NE inhibitors 
in that context. 
 
The primary aim of the work described in this chapter was to investigate the 
effects of augmentation of respiratory system NE-inhibitor molecules on the function 
and phenotype of DCs.  The work described in this chapter was primarily performed 
using an adenovirus (Ad)-based strategy (also see Chapter 5) to over-express the 
genes of interest. This approach may allow the evaluation of these constructs for 
gene therapy strategies.  Recombinant Ad gene transfer represents an effective 
method for the transfection of non-dividing cells, such as DCs (Miller et al., 2002). 
On the other hand, Ad DNA is episomal, reducing the risk of insertional mutagenesis 
associated with retroviral gene transfer. The Ad gene transfer approach uses 
replication-deficient Ad vectors which are both E1 and E3 deleted, encoding the 
cDNA for the genes of interest which are under the control of the powerful murine 
CMV promoter, to facilitate cellular expression of the transgene (Sallenave et al., 
1998).  
 
The decision was taken to use elafin in this part of the project, primarily 
because previous studies by investigators in our laboratory and other groups had 
demonstrated that elafin has various immunomodulatory properties, depending on 
the cells and tissues in which it is expressed (see Chapter 1, section 1.7.1.1). In 
addition, elafin transgenic (eTg) mice were available in house. The eTg mouse line 
had previously been developed using a 6.3-Kb fragment containing the human elafin Chapter 4: In vivo modulation of dendritic cells by elastase specific inhibitor (elafin) 
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cDNA under control of the murine CMV promoter (the same as the promoter used in 
the Ad systems), which encodes full length elafin molecule (Sallenave et al., 2003). 
Therefore, in addition to the WT mice, eTg mice were also used in the in vivo 
experiments. It should be noted that the rest of the experiments described herein were 
performed using C57BL/6J WT mice. The decision to use this strain of mouse, rather 
than the BALB/c strain used in previous sections, was made due to the background 
of our in-house eTg mice which were derived from C57BL/6J × CBA strains, 
enabling direct extrapolation and comparison of the data generated in this study.  
 
Since its characterisation in early 90’s (Wiedow et al., 1990; Sallenave and 
Ryle, 1991; Sallenave et al., 1992), elafin has been intensively studied in our 
laboratory, and previous studies by our group (Simpson et at. 2001b) have used the 
Ad gene transfer technology to demonstrate that Ad augmentation of elafin protects 
human alveolar epithelial (A549) cells against the injurious effects of both NE and 
whole activated neutrophils in vitro, and protects murine lungs against acute 
inflammatory injury by Pseudomonas aeroginosa (P.a.)  in vivo. Relatedly, 
McMichael et al. (2005a) also demonstrated that i.t. instillation of Ad-elafin 
significantly reduced the lung Staphylococcus aureus (S.a.) load. Moreover, elafin 
over-expression has been shown to enhance human neutrophil migration in vitro, and 
to augment LPS-mediated neutrophil migration into WT and eTg murine airways in 
vivo (Simpson et al., 2001a; Sallenave et al., 2003). 
 
The source of DCs used in this study was from murine pulmonary DCs. As 
mentioned above, data presented in Chapter 3 demonstrated that both purified NE 
and lung sputa with detectable NE activity could down-regulate DC CSMs and 
consequently affect their T cell-stimulatory capacity. Additionally, NE interfered 
with normal maturation of iDCs in the presence of LPS and reduced the output of the 
pro-inflammatory cytokines IL-12 and TNF-α. The experiments described herein 
were undertaken to investigate whether in vivo genetic augmentation of an NE 
specific inhibitor (elafin) could modulate DC phenotype and function.  
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4.2. RESULTS 
 
4.2.1. Effects of elafin gene augmentation on pulmonary DCs 
 
While studying the effects of NE on DCs in vitro, parallel experiments, 
performed by other members of the laboratory, using two independent systems of 
elafin over-expression in vivo (recombinant Ad [Ad-elafin] and an eTg mouse line) 
indicated that these animals had an enhanced primary immune response towards Ad 
infections (Roghanian et al., 2006b). These intriguing observations led us to 
hypothesise that at least in part some of these effects are due to the influence of 
elafin expression on pulmonary DCs. As mentioned, data presented in Chapter 3 
indicated that NE could be down-regulating DC function and hence expression of a 
specific NE inhibitor such as elafin during infection/inflammation could be an ideal 
strategy to reverse these effects. With regards to these observations, it was deemed 
necessary to study the effects of elafin over-expression on DCs in vivo, as described 
below. 
 
In the lung, DCs reside within and beneath airway epithelium,
 in alveolar 
septa, in the connective tissue surrounding pulmonary
 veins and airway vessels, and 
in the lung vascular compartment (Holt et al., 1990).
 Various cell surface markers, 
including products encoded by the MHC class I and II genes, CSMs, adhesion 
molecules, and FcRs, can be used to discriminate lung DCs from other cell types, and 
to characterise their phenotype and function (Masten et al., 1997; von Garnier et al., 
2005; de Heer et al., 2005). Murine DCs are identified by their expression
 of CD11c 
and have been divided into three major subsets, i.e.,
  myeloid, lymphoid, and 
plasmacytoid, based on the differential
  expression of CD11b and CD45R/B220. 
Murine
  myeloid DCs co-express CD11c and CD11b, but lack CD45R/B220.
 
Lymphoid DCs do not express CD11b or CD45R/B220. Plasmacytoid
 DCs (pDCs) 
co-express CD11c and CD45R/B220, but do not express CD11b (Maraskovsky et al., 
1996; Pulendran et al., 1999; Nakano et al., 2001). In addition, as mentioned, 
different subsets of lung DCs are differentially distributed and can be classed into: 1) 
conducting airway DCs, 2) interstitial DCs, and 3) alveolar DCs (see Figure 1.5). Chapter 4: In vivo modulation of dendritic cells by elastase specific inhibitor (elafin) 
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As DCs are a rare population, representing only around 1% of total lung cells 
in the absence of ongoing inflammation and immune responses (Robbins et al., 2003; 
Masten et al., 2004), their isolation is extremely laborious. Hence, at the start of this 
part of the project it was indispensable to choose a reliable, economical and efficient 
method to analyse lung DCs. Of the few lung DC analysis strategies available at the 
time of this project three were chosen and carried out in order to find an ideal 
protocol for our experiments (see below). In all the following experiments, lungs 
were perfused to remove blood cells and hence minimise contamination of the cell 
preparations with blood monocytes and circulating APCs (Figure 4.1). Enzymatic 
digestion of the lung tissue to extract viable interstitial lung cells was accomplished 
with collagenase A. Also DNase was included in the enzyme solution to minimize 
cell loss due to DNA-induced clumping. The cells were then subjected to red cell 
lysis treatment. In the final step, freshly isolated cells were stained with a range of 
cell surface markers (see below). The detailed procedure for preparation of lung 
single cell suspensions has been described in detail in Chapter 2 (section 2.2.4.1.2). 
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Figure 4.1. Perfusion of murine lungs   
 
A) Uninflated murine lungs cannulated in situ, before perfusion.  B) After perfusion, showing partial 
inflation of lungs, and complete clearing of blood. Pictures taken from Dr Sharon Ahmed’s Ph.D. 
thesis (CIR, Edinburgh). 
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4.2.1.1. Isolation of lung APCs by fluorescence-activated cell sorter (FACS) 
 
  The FACS Vantage SE flow cytometer (Becton Dickinson, CA) could be 
applied to rapidly separate the cells in a suspension on the basis of size and the 
colour of the fluorescence conjugated to the Abs used to label cell surface markers of 
interest. The cells are not damaged by the process. In fact, because the machine can 
be set to ignore dead cells, the percent viability of the sorted cells can be higher than 
that in the original suspension. The lung single cell suspensions, pooled from lungs 
of 4 naïve C56Bl/6J mice, were blocked with mouse serum prior to being stained 
with mAbs raised against mouse CD11c (clone N418), and MHCII (clone 2G9), as 
described in detail in Chapter 2 (section 2.2.4.1.2). They were then washed and 
resuspended at ~5×10
6 cells/ml (~30×10
6 total cells from 4 pooled mouse lungs) of 
PBS containing 0.1% BSA, and put through the cell sorter. In this way, two major 
populations of APCs could be selected according to their expression levels of CD11c 
and MHCII. Figure 4.2 shows the FACS data analysing the cells before and after 
sorting of lung cells. The first population (P1) was highly positive for CD11c and 
had no/low expression levels of MHCII, which was considered to consist of 
macrophages/monocytic cells. The second population (P2) was highly positive for 
both CD11c and MHCII and was considered to represent ‘bona fide’ DCs (see below 
for rationale). The corresponding representative cytospin figures of the two isolated 
populations are demonstrated in Figure 4.3 A. The CD11c
+high MHCII
+low (P1) and 
CD11c
+high MHCII
+high (P2) cell population purities were relatively high (around 90 
and 70%, respectively), although there were still contaminant cells (as observed in 
the case of CD11c magnetically-purified cells described in the following section). 
Despite this high purity, there were limitations with the final cell numbers obtained, 
as it was only possible to get around 2×10
5 cells/mouse in P1 and ~1×10
5 cells/mouse 
in P2. For this reason it was just possible to stain the cells for the three CSMs (CD40, 
CD80 and CD86). As shown in Figure 4.3 B P1 population was almost negative for 
CD40 and CD86, but strongly positive for CD80 (31.8% vs 7.6% in P2).  On the 
other hand, the P2 population had a higher expression of CD40 (3.2% vs 1% in P1) 
and CD86 (12.8% vs 1.4% in P1) and around 8% were also stained positively with 
CD80.  Chapter 4: In vivo modulation of dendritic cells by elastase specific inhibitor (elafin) 
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Figure 4.2. Sorting of lung APCs 
 
Lungs of WT mice (n=4) were perfused and pooled cells suspensions were prepared 
as described in Materials and Methods (Chapter 2). They were then stained with 
FACS mAb to CD11c and MHCII, resuspended at ~5×10
6 cells/ml in PBS containing 
0.1% BSA and passed through the fluorescence-activated cell sorter (FACS Vantage 
SE flow cytometer; Becton Dickinson, CA). A) Unsorted naïve lung cells. B) 
CD11c
+high MHCII
+low (P1) selected by sorting. C) CD11c
+high MHCII
+high  (P2) 
selected by sorting. Data are representative of two independent experiments. 
 
R1
MHCII 
CD11c 
A.
B. 
C. 
P1 
P2 
3.3% 
90.3% 
0%
  P1 
 
11.2% 
R1 
68.3% 
1.7% 
   P2 
 
1.74%
8.8% 
0.9% Chapter 4: In vivo modulation of dendritic cells by elastase specific inhibitor (elafin) 
  150
 
 
 
 
 
 
Figure 4.3. Analysis of APCs isolated by lung cell sorting 
 
See legend of Figure 4.2 for details. A) Cytospin pictures of CD11c
+high MHCII
+low 
(P1) and CD11c
+high MHCII
+high  (P2) isolated by FACS. B) Surface CSM phenotype 
of P1 (left panel) and P2 (right panel) of cells shown. Sorted P1 and P2 populations 
were washed and stained with PE-conjugated mAbs to CD40, CD80 and CD86 and 
analysed by flow cytometry. Percentage values of positive cells compared to isotype-
matched control Ab-stained cells are shown in M1 regions. 
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4.2.1.2. Isolation of lung APCs by CD11c MicroBeads 
  
CD11c MicroBeads (Miltenyi Biotec Ltd., Bergisch Gladbach, Germany) 
were available for the isolation of mouse DCs from single cell suspensions of 
lymphoid and non-lymphoid tissues. Unlike in humans, in mice CD11c is expressed 
on all defined DC subsets making them easier to isolate. The lung single cell 
suspensions, pooled from the lungs of 4 naïve C56Bl/6 mice, were washed once and 
resuspended in ice cold MACS buffer (PBS containing 1% BSA and 2mM EDTA) 
and Miltenyi CD11c MicroBeads as per the manufacturer’s protocol.  The cells were 
incubated for 15 minutes at 4-6
oC, then washed in 10-20× the volume of MACS 
buffer.  As the cell count at this stage was consistently less than 10
7 per tube, the 
cells in each tube, were resuspended in 500µl MACS buffer ready for magnetic cell 
separation with an AutoMACS system (Miltenyi Biotec Ltd.).  This method yielded 
around 1×10
5 CD11c
+-enriched APCs per mouse, which showed >95% viability as 
determined by trypan blue dye exclusion. Due to very low yield of cells it was not 
possible to analyse cells for CSM expression and other cell surface markers, apart 
from the standard markers (CD11c and MHCII) used throughout this project. Figure 
4.4 shows the results of the lung CD11c
+ cell enrichment using AutoMACS system. 
The top panel represents the forward and side scatter of the cell profiles from left to 
right for: whole lung cells before separation, and the negative and positive cell 
fractions following the CD11c
+ cell enrichment. The bottom panel shows the 
subpopulations of cells according to their expression of CD11c and MHCII. 
Following the CD11c selection, approximately 50% of the cells were positive for 
CD11c (Figure 4.4 B), compared to only 6% in the whole lung cell suspension (left 
panel) and ~4% in the negative fraction (middle panel). In addition, the cytospin 
picture of CD11c
+-enriched cells shows cells typical macrophage/DC characteristics 
and phenotype. 
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Figure 4.4. Lung CD11c
+ cell magnetic sorting 
 
The lung single cell suspensions, pooled from lungs of 4 naïve C56Bl/6J mice, were washed once and 
resuspended in 400 µl ice cold MACS buffer and 100 µl Miltenyi CD11c MicroBeads (Miltenyi 
Biotec Ltd., Bergisch Gladbach, Germany) as per the manufacturer’s protocol.  The cells were 
incubated for 15 minutes at 4-6
oC, then washed in 10-20× the volume of MACS buffer.  As the cell 
count at this stage was consistently less than 10
7 per tube, the cells in each tube, were resuspended in 
500 µl MACS buffer ready for magnetic cell separation with an AutoMACS system (Miltenyi Biotec 
Ltd.). Positive (CD11c
+ enriched population) and negative fractions were stained with mAbs to 
CD11c and MHCII and cell were analysed by flow cytometry. A) FCS/SSC plots, B) Double stained 
cells, and C) cytospin picture of CD11c
+ enriched cells (positive fraction). 
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4.2.1.3. Analysis of lung APCs using whole lung cells 
 
  Since the two methods described above yielded very low number of cells and 
did not allow simultaneous analysis of other cell types such as T cells and 
neutrophils in the lung tissue, it was decided to analyse the whole lung cell 
suspension. This was done by using multicolour flow cytometric analysis of the cells. 
The mAb to mouse CD11c used was conjugated to APC fluorochrome, MHCII was 
conjugated to FITC fluorochrome, and the rest of the cell surface markers used here 
were conjugated to PE fluorochrome. Isotype- and fluorochrome-matched control 
Abs to each mAb were also used to take into account for any non-specific staining.  
  
4.2.1.3.1. The effect of elafin over-expression (Ad-elafin) on lung APCs 
To examine the effects of elafin over-expression on pulmonary APCs of WT 
C57BL/6J mice, 3-4 animals per group received i.t. instillations of either PBS, Ad-
null (2.5×10
8 plaque-forming units [pfu]), or Ad-elafin (2.5×10
8 pfu). To investigate 
which cell types could be transfected and express the transgene in mouse lungs, Lei 
et al. (1998) delivered i.t. an Ad-LacZ vector into mouse lungs, and lung tissues were 
processed for β-galactosidase histochemical staining 24  hours post-gene transfer. 
Microscopic examination demonstrated that β-galactosidase was mainly localized to 
bronchial and alveolar epithelial cells and to a lesser degree, alveolar macrophages. 
As expected, they found no staining in lungs from mice treated with the control 
vector Ad-null. These findings are consistent with those of our groups and the 
published data in the literature (Xing et al, 1994). It should be mentioned that the 
preparation of mouse lungs and staining of the cells for flow cytometry were kindly 
performed by Miss Tara A. Sheldrake in this part of the project and Prof. Jean-
Michel Sallenave performed all the i.t. instillations. 
In the first instance, to examine the effect of elafin expression on lung APCs, 
the experimental animals were anaesthetised on day 4 and their lungs and tracheae 
were perfused with PBS and removed en bloc. Dual labelling of cells with CD11c 
and MHCII allowed identification of 2 main CD11c
+ ‘high’ cell populations (G1), 
one being MHCII
+ ‘low’ (G2) and the other MHCII
+ ‘high’ (G3) (Figure 4.5; see Chapter 4: In vivo modulation of dendritic cells by elastase specific inhibitor (elafin) 
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below for details). At this early time point there were no detectable levels of elafin in 
the BAL fluid of the animals that received a dose of Ad-elafin; hardly if any increase 
in the number of neutrophils and lymphocytes in the lungs of mice treated with the 
Ad vectors compared to control PBS-treated group of mice (data not shown). 
However, mice receiving either Ad-null or Ad-elafin had a slight increase in the 
percentage of CD11c
+high MHCII
+high cells in G3 on day 4 of the experiment (Figure 
4.5 C), which could be as a result of early immune responses due to the presence of 
the Ad particles in the lungs. There were also no major differences in expression of 
cell surface markers analysed (data not shown).  
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Figure 4.5. Lung myeloid cell population analysis 4 days post Ad i.t. instillation 
  
Lungs of WT mice (4 mice per group) treated at day 0 with either PBS, Ad-null or 
Ad-elafin (2.5×10
8 pfu) were perfused on day 4 and pooled cells suspensions were 
prepared as described in Materials and Methods. A) A gate (R1) was created by 
FCS/SSC analysis. This gate was analysed for CD11c
+ cells and contained more than 
90% of total lung CD11c
+ cells. B and C) These cells were analysed for CD11c and 
MHCII expression and their corresponding isotype-matched control mAbs 
(Armenian hamster [Arm. Ham.]  IgG-PE and Rat IgG2aκ-FITC, respectively). The 
cells were subdivided in 4 gates CD11c low (G4); CD11c
+high MHCII
+high (G3); 
CD11c
+high MHCII
+low (G2) and total CD11c (G1). Numbers in brackets indicates 
total % of cells (ungated). Cells were then analysed within G1 and G3 for expression 
of CD3, CD40, CD80, CD86, CD11b, B220, Gr1 and F4/80 (not shown). 
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The level of the elafin transgene in the lungs of mice given Ad vectors has 
been shown to peak at around a week post Ad-elafin i.t. infection by previous 
members in our laboratory (Simpson et al., 2001a). Hence, with regards to this and 
also to similar data published by our collaborators using these vectors (Wang et al., 
2000), the decision was taken to examine the lungs of treated animals 10 days post 
infection. In this way, it was expected that the elafin transgene would have been 
given reasonable time to express in the lung, and that it would be possible to detect 
any resulting changes in the lungs within this time-frame. WT mice do not express 
elafin, and as expected elafin was undetectable in WT mice receiving either PBS or 
Ad-null. Ad-elafin treatment of WT mice resulted in detectable levels of human 
elafin (5598.05 pg/ml ± 857.08; n=4 mice/group, Figure 4.6 A) in BAL fluid by day 
10 of the experiment, which were, expectedly, lower than those obtained in the ‘day 
5 acute models’ by our group (Simpson et al., 2001a; McMichael et al., 2005a). 
When digested lung cells were cultured ± LPS (100ng/ml) ex vivo for 24 hours, cells 
from Ad-elafin-treated lungs actively secreted human elafin which was significantly 
increased in the presence of LPS (297 vs 665.5 pg/ml, respectively; Figure 4.6 B). 
This observation, as described above, is probably due to the ability of LPS to activate 
the elafin murine CMV promoter (which contains NF-κB sites) in Ad-elafin-infected 
cells, as shown before (Simpson et al., 2001a). 
 
As hypothesised, when BAL fluid differential counts were performed 10 days 
post treatment (due to experimental limitations the total cell counts were not 
recorded) it is clear from the cytospins that Ad-elafin treated mice had a higher 
number of leukocytes in their BAL fluid than the control groups (Figure 4.7). As 
shown in Table 4.1, Ad-elafin-treated mice showed a significant increase in 
percentage of lymphocytes compared to Ad-null and PBS controls (Ad-elafin vs Ad-
null: p=0.0012). In addition, local elafin production induced an increase in BAL fluid 
neutrophils as observed previously (Simpson et al., 2001a), although it did not reach 
significance, whereas it caused a reduction in percentage of monocytes (Ad-elafin vs 
Ad-null: p=0.0011). 
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Figure 4.6. Elafin levels in BAL fluid (day 10) and in lung cell supernatants 
cultured ex vivo  
 
On day 0, C57BL/6J WT mice (4 mice/group) were treated intra-tracheally with either PBS, Ad-null 
(2.5×10
8 pfu) or Ad-elafin (2.5×10
8 pfu). On day 10 of the experiment, mice were sacrificed, BAL was 
performed and; A) BAL fluid was analysed by elafin ELISA (4 mice/group). B) Four million digested 
whole lung cells pooled from 3 mice in each group were washed in PBS and plated in a 12-well cell 
culture plate in 2ml complete RPMI medium ±100ng/ml LPS and supernatant was collected 24 hours 
post culture and analysed for the presence human elafin by ELISA. 
A. 
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Figure 4.7. Inflammatory cells in BAL fluids (day 10) 
 
On day 10 of the experiment, mice were sacrificed, BAL was performed and cell 
differential analysis was performed after centrifugation (2000 × g for 5 minutes). 
Cytospinning (100 × g for 3 minutes at room temperature) was performed and slides 
were stained with Diff-quick (Dade Diagnostika, GmbH, Germany) and fixed. 
Orange arrow head showing an APC, and red and blue arrows indicating neutrophil 
and lymphocyte respectively. Representative pictures are shown (n=4 mice/group).  
Ad-elafin 
Ad-null 
PBS 
A.
B.
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Table 4.1. Bronchoalveolar lavage cell differential (WT mice) 
 
On day 10, mice were sacrificed, BAL was carried out and cell differential analysis 
was blindly performed (in order to prevent biasing) by Prof. Sarah Howie after 
centrifugation (2000 × g for 5 minutes). Cytospinning (100 × g for 3 minutes at room 
temperature) was performed and slides were stained with Diff-quick. n represents the 
number of animals used in the experiment and results are expressed as % of total 
BAL cells (values represent mean and standard deviations [in brackets]). * indicates 
statistical significance, as compared to the Ad-null treatment (unpaired t-test 
analysis). p=0.0011 for myeloid cells and p=0.0012 for lymphocytes. 
 
 
 
 
 
 
 
 
 
 
 
The clear increase in percentage of lymphocytes in WT mice treated with Ad-
elafin (Table 4.1) indicated a need to analyse the type of immunological response 
generated by this construct in the lungs of treated mice. IL-12, a heterodimeric 
cytokine consisting of two subunits (p35, and p40), is a pro-inflammatory cytokine 
secreted by activated DCs that has been recognised to play a role in pulmonary host 
defences (see discussions). As Figure 4.8 demonstrates, ELISA cytokine analysis 
revealed that BAL fluid IL-12p40 levels of Ad-elafin-treated mice were significantly 
higher compared to Ad-null-treated mice (p<0.001). In addition, supernatants of Ad-
elafin treated lung cells cultured ex vivo secreted significantly higher levels of elafin 
compared to control groups (p<0.001; Figure 4.8B). Furthermore, cytokine analysis 
revealed that type 1 cytokines IFN-γ and TNF-α levels were also significantly higher  
in Ad-elafin-treated mice (p<0.01) compared to PBS and Ad-null-treated mice 
(Figure 4.9), although in general there were very low compared to IL-12p40 levels.  
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Figure 4.8. IL-12p40 levels in BAL fluid (day 10) and in lung cell supernatants 
cultured ex vivo  
 
On day 0, C57BL/6J WT mice (4 mice/group) were treated i.t. with either PBS, Ad-
null (2.5×10
8 pfu) or Ad-elafin (2.5×10
8 pfu). On day 10 of the experiment, mice 
were sacrificed, BAL was performed and; A) BAL fluid was analysed by IL-12p40 
ELISA. B) Four million digested whole lung cells pooled from 4 mice in each group 
were washed in PBS and plated in a 12-well plate in 2ml complete RPMI medium 
and supernatant was collected 24 hours post culture and analysed for the presence IL-
12p40 by ELISA. * indicates statistical significance between PBS and Ad-null-
treated mice (p=0.0161), and ** indicates statistical significance (p<0.001) between 
Ad-null and Ad-elafin treatments (unpaired t-test analysis). 
* 
** 
** 
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Figure 4.9. IFN-γ and TNF-α levels in BAL fluid 
 
BAL fluid (see Figure 4.6 legend) was analysed for IFN-γ and TNF-α content by 
ELISA (see Materials and Methods, Chapter 2). BAL fluid samples collected from 
four mice were analysed per group and * indicates statistical significance (p<0.01), 
as compared to the Ad-null treatment (unpaired t-test analysis). 
 
* 
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Whole lung single cell suspensions (n=3 mice per group; pooled samples) 
were stained with mAbs to CD11c and MHCII, as above. In addition to the data 
generated in the two other CD11c
+ cell enrichment methods (see above; Figure 4.2 B, 
4.2 C and 4.4 A), back-gating analysis revealed that more than 90% of CD11c
+ cells 
were found within the R1 gate. Ad-elafin gene transfer increased the total number of 
CD11c
+ lung cells compared to those treated with Ad-null and PBS (Figure 4.10). 
The cells from the R1 region were further divided into four subpopulations (G1-G4) 
on the basis of CD11c and MHCII expression, as mentioned above. Dual labelling of 
cells with CD11c and MHCII allowed identification of 2 main CD11c
+ ‘high’ cell 
populations (G1), one being MHCII
+ ‘low’ (G2) and the other MHCII
+ ‘high’ (G3). 
G4 population consisted of CD11c
+ ‘low’ and MHCII
+ ‘high’ cells. In line with the 
literature, as mentioned above, the CD11c
+high MHCII
+high G3 gate were considered 
to represent ‘bona fide’ DCs and CD11c
+high  MHCII
+low to be 
macrophages/monocytic cells for the following reasons: ‘naïve’ PBS-treated mice 
had a very low percentage of CD11c
+high MHCII
+high cells (around 1% of total lung 
cells), consistent with them being lung DCs (Gonzalez-Juarrero et al., 2001; Robbins 
et al., 2004; von Garnier et al., 2005). This population also expanded significantly 
upon Ad treatment (1.7% and 7.6% of total lung cells, after Ad-null and Ad-elafin 
treatments respectively, compared to 0.8% in PBS-treated mice, Figure 4.11). 
Furthermore, in PBS-treated mice, when cells were labelled with Abs to F4/80, a 
macrophage marker, about 32% of CD11c
+high MHCII
+low cells were labelled whereas 
only 15% of CD11c
+high MHCII
+high cells were positive for F4/80 (Figures 4.11 and 
4.12). This analysis shows that the percentage of CD11c
+high MHCII
+high cells (G3) 
was markedly increased in WT mice treated i.t. with Ad-elafin. Interestingly, Ad-
elafin also induced a small increase in the number of cells in G4 compared to Ad-null, 
which may be B lymphocytes (Figure 4.11). When cell surface markers such as the 
CSMs were analysed on these selected population (G1, G2 and G3), increased levels 
of CD80 and CD86 were observed in Ad-elafin treated mice (Figure 4.11, and Figure 
4.12), particularly in the double positive ‘DC G3’. Of note, the level of CD40 was 
low in PBS-treated mice, compared to CD80 and CD86 and was not induced by Ad 
treatments. In addition Ad-elafin-treated mice had higher expression levels of CD11b 
on these populations, compared to control groups (see Figure 4.13 below for details). Chapter 4: In vivo modulation of dendritic cells by elastase specific inhibitor (elafin) 
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Figure 4.10. Total lung CD11c
+ cells 10 days post Ad i.t. instillation 
 
See legend of Figure 4.6 for details. Graph showing % of CD11c
+ cells in total lung 
single cell digest taken from treated mouse lungs (dotted bars), as well as % of 
CD11c
+ cells in R1 selected on FCS/SSC plot (black bars). See Figure 4.11 for dot 
plots. n=3 mice/group. Chapter 4: In vivo modulation of dendritic cells by elastase specific inhibitor (elafin) 
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Figure 4.11 (Part A). Lung myeloid cell population analysis 10 days post PBS i.t. instillation 
 
See legend of Figures 4.5 and 4.6. A) R1 gate was selected on FCS/SSC plot, analysed for CD11c
+ 
cells and was shown to contain more than 90% of total lung CD11c
+ cells. The cells were analysed for 
CD11c and MHCII expression and subdivided in 4 gates: CD11c
+low (G4); CD11c
+high MHCII
+high 
(G3); CD11c
+high MHCII
+low (G2) and total CD11c (G1). Corresponding isotype-matched control Abs 
(Armenian hamster [Arm. Ham.] IgG-PE and Rat IgG2aκ-FITC, respectively) to CD11c and MHCII 
were also used  to account for unspecific staining. Numbers in brackets indicates total % of cells 
(ungated). B) Cells were then analysed within G3 for CD40, CD80, CD86, B220, Gr1 and F4/80 
expression (blue histograms) and their corresponding isotype-matched Abs (black line); n=1 (3 
mice/group). Percentage values of positive cells are indicated on top right of the histograms. 
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Figure 4.11 (Part B, continued). Lung myeloid cell population analysis 10 days 
post Ad-null i.t. instillation 
 
See legend of Figures 4.11, Part A. A) R1 gate was selected on FCS/SSC plot, analysed for CD11c
+ cells. The 
cells were analysed for CD11c and MHCII expression and subdivided in 4 gates: CD11c
+low (G4); CD11c
+high 
MHCII
+high (G3); CD11c
+high MHCII
+low (G2) and total CD11c (G1). Corresponding isotype-matched control Abs 
(Armenian hamster [Arm. Ham.] IgG-PE and Rat IgG2aκ-FITC, respectively) were also used. Numbers in 
brackets indicates total % of cells (ungated). B) Cells were then analysed within G3 for CD40, CD80, CD86, 
B220, Gr1 and F4/80 expression (blue histograms) and their corresponding isotype-matched Abs (black line); 
n=1 (3 mice/group). Percentage values of positive cells are indicated on top right of the histograms. 
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Figure 4.11 (Part C, continued). Lung myeloid cell population analysis after Ad-
elafin i.t. instillation 
 
See legend of Figures 4.11, Part A. A) R1 gate was selected on FCS/SSC plot, analysed for CD11c
+ cells. The 
cells were analysed for CD11c and MHCII expression and subdivided in 4 gates: CD11c
+low (G4); CD11c
+high 
MHCII
+high (G3); CD11c
+high MHCII
+low (G2) and total CD11c (G1). Corresponding isotype-matched control Abs 
(Armenian hamster [Arm. Ham.] IgG-PE and Rat IgG2aκ-FITC, respectively) were also used. Numbers in 
brackets indicates total % of cells (ungated). B) Cells were then analysed within G3 for CD40, CD80, CD86, 
B220, Gr1 and F4/80 expression (blue histograms) and their corresponding isotype-matched Abs (black line); 
n=1 (3 mice/group). Percentage values of positive cells are indicated on top right of the histograms. 
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Figure 4.12. WT mouse lungs myeloid population analysis after Ad i.t. 
instillation 
 
Lungs of WT mice (n=3 mice/group) treated at day 0 with PBS, Ad-null or Ad-elafin 
(2.5×10
8 pfu/mouse) were perfused on day 10 and pooled cells suspensions were 
prepared. These cells were analysed for CD11c and MHCII expression and were 
subdivided in 4 gates CD11c ‘low’ (G4); CD11c
+high MHCII
+high (G3); CD11c
+high 
MHCII
+low (G2) and total CD11c (G1). Cells were then analysed within G1, G2 and 
G3 for expression of CD40, CD80, CD86, CD11b, Gr1, F4/80 and BB20 compared 
to their corresponding isotype-matched control Abs.  
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  CD11b (also known as Mac-1 or CR3) is a member of the β2-integrin family 
of cell surface adhesion molecules, and plays an important role in the initiation of 
leukocyte adherence to and subsequent migration through vascular endothelial cells. 
As shown in Figure 4.12, following both Ad-null and Ad-elafin treatment, the 
expression of this marker was up-regulated on cell populations in G1-G4 gates 
indicating that these cells originated from myeloid precursors and that these CD11b
+ 
cells form a large part of APC augmentation in the lungs. To analyse the expression 
of CD11b by the lung APCs in more detail, FACS plots of CD11c/CD11b were also 
produced (Figure 4.13 A). These indicated that Ad treatment on its own was able to 
change the profile of the CD11b expressing cells and there was an increase in the 
population of CD11c
+highCD11b
+high (DCs; 1.55% vs 0.78% respectively) as well as 
CD11c
+lowCD11b
+high (monocytes/macrophages; 3.46% vs 2.23% respectively) 
compared to PBS-treated mice (Figure 4.13). However, as Figure 4.13 A 
demonstrates, compared to mice treated with Ad-null control construct, Ad-elafin-
treated mouse lungs showed a dramatic rise in CD11c
+high CD11b
+high cells (11.76% 
vs 27.27%, respectively) which are thought to be myeloid DCs. Conversely there was 
a decrease in the CD11c
+low CD11b
+high population (monocytes/macrophages) 
compared to Ad-null group (Ad-null vs Ad-elafin; 26.66% vs 11.44%). Analysis of 
whole lung cell suspensions (ungated) indicated that compared to Ad-null group, Ad-
elafin-treated mice had increased numbers of CD11c
+high CD11b
+low (DC precursors) 
and CD11c
+high CD11b
+high myeloid DCs (2.35% vs 4.89; 1.55 vs 7.16%), whereas 
there was not a considerable difference in CD11c
+low CD11b
+high populations 
(monocytes/macrophages) in these groups (3.46% vs 3.0%). 
 
 
 
 
 
 
 
 
 Chapter 4: In vivo modulation of dendritic cells by elastase specific inhibitor (elafin) 
  169
 
 
 
 
 
 
 
 
Figure 4.13. Lung CD11b expression analysis 10 days post Ad i.t. instillation 
 
See legends of Figure 4.6 and Figure 4.11. A) The digested whole lung cells (pooled 
from 3 mice/group) were analysed (R1) for CD11c and CD11b expression and 
subdivided in 4 gates. Corresponding isotype-matched control mAbs were also used 
to account for unspecific staining (not shown). Numbers in brackets indicates total % 
of cells (ungated). B) Schematic diagram showing how elafin could influence 
differentiation of monocytes/macrophages (CD11c
+low CD11b
+high) into iDCs 
(CD11c
+high CD11b
+high) and mDCs (CD11c
+high CD11b
+high MHCII
+high) following 
over-expression in lung tissue. 
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4.2.1.3.2. The effect of endogenous elafin over-expression (eTg) on lung APCs 
 
  To examine whether the elafin eTg mice also behaved in the same way to 
those Ad-elafin-treated WT mice, eTg mice as well as their corresponding WT 
controls were treated with Ad-null (2.5×10
8 pfu/mouse) or PBS and their lungs were 
examined 10 days post treatment, as above.  
 
As expected, since mice do not have an elafin ortholog, elafin was not 
detected in the BAL fluids of naïve eTg mice receiving PBS or WT control groups 
receiving either PBS or Ad-null, whereas Ad-null increased elafin secretion in the 
eTg mouse lungs (4120.09 pg/ml ± 1151.04; n=4 mice). As observed above, when 
BAL differential counts were performed 10 days post treatment, as shown in Table 
4.2, Ad-null-treated eTg mice showed increased percentage of lymphocytes 
compared to the controls. In addition, eTg mice treated with Ad-null had increased 
BAL fluid neutrophil percentage, whereas there was a reduction in percentage of 
myeloid cells, although it did not reach significance. Following whole lung cell 
analysis, compared to the three control groups, Ad-null-treated eTg mice contained 
higher numbers of CD11c
+high MHCII
+high and CD11c
+high CD11b
+high cells (Figures 
4.14 and 4.15), although their numbers were not as high as the ones observed in WT 
mice receiving Ad-elafin (see above). Furthermore, total CD11c
+ cells (G1) in Ad-
null-treated eTg lungs expressed higher levels of CD11b, CD80 and CD86 compared 
to Ad-null-treated WT and PBS-treated eTg mouse lungs (data not shown). Due to 
the low recovery, it was not possible to analyse the CSMs in the CD11c
+high 
MHCII
+high DC population of eTg mice (G3). 
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Table 4.2. Bronchoalveolar lavage cell differential (WT/eTg mice) 
 
On day 0, elafin transgenic (eTg) mice and their WT controls were treated i.t. with either PBS or Ad-
null (2.5×10
8 pfu). On day 10, mice were sacrificed, BAL was carried out and cell differential analysis 
was blindly performed (in order to prevent biasing) by Prof. Sarah Howie after centrifugation (2000 × 
g for 5 minutes). Cytospinning (100 × g for 3 minutes at room temperature) was performed and slides 
were stained with Diff-quick. n represents the number of animals used in the experiment and results 
are expressed as % of total BAL cells (Values represent mean and standard deviations [in brackets]). 
 
 
 
 
 
 
 
Figure 4.14. eTg mouse lungs myeloid population analysis 
 
See legend of Table 4.2, above. On day 0, eTg mice  and their WT controls were treated i.t. with either 
PBS or Ad-null (2.5×10
8 pfu). The digested lung single cells in R1 (same as above, see Figure 4.11) 
were analysed for CD11c and MHCII expression. Corresponding isotype-matched control Abs 
(Armenian hamster [Arm. Ham.]  IgG-PE and Rat IgG2aκ-FITC, respectively) to CD11c and MHCII 
were also used to account for unspecific staining (not shown).  Data are representative of 2-3 
independent experiments each containing cells pooled from 2-4 mice/group.  
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Figure 4.15. Percentage expression of APCs in eTg mouse lungs 
  
See legend of Table 4.2 and Figure 4.14. R1 gate was selected on FCS/SSC plot, 
analysed for CD11c
+ cells and was shown to contain more than 90% of total lung 
CD11c
+ cells. The cells were analysed for CD11c, CD11b and MHCII expression. 
Data are representative of 2-3 independent experiments each containing cells pooled 
from 2-4 mice/group. * indicates statistical significance (p<0.01), as compared to the 
Ad-null-WT and PBS-eTg treatments (unpaired t-test analysis).  
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4.2.2. Ad-elafin over-expression for genetic vaccination 
 
Having demonstrated an enhanced in vivo primary response (involving an 
increase in DC numbers and activation) to Ad in WT mice receiving Ad-elafin and in 
eTg mice receiving Ad-null (see above), our group endeavoured to investigate 
further the role of elafin on a secondary immune response. This part of the project 
was realised by Prof. Jean-Michel Sallenave, Mr. Steve D. Williams and Miss. Tara 
A. Sheldrake, and that my contribution was limited to the preparation and 
histological analysis of the lung sections to examine lung CD11c
+ cell numbers 
following Ad vaccination. PBS, Ad-null, Ad-elafin and Ad-GMCSF (‘positive’ 
control) were administered by i.t. on day 0 and the mice were challenged on day 14 
with Ad-LacZ (by the same route), to allow us to assess the efficiency of Ad-elafin 
vaccination by measuring β-galactosidase expression. Three days later (day 17 of 
experiment) mice were sacrificed and samples analysed (Figure 4.16). Using the Ad-
elafin vaccination and Ad-LacZ challenge protocol as a convenient read-out, our 
group showed that Ad-elafin treatment was able to induce blocking Abs against Ad-
LacZ in vitro, and significantly prevented consequent Ad-LacZ infection of murine 
lungs in vivo (see Roghanian et al. [2006b] for details).  
 
 
 
 
 
Figure 4.16. Protocol for investigating the role of elafin as a mucosal vaccine 
adjuvant 
 
To assess the role of elafin on a secondary immune response, WT mice (3-5 mice/group) were treated 
on day 0 as shown above. Ad-GMCF was included as a positive control. On day 14 of experiment all 
mice were treated with a second dose of Ad (Ad-LacZ) and were sacrificed on day 17 and various 
parameters were analysed as shown.  
Day 14: In vivo recall: 
  -2.5×10
8 pfu Ad-LacZ  
 Day 17: harvest   -BAL fluid 
-Lung 
-Serum 
-Spleen 
Day 0: Intratracheal instillation:   
- PBS 
              - 0.3×10
8 pfu Ad-null        + 2.2×10
8 pfu
 Ad-null 
 -  0.3×10
8 pfu Ad-elafin     + 2.2×10
8 pfu
 Ad-null 
 -  0.3×10
8 pfu Ad-GMCSF + 2.2×10
8 pfu
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To follow up from previous in vivo Ad-elafin gene transfer studies, the 
presence of lung DCs in this vaccination protocol was studied by 
immunohistochemistry (Figure 4.17). In line with the FACS data investigating the 
effect of elafin on lung APCs (see above), many more CD11c
+ cells (labelled ‘red’ 
with PE; see open arrow) were evident in the airways and in the lung interstitium of 
Ad-elafin- and Ad-GMCSF-treated mice, as compared to the PBS and Ad-null 
groups (Ad-elafin vs Ad-null: p=0.0328). Furthermore, these APCs seem to localise 
around the airways and show the presence of numerous typical dendrites (as 
indicated with white arrow-heads) suggesting an activated phenotype. PE-conjugated 
isotype-matched control Ab was also used on histological section and was shown to 
be negative (not shown). 
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Figure 4.17 (Part A). Histological analysis of CD11c
+ cells in lungs given Ad 
constructs (see next page for figure legend) 
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Figure 4.17 (Part B, continued). Histological analysis of CD11c
+ cells in lungs 
given Ad constructs 
 
Mice received i.t. either PBS, Ad-null (0.3×10
8 pfu), Ad-elafin (0.3×10
8 pfu), or Ad-
GMCSF (0.3×10
8 pfu) as adjuvant treatments and were simultaneously immunised 
with Ad-null (2.5×10
8 pfu) via the i.t. route at day 0 (apart from PBS controls).  All 
mice received Ad-lacZ (2.5×10
8 pfu) at day 14 and were culled on day 17. Lungs 
were obtained and tissue sections (15µm) were cut from OCT-inflamed lungs using a 
microtome with a cabinet temperature at -30° C, mounted on polylysine-coated slides 
and fixed with 100% methanol. A) Cells were labelled with PE-conjugated hamster 
anti-mouse CD11c (white arrow) and the nuclei were counterstained with TO-PRO-3. 
Digital images were acquired with a confocal microscope at various magnifications. 
White arrow-heads indicate extended dendrites in lungs treated with Ad-elafin and 
Ad-GMCSF. Representative confocal images of ×5 (left panel) and ×83 (right panel) 
magnifications are shown. B) Quantification of CD11c
+ cells was done by counting 
three fields per experimental group taken using a 10× magnification. Representative 
figures are shown (n=2 mice/group).  
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4.3. DISCUSSION 
 
  The principal novel observation arising from the data in this chapter is that 
the antimicrobial NE inhibitor ‘elafin’ is capable of affecting DC phenotype and 
function, and by doing so could bridge the innate and adaptive branches of the 
immune system. Discussion of the results presented in this chapter will be divided 
into two separate sections, as follows. 
 
4.3.1. The in vivo effects of elafin on lung APCs and adaptive immunity 
 
Our group has previously shown that the antimicrobial/NE inhibitor elafin, 
when over-expressed in an Ad vector, is able in an acute model to induce an 
inflammatory cell influx after lung LPS treatment (Simpson et al., 2001a). In that 
study, a very small dose of Ad-elafin (0.3×10
8 pfu), which was apparently non 
inflammatory by itself, was able, in conjunction with LPS, to induce the influx of 
neutrophils and macrophages in the lung 24 hours after LPS treatment (5 days post 
Ad-treatment). This increase was shown to be due to the LPS-mediated up-regulation 
of the murine CMV promoter in the Ad-elafin construct (which contains many NF-
κB sites), resulting in increased secretion of elafin in the lung. The activity of elafin 
on innate immune cells was confirmed in vitro, using Ad vectors (Simpson et al., 
2001a), as well as in vivo, by using a non-viral approach where newly characterised 
eTg mice were given LPS i.t. and the lung innate immune parameters were studied 
24 hr later (Sallenave et al., 2003). Altogether, these results suggested that  in 
addition to its role in an acute model of innate immunity, elafin, a molecule also up-
regulated by bacterial LPS and early wave cytokines such as IL-1 and TNF in human 
epithelial cells (Sallenave et al., 1994), may be involved in the initiation of mucosal 
events leading to adaptive immunity. Therefore, as a model system, our group went 
on to examine the influence of elafin on immunity against adenovirus (Ad), a well 
researched pathogen as a potential tool in gene therapy (Volpers et al., 2004; Liu et 
al., 2003; Yang et al., 1995; Yang et al., 1994) and itself a potential infectious agent 
implicated in chronic lung diseases such as COPD and emphysema (Higashimoto et 
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of elafin expression described above (Ad-elafin and eTg mice), it was demonstrated 
that elafin induces a type 1-biaised inflammatory and immunological response 
(cellular and humoral) in the lungs and spleens of mice over-expressing elafin 
(Roghanian et al., 2006b). Indeed, in conditions such as psoriasis
1, where a type 1 
cytokine pattern predominates (Toichi et al., 2006; Lew et al., 2004), high 
concentrations of elafin are found (Pfundt et al., 2000; Nonomura et al., 1994; 
Schalkwijk et al., 1993); which indicate that elafin might be involved in the skewing 
of Th1 responses in this situation. Interestingly, in agreement with this, in an earlier 
study where psoriatic plaque skin-derived DCs were used to support immune 
responses to resting peripheral blood T cells, these psoriatic plaque skin-derived DCs 
mediated a Th1 T cell response with high levels of IL-2 and IFN-γ but not IL-4 or 
IL-10, compared to blood DCs and healthy dermal DCs (Nestle et al., 1994). 
 
In order to demonstrate how elafin is able to bridge between the innate and 
adaptive immunity in the lung, the decision was then taken to examine whether the 
effects described for elafin were likely to be mediated through the increase in 
numbers and/or activation status of lung APCs. Firstly, it was necessary to adapt the 
best protocol to analyse the murine lung APCs, which also supported simultaneous 
phenotypical analysis of other lung leukocyte populations (see above). By analysing 
whole lung single cell suspensions, in agreement with von Garnier et al. (2005), 
CD11c
+high MHCII
+high cells were defined as bona fide lung DCs and CD11c
+high 
MHCII
+low cells as lung monocytes/macrophages, the latter population expressing 
higher levels of the F4/80 marker than CD11c
+high MHCII
+high cells. Using the Ad-
elafin system of delivery (Figures 4.10 and 4.11), it was established that elafin over-
expressers exhibited higher numbers of total lung CD11c
+high cells and CD11c
+high 
MHCII
+high cells (DCs). In addition, Ad-elafin treatment induced higher levels of 
CD80 and CD86 in the latter cell population, showing that DCs were activated, in 
accordance with the increased levels of  lung TNF-α and IL-12 (a pro-inflammatory 
cytokine produced abundantly by activated DCs) observed in BAL fluids of treated 
animals (Figures 4.8 and 4.9 respectively). IL-12 activates a transcription factor, 
                                                 
1 A common inflammatory skin disease that involves infiltration of leukocytes, activation of skin-
resident cells and increased production of numerous cytokines, chemokines and inflammatory 
molecules. A type 1 cytokine pattern predominates in psoriasis. Chapter 4: In vivo modulation of dendritic cells by elastase specific inhibitor (elafin) 
  179
STAT4, in Th0 cells that results in IFN-γ production and differentiation into the Th1 
phenotype, enhancing cell-mediated immunity against airway infections caused by 
viruses, mycobacteria, fungi, and some parasites (Michailowsky et al., 2001; Hogan 
et al., 1998; Wakeham et al., 1998; Hoag et al., 1997). Incidentally, mice receiving 
Ad-elafin also had significantly higher concentrations of IFN-γ in their BAL fluid 
compared to controls (Figure 4.9), which is in agreement with increased levels of 
BAL fluid IL-12 and higher percentage of lymphocytes detected in these animals 
(Table 4.1). Of note, the level of CD40 was low in PBS-treated mice and was not 
induced by Ad treatments (Figures 4.11 and 4.12). This is in agreement with data 
published by Dodge et al. (2003) showing that murine pulmonary DCs expressed low 
levels of CD40.   
 
Murine DCs have been traditionally identified by their expression of CD11c 
and in addition, DC subsets have been described, based on the expression of CD11b, 
CD8α, and CD45R/B220 (Bjorck, 2002; Nakano et al., 2001; Bjorck, 2001). Hence, 
the presence of plasmacytoid DCs (pDCs) (CD45R/B220) was investigated and it 
was found that more than 90% of CD45R/B220 cells were present in the CD11c
+high 
MHCII
+high cells population (Figures 4.11 and 4.12). However, there was no 
difference in the % expression of this marker on CD11c
+high MHCII
+high cells 
between the experimental treatments, PBS, Ad-null and Ad-elafin (12.95, 12.7, and 
11.46 %, respectively), suggesting that elafin does not modulate pDCs. 
 
In the present study the levels of the myeloid marker CD11b on different cell 
populations (G1-3) was also measured and it was shown that CD11b was elevated on 
Ad-elafin-treated mouse APCs (Figures 4.11 and 4.12). To analyse the expression of 
CD11b in more details FACS plots of CD11c/CD11b were generated (Figure 4.13 A). 
These indicated that compared to mice treated with Ad-null, Ad-elafin-treated mouse 
lungs showed an increase in CD11c
+high CD11b
+high cells (11.76% vs 27.27%, 
respectively); supporting the argument that the precursor cells responsible for the 
increase in DC numbers following elafin augmentation are myeloid CD11b
+ 
monocytes/macrophages (Figure 4.13 B). These observations are further 
strengthened by data published by our collaborators (Wang et al., 2000) showing
 that Chapter 4: In vivo modulation of dendritic cells by elastase specific inhibitor (elafin) 
  180
Ad-GMCSF promotes the differentiation and activation of a myeloid
 DC population 
primarily by acting on macrophages during pulmonary
 immune
 responses. This is 
also supported by earlier studies suggesting the potential of macrophages to 
differentiate to DCs (Palucka et al., 1998; Zou et al., 2000; see Chapter 1, Figure 1.4); 
as seen in elafin-expressing mice in the current study. 
To confirm the effects of elafin seen in WT mice, eTg mouse lungs were also 
examined following Ad infection to induce elafin expression (see above). As shown 
in Figures 4.13 and 4.14, in line with previous observations seen in Ad-elafin-treated 
WT mice, following the induction of the endogenous elafin in eTg mouse lungs the 
percentage and activation status of APCs was greatly increased.  
In summary, the experiments presented in the latter part of this chapter, using 
a dual approach of gene transfer, showed that the antimicrobial/NE inhibitor 
molecule elafin is able to augment lung APC numbers and their activation status. The 
adjuvant property of elafin is particularly important in cases where mucosal tolerance 
has to be overcome. This is the case in the lung environment where a default Th2 
response has been demonstrated in steady state conditions (Dodge et al., 2003; 
Akbari et al., 2001; Stumbles et al., 1998), with lung DCs exhibiting an immature 
type 2 phenotype. This phenotype, which may have evolved to keep in check 
potentially damaging uncontrolled type 1 responses to innocuous inhaled non-
replicative antigens, needs to be overcome in the presence of replicative pathogens, 
such as viruses and intra-cellular pathogens. Additionally, since innate immune 
products such as NE (Chapter 3; Roghanian et al., 2006a) and exogenous stimuli 
such as CS have been shown both in vitro (Vassallo et al., 2005; Guinet et al., 2004; 
Nouri-Shirazi and Guinet, 2003) and in vivo (Robbins et al., 2005; Franco et al., 
personal communication) to cause a reduction in DC numbers and maturation as well 
as a decrease in their antigen-presenting capacity and/or to skew immunity towards 
type 2 responses (Vassallo et al., 2005), the increase in the number of lung DCs and 
the type 1 responses elicited  by over-expressing elafin (Roghanian et al., 2006b), 
may be beneficial in the context of COPD/CF infections and exacerbations. 
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4.3.2. How does elafin regulate DC numbers and activation status? 
 
The effects of elafin on lung APCs, in particular DCs, presented here, are 
very encouraging. However, the exact mechanism is not yet understood and requires 
further investigation. The possible mechanisms by which elafin may be exerting its 
effects on APCs are listed below.  
 
The increase in lung CD11c
+ cell numbers following Ad-elafin treatment 
suggests that elafin may be a chemoattractant and/or an activator of lung DCs (see 
Chapter 5). Alternatively, as indicated above (Figures 4.13 and 4.15), locally 
secreted elafin might be acting on CD11b
+ myeloid monocytes/macrophages and 
induce their differentiation into DCs (see Chapter 1, section 1.2.6). 
 
On the other hand, locally produced elafin may act via other indirect 
mechanisms, through for example the inhibition of NE. Indeed, data presented in 
Chapter 3 indicated that NE, is able to down-regulate DC CSMs, and affects 
negatively their ability to present antigen to lymphocytes (Roghanian et al, 2006a). 
Hence, over-expression of elafin may rescue DC function by restoring DC activation 
and or prevent NE-mediated DC inactivation.  
 
It could also be argued that Ad-elafin may have migrated from the lung to the 
regional lymph nodes (LN) and spleen and have directed transgene expression at 
these immune sites and skewed a Th1 response in the LNs. This has not been 
investigated with lung delivery of Ad vectors, but is more likely to occur in eTg mice 
since elafin RNA has been detected in most tissues including the lymphocyte-rich 
organs, such as the spleen and thymus (Sallenave et al., 2003). It is possible that 
secretion of elafin in the spleen milieu may increase lymphocyte responses, either 
directly or through activation of splenic DCs.  
 
Recent evidence indicates that activation of DCs involves cellular 
communication with neutrophils (Megiovanni et al., 2006; van Gisbergen et al., 
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that were stimulated with tachyzoites of Toxoplasma gondii (T. gondaii) have been 
found to induce DC maturation, as well as IL-12 and TNF-α production by DCs; 
whereas depletion of neutrophils from T. gondii-infected mice inhibits IL-12 and 
TNF-α production upon re-stimulation of DCs with T. gondii. In that context, in 
addition to activated DCs, T. gondii-stimulated neutrophils themselves produced IL-
12 and TNF-α (Bliss et al., 1999a and 1999b). In a related study, Megiovanni et al., 
(2006) demonstrated that human monocyte-derived DCs acquired Candida albicans-
derived antigens from both live and apoptotic neutrophils and thus elicited antigen-
specific T cell responses in vitro. Indeed, over-expression of elafin has been shown 
to significantly augment LPS-mediated neutrophil migration into the airways in vivo, 
and to significantly enhance neutrophil migration in vitro (Simpson et al., 2001a). 
Similarly lung neutrophils were increased in elafin over-expressers in the current 
study, although this was not significant (Tables 4.1 and 4.3). Therefore, it could be 
argued that chemoattraction of neutrophils to inflammatory tissues by elafin leads to 
increased local production of TNF-α, leading to DC activation. Figure 4.18 shows 
the proposed two-step process by which neutrophils induce DC maturation. The first 
step involves the formation of a cellular contact zone or synapse between neutrophils 
and DCs through interactions between the β2-integrin CD11b (Mac-1) and C-type 
lectin DC-SIGN (van Gisbergen et al., 2005b), followed by the second step which is 
mediated by TNF-α production by neutrophils (Bennouna et al., 2005 and 2003). 
 
Last but not least, increased lung APC numbers following elafin over-
expression might be indirectly due to the action of GM-CSF in the lungs of these 
mice. Indeed, TNF-α has been shown to induce the production of GM-CSF by 
fibroblasts and airway epithelial cells (Leizer T et al., 1990; Hashimoto et al., 2000; 
Daffern et al., 1999). Relatedly, TNF-α has been shown to stabilise GM-CSF RNA 
in stimulated cells (Akashi et al., 1991). Although in the current study BAL fluid 
GM-CSF was not measured, these data suggest that the elafin-induced TNF-α 
production in mouse lungs could also influence the expression of GM-CSF, which 
could in turn enhance DC numbers and activity by acting on precursor cells, as 
previously reported (Wang et al., 2000). A way to test this hypothesis in future 
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and investigate whether or not, in the presence of anti-TNF-α Abs, local elafin 
production increases lung APCs as demonstrated here. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18. Cross-talk between neutrophils and DCs 
 
Activated neutrophils interact with iDCs through binding of receptors such as DC-SIGN by CD11b 
(Mac-1), to form a synapse that enables transmission of TNF-α from the activated neutrophils to iDCs. 
TNF-α secretion from activated neutrophils induces maturation of iDCs, which results in up-
regulation of CSMs, and the potential of these DCs to strongly stimulate the proliferation of T cells. 
Activated neutrophils instruct iDCs to mature into IL-12-secreting mDCs that induce Th1 polarisation. 
Adapted from van Geijtenbeek et al., 2005a. 
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4.4. SUMMARY 
 
The results presented in this chapter demonstrate that Ad-mediated 
expression of an NE specific inhibitor (elafin) in WT murine lungs, as well as 
induction of elafin secretion in eTg murine lungs, results in increased number 
(immunofluorescence) and activation status (flow cytometric measurement) of 
CD11c
+high/MHCII
+high lung DCs in vivo (as evidenced by higher levels of DC CSMs 
and higher concentrations of pro-inflammatory cytokines in elafin-producing lungs). 
These data suggest that elafin is acting either directly or indirectly (e.g., induction of 
TNF-α) on lung DCs to induce their activation. Alternatively, elafin might be acting 
as a chemotactic factor for DCs in the lungs (see Chapter 5). In summary these 
findings suggest that augmentation of the antimicrobial/NE inhibitor elafin is able to 
bridge the innate and adaptive immunity by activating antigen presenting DCs in the 
lung and possibly in other mucosal tissues. Figure 4.19 summarises the possible 
mechanisms by which elafin might be exerting its effects on lung DCs.  
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Figure 4.19. Possible effects of elafin augmentation on pulmonary DCs 
 
Schematic diagram demonstrating possible mechanisms by which natural NE 
inhibitors such as ‘elafin’ could modulate DCs in vivo.  1) Elafin may be a 
chemoattractant and/or activator of lung DCs, 2) elafin might be acting on CD11b
+ 
myeloid monocytes/macrophages and induce their differentiation into CD11b
+ 
CD11c
+ DCs, 3) elafin may rescue DC function by restoring DC activation and or 
prevent NE-mediated DC inactivation, e.g., cleavage of DC cell surface receptors, 4) 
elafin secretion/leakage from the lung to the regional lymph nodes and spleen may 
increase lymphocyte responses, either directly or through activation of splenic DCs, 
5) Chemoattraction of neutrophils by elafin may result in direct neutrophil:DC 
interactions and hence increased production of TNF-α by activated neutrophils, 
leading to DC activation (see legend of Figure 4.18), and 6) elafin-induced TNF-α 
production in the lungs could also influence the expression of GM-CSF, which could 
in turn enhance DC numbers and activity by acting on precursor cells. 
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CHAPTER 5 
 
IN VITRO EFFECTS OF NATURAL NEUTROPHIL ELASTASE 
INHIBITORS ON DENDRITIC CELLS 
 
5.1. AIMS AND BACKGROUND 
 
In recent years a number of endogenous antimicrobial molecules (e.g., 
defensins and LL-37) have been found to profoundly modulate DC function and 
migration (Yang et al., 1999; Biragyn et al., 2002; Davidson et al., 2004). Due to 
similarities in their expression patterns, structure and antimicrobial properties with 
natural NE inhibitors (e.g., elafin and SLPI), it was hypothesised that these NE 
inhibitors could also affect DC responses during infection/inflammation. Moreover, 
in the preceding results chapter it was demonstrated that the augmentation of an NE 
specific inhibitor (elafin) could increase lung DC numbers and their activation status 
(Roghanian et al., 2006b). Both SLPI (Nakamura et al., 2003; Taggart et al., 2005) 
and  α1-protease inhibitor (α1-PI; Spencer et al., 2004; Aldonyte et al., 2004; 
Janciauskiene et al., 2004) have also been found to have various immunomodulatory 
properties, rendering them as potential candidates in immunotherapeutic 
interventions. Thus the primary aim of the work described in this chapter was to 
investigate the direct effects of respiratory system NE inhibitors on the function and 
phenotype of DCs in vitro.  As mentioned in Chapter 4, this was primarily carried out 
using an adenovirus (Ad)-based strategy. The Ad gene transfer approach uses 
replication-deficient Ad vectors which are both E1 and E3 deleted, encoding the 
cDNA for the genes of interest (namely eotaxin, elafin, SLPI and α1-PI used in this 
part of the project) which are under the control of the powerful murine CMV 
promoter, to facilitate cellular expression of the transgene (Sallenave et al., 1998).  
 
The source of DCs used in this study was the murine (BALB/c) bone marrow 
(BM), as described in Chapter 3. The experiments described herein were undertaken 
to investigate the mechanism by which elafin could increase lung DC numbers and 
activation status; and to examine whether in vitro genetic augmentation of NE Chapter 5: In vitro effects of natural neutrophil elastase inhibitors on dendritic cells 
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inhibitors, namely ‘human elafin’, ‘murine SLPI’ and ‘murine  α1-PI’, could 
modulate DC phenotype and function in a similar fashion to defensins and LL-37 
(Yang et al., 1999; Biragyn et al., 2002; Davidson et al., 2004). 
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5.2. RESULTS 
 
5.2.1. Increasing Ad infection efficiency of DCs in vitro 
  
  Prior to infection of iDCs with Ad vectors expressing NE inhibitors in vitro, 
since myeloid cells are relatively refractory to Ad infection, the decision was taken to 
optimise the infection of the cells. To date a few strategies have been described that 
greatly increase infection efficiency of Ad vectors, some of which are routinely used 
in our laboratory. These include the use of polycation complexes (Di Nicola et al., 
2000) such as lipofectamine, calcium phosphate precipitates (Fasbender et al., 1998) 
and the centrifugal methods (Nishimura et al., 2001a and 2001b). Employment of 
such strategies firstly helps to increase the infection efficiency and secondly to 
reduce the multiplicity of infection (MOI) of Ad needed to infect majority of the 
cells, hence using fewer immunogenic particles in the experimental system. Since 
iDCs are highly phagocytic and also are very sensitive to their surrounding 
microenvironment, it was decided to use the centrifugal method as it is the least 
manipulative method of the three. In this method, centrifugal force is applied to 
enhance efficiency of Ad-mediated gene transduction. In this part of the study, Ad-
GFP was used to investigate these effects, since GFP expression by infected cells 
could be viewed by fluorescent microscopy, and also is readily detectable by flow 
cytometry (on FL1 channel).  Figure 5.1 demonstrates that iDCs could be readily 
infected with Ad vectors (Ad-GFP in this case). Then, to assess the most efficient Ad 
infection protocol, iDCs were either infected with Ad-GFP at an MOI of 100 on 
plates or transferred to Eppendorf tubes and infected under centrifugal force, as 
explained in Chapter 2 (section 2.2.4.2.1). As shown in Figure 5.2, ~70% of the cells 
cultured on plates were infected with Ad-GFP, compared to ~76% infected by 
centrifugal force in Eppendorf tubes. Notably, the MFI of the GFP expressing cells 
following the centrifugal method was 706 (more than double) compared to only 313 
in the plate infected DCs. Therefore, it was decided to use the centrifugal method for 
infecting DCs in vitro to achieve higher infection efficiencies in the experiments 
described throughout this chapter. 
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  It was also important to assess the effect of the centrifugal method on the 
activation status of DCs and determine whether it had any effects on them. Hence, 24 
hours post treatments both uninfected and Ad-GFP infected DCs were stained with 
mAbs to the CSMs (CD40, CD80 and CD86) and analysed by flow cytometry. As 
Figure 5.3 demonstrates (for simplicity only CD86 data shown) there was not a 
notable difference between the plate control uninfected iDCs with the centrifugal 
control DCs (CD86 MFI 94 vs 111, respectively) indicating that the centrifugal 
method did not interfere with the downstream experiments, discussed in this chapter. 
However, control (plate) Ad-GFP-infected DCs expressed lower levels of the CD86 
than the centrifugal Ad-GFP-infected cells (MFI 239 vs 312, respectively). Similar 
results were obtained with CD40 and CD80 (data not shown). 
 
 
                              
 
Figure 5.1. Infection of iDCs by Ad 
 
On day 10 of the culture, iDCs were washed with PBS and incubated with Ad-GFP for 1 hour in 
plates to be infected. They were then washed and supplemented with complete RPMI medium and 
incubated at 37°C for 24 hours before being examined by fluorescent microscopy. GFP
+ DCs under a 
fluorescent microscope (×400) are shown above. White arrow indicating nucleus in (A) and white 
arrow head showing DC dendrite in the bottom left picture (C). (B) and (D) show merged light and 
fluorescent microscope pictures of infected DCs. Representative picture are shown. 
D. 
A.  B. 
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Figure 5.2. Ad-GFP infection of DCs: Centrifugal method to increase infection 
efficiency 
 
In total 3×10
6 DCs were resuspended in serum-free medium and Ad-GFP used at an MOI of 100 was 
used. The cells were either cultured in 6-well plates and incubated at 37°C for 1 hour to be infected 
(top plots) or were transferred to a 1.5ml Eppendorf tube and centrifuged at 2000 × g at room 
temperature for 1 hour (bottom plots). The infected cells were then washed with PBS to remove free 
viral particles and resuspended in complete medium containing GM-CSF and incubated at 37°C for 24 
hour before being stained with CD11c-APC Ab (isotype-matched Ab staining is not shown) and 
analysed by FACS. Representative plots of 3 independent experiments are shown; A) shows forward 
and side scatter plot of infected DCs, B) shows profile of unstained/uninfected DCs, and C) shows 
profiles of unstained DCs and Ad-GFP-infected DCs using either the conventional plate method (top 
right plot) or the centrifugal method (bottom right plot). 
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Figure 5.3. Assessment of DC maturation status following infection 
 
DCs were infected with Ad-GFP either in plate or in Eppendorf tube by the centrifugal 
method, as explained in Figure 5.1 legend, and stained with anti-CD86-PE mAb to assess the 
activation status of DCs 24 hour following treatment. A) Uninfected control (top histogram) 
and Ad-GFP infected (bottom histogram) DCs cultured in plate, and B) Uninfected control 
(top histogram) and Ad-GFP infected (bottom histogram) DCs using the centrifugal method. 
Control; ctrl. Representative plots of at least 3 independent experiments are shown. 
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5.2.2. Optimisation of Ad MOI for DC infection in vitro 
  
Once it was established that the centrifugal method greatly enhances the 
infection efficiency of DCs by Ad-GFP, it was necessary to optimise the MOI of Ad 
used to infect the cells. As mentioned above, the MOI optimisation would be 
beneficial for two important reasons; (i) using less Ad particles to avoid unnecessary 
activation of iDCs, and (ii) minimising the amount of Ad vector resulting in 
maximum infection would be more economical. Initial experiments were therefore 
undertaken to investigate the optimal MOI of Ad for infecting iDCs. Once again, Ad-
GFP was used as an indicator of infection and the cells were assessed by fluorescent 
microscopy and FACS 24 hours following infection. These experiments 
demonstrated that the optimum MOI of Ad was around 100 where around 70% of the 
cells were expressing the GFP (Figure 5.4); that using higher MOIs would not be 
useful. 
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Figure 5.4. Infection of DCs with Ad-GFP 
 
Optimum MOI for DC infection was determined using an Ad-GFP vector. DC enriched populations 
were infected with increasing MOI of Ad using the centrifugal method for 1 hour as explained in the 
legend of Figure 5.3. Cells were then washed and incubated at 37°C for a further period of 24 hours. 
Cells were then harvested and GFP expression determined by flow cytometry. The mean (±SD) of 
GFP
+ cells from 3 individual titrations was plotted. Chapter 5: In vitro effects of natural neutrophil elastase inhibitors on dendritic cells 
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5.2.3. NE inhibitors and DCs 
 
  To investigate the direct effect of NE inhibitors in isolation on DC activation 
status, iDCs were infected with Ad vectors expressing one of the three main NE 
inhibitors (i.e., Ad-elafin, Ad-SLPI/GFP and Ad-α1PI) present in the lung and 
analysed for expression of the CSMs 24 hours post infection, as described above. In 
the experiments described here an empty Ad construct (Ad-null) or Ad expressing 
murine eotaxin (a secreted chemokine of similar molecular mass to elafin and SLPI, 
with no known effects on DCs) were used as controls. The data from three 
independent experiments have been summarised in the top graph in Figure 5.5. 
Compared to uninfected iDCs, the empty Ad-null and Ad-eotaxin (data not shown in 
this figure, see below) were slightly immunogenic (but not statistically significant), 
inducing cell activation as assessed by CSM expression levels 24 hours post 
infection. 
 
It should be noted that, assessment of DCs infected with the Ad vectors 
showed that Ad-infection did not induce apoptosis/necrosis in DCs as determined by 
trypan blue dead cell exclusion assay and staining by PI and annexin-V, 24 hours 
post Ad-infection (not shown).  
 
5.2.3.1. Effect of human elafin on DCs 
 
  As shown in Figure 5.5, iDCs infected with Ad-elafin vectors were 
expressing higher levels of CSMs than the control infected group. Nevertheless, 
although this observation was consistent, the increased CSMs expression following 
Ad-elafin infection never reached significance. To assess whether the cells infected 
with Ad-elafin were able to produce detectable levels of elafin protein, ELISAs were 
performed on Ad-infected DC supernatants. As shown in Figure 5.6, DCs infected 
with Ad-elafin secreted detectable levels of elafin in the supernatant. The secretion of 
elafin was further enhanced by adding LPS/TNF-α to the sample indicating that, as 
previously observed by our group (Simpson et al., 2001a), these mediators could up-
regulate the transgene elafin expression presumably by activating the murine CMV Chapter 5: In vitro effects of natural neutrophil elastase inhibitors on dendritic cells 
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promoter (which is inflammation-inducible; Simpson et al., 2001a). Of the two 
stimuli, TNF-α had the most potent effect and almost doubled the elafin 
concentration produced by infected DCs. Since murine cells do not code for the 
elafin gene, as expected, uninfected iDCs and Ad-null-infected cells did not produce 
any detectable elafin protein in their supernatants. We had previously shown that 
full-length elafin is able to bind both smooth and rough forms of LPS and modulate 
consequent macrophage responses to LPS (McMichael et al., 2005b). However, it 
should be noted that Ad-elafin-infected DCs matured (as measured by staining for 
CD40, CD80, CD86 and MHCII surface markers) in the same way as Ad-null-
infected DCs in response to LPS/TNF-α, indicating that the presence of elafin does 
not (at least at these concentrations) affect DC responses to these stimuli (data not 
shown).  
 
  Since the iDC Ad-elafin experiments were not conclusive, further attempts 
were made to elucidate whether purified/recombinant elafin was able to directly 
affect the phenotype and function of DCs in vitro. However there was not sufficient 
material available in-house to perform properly controlled experiments at the time 
this study was undertaken. To circumvent this hurdle, human elafin was purified 
from supernatants of Ad-elafin-infected epithelial cells. However, these experiments 
were hampered by the findings that the purified elafin also contained contaminations 
such as endotoxins and immunoglobulin (Ig) fragments (washed from the affinity 
chromatography column) which interfered with the DC activation assay (data not 
shown) and made it impossible to interpret the data. 
 
  Previously, our group had detected the cDNA for elafin in various tissues 
(including the BM and blood) of the eTg mice generated in house (Sallenave et al., 
2003). Therefore, in a parallel experiment, BM cells were taken from eTg mice and 
their WT control littermates, and cultured with GM-CSF to generate DCs (as 
previously described in Chapter 3). The eTg- and WT-derived iDCs were then 
stimulated with LPS for a further period of 24 hours and assessed by flow cytometry 
to investigate whether endogenous elafin production would influence DC 
differentiation and phenotype. As shown in Figure 5.7, DCs generated from eTg Chapter 5: In vitro effects of natural neutrophil elastase inhibitors on dendritic cells 
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mice matured in a similar manner to WT-derived DCs in response to LPS stimulation. 
It should be mentioned that elafin could not be detected by ELISA in supernatants of 
eTg iDCs/mDCs. Overall these experiments showed that there were no significant 
differences in CSMs levels expressed on iDCs and mDCs generated from eTg 
compared to CSM levels of iDCs and mDCs which were derived from WT mice 
control group. 
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Figure 5.5. Infection of iDCs with Ad expressing NE inhibitors 
 
On day 10 of the culture iDCs were infected with MOI 100 of Ad-elafin, Ad-SLPI/GFP or Ad-α1PI as 
explained in the legend of Figure 5.3 Ad-null and Ed-eotaxin were used as control for background Ad 
infection. Twenty four hours post infections cells were washed with PBS and stained with CSM Abs 
and analysed by flow cytometry. A) Graph showing DC CSMs expression following infection by Ad 
vectors (MFI ± SD of three independent experiments). B) Representative FACS histograms for CD86 
(left; Ad-elafin, centre; Ad-mSLPI/GFP and right; Ad-α1PI [open black histograms] vs Ad-null [filled 
grey histogram]). * indicates statistical significance (p<0.05) compared to control Ad-null infected 
DCs; n=3 independent experiments. 
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Figure 5.6. Elafin concentrations in infected DC supernatant 
 
10
6 iDCs were infected with MOI 100 of either Ad-null or Ad-elafin on day 10 of the DC culture as 
previously described. To some Ad-elafin infected cells either LPS or TNF-α (at a final concentration 
of 100ng/ml and 5ng/ml respectively) were added at the same time of infection. Supernatants were 
collected 24 hours post treatment and were analysed by elafin ELISA for presence of secreted elafin. 
Representative data shown (n=2). 
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Figure 5.7. Generation of DCs from WT and eTg mice 
 
DCs were generated from BM cells taken from eTg or WT mice (2 mice per group) by culturing cells 
in complete medium containing GM-CSF, as described in Chapter 2. On day 10 the cells were 
stimulated with 100ng/ml LPS and 24 hours post treatment the cells were washed and stained with 
FACS Abs to CSMs. Representative data of 3 independent experiments are shown. Chapter 5: In vitro effects of natural neutrophil elastase inhibitors on dendritic cells 
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5.2.3.1.1. Chemoattraction of iDCs by elafin 
 
The experiments presented above showed that direct infection of iDCs with 
Ad-elafin does not induce significant up-regulation of their CSMs, failing to provide 
any direct link between elafin and DC activation (as measured with CSMs). However, 
in vivo data presented in Chapter 4 clearly demonstrated that elafin over-expression 
in the lungs of WT and eTg mice resulted in increased number of activated DCs 
(expressing high levels of CD80 and CD86). Another possible mechanism by which 
elafin could be involved in the up-regulation of the lung DC numbers is 
chemoattraction of DCs. To test this hypothesis, the murine Clara (bronchial 
epithelial) DJS2-2 cell line was employed, as this cell line has been derived from the 
lung tissue and is a suitable in vitro model in this case. Clara cells were infected with 
Ad-elafin or Ad-null vectors in serum
-ve medium containing 0.1% BSA and 
supernatants were collected 48 hours post infection and placed in the bottom 
chamber of the polyvinyl uncoated trans-well (5µm pore) plates. Uninfected Clara 
cell supernatant and the chemokine MIP-3α (a known ligand for CCR6 expressed by 
iDCs; Dieu et al., 1998) were used as the negative and positive controls, respectively. 
Freshly generated iDCs (1×10
5) were then washed and resuspended in serum
-ve 
medium and placed on the top chamber of the trans-well and incubated for 90 
minutes at 37°C. Following incubation, iDCs remaining in the top chambers, iDCs 
adhered onto the bottom side of the trans-well membranes, and iDCs that had 
migrated to the bottom chambers were analysed and counted, as described in Chapter 
2 (section 2.2.4.2.5.).  
 
  Although not controlled for random movement of iDCs (chemokinesis), 
Figure 5.8 demonstrated that higher number of iDCs were detected in the bottom 
chambers when elafin-containing Clara media or MIP3α were used, and conversely 
lower number of iDCs were detected in the top chambers in these groups, compared 
to Ad-null-Clara medium and Clara medium alone (Figure 5.8 A). On the other hand, 
when the trans-well membranes were examined, it was found that higher number of 
cells had migrated through the membranes and had adhered to the lower side of the 
membranes in elafin-Clara and MIP3α groups (Figure 5.8 B). It should be noted that Chapter 5: In vitro effects of natural neutrophil elastase inhibitors on dendritic cells 
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this experiment was only performed once and unfortunately there was not enough 
time and recombinant elafin protein to further optimise this system. Nevertheless, 
these preliminary data, currently pending further conclusive investigations, are 
encouraging and hint towards potential effects of elafin on iDCs migration. 
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Figure 5.8. Elafin chemoattracts iDCs in transmigration assay 
 
To investigate possible chemotactic properties of elafin on iDCs, Clara cells were infected with MOI 
100 of Ad-elafin or Ad-null in serum
-ve DMEM medium for 48 hours and 600µl of the collected 
supernatants were pipetted in the lower chamber of the trans-well Costar plate.10
5 iDCs were 
resuspended in 100µl DMEM medium containing 0.1% BSA and placed in the upper chamber. The 
plate was then incubated at 37°C for 90 minutes. Following incubation, A) iDCs remaining in the top 
chambers, iDCs that had migrated to the bottom chambers, and B) iDCs stuck onto the bottom side of 
the trans-well membranes were analysed and counted, as described in Chapter 2 (section 2.2.4.2.5.). 
Uninfected Clara cell supernatant and the chemokine MIP-3α (100ng/ml in Clara sup.) were used as 
the negative and positive controls, respectively; n=1, duplicate wells. 
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5.2.3.2. Effect of murine SLPI on DCs 
 
  iDCs infected with Ad construct expressing the murine SLPI as well as GFP 
(Ad-SLPI/GFP), expressed significantly higher levels of CSMs compared to Ad-
control infected DCs (Figure 5.5). Since the infected cells also expressed low levels 
of GFP which was earlier shown to activate iDCs (see Figure 5.3), these observations 
had to be interpreted with caution and, as for Ad-elafin-infected DCs, were not 
conclusive. However, recombinant murine SLPI was available in-house and made it 
possible to investigate the direct effect of this protein on DCs. On day 10 of culture, 
iDCs were treated with various concentrations of murine SLPI (10-1000 nM) ± LPS 
(100ng/ml) for 24 hours and analysed by FACS. SLPI treatment of DCs did not 
affect the DC phenotype at all and LPS was able to fully mature the cells irrespective 
of the SLPI concentration/presence (data not shown). This is despite the fact that 
SLPI has previously been shown to suppress monocyte/macrophage responses to 
bacterial LPS (Taggart et al., 2002; Yang et al., 2005). 
 
  To mimic the experiments performed by Davidson et al. (2004) in which 
investigators showed that LL-37-derived human DCs displayed significantly higher 
endocytic capacity, modified phagocytic receptor expression and function, up-
regulated CSM expression, enhanced secretion of Th1-inducing cytokines, therefore 
promoting Th1 responses in vitro; as opposed to adding recombinant SLPI or 
infecting cells with Ad-SLPI/GFP on day 7, BM cells were also cultured in the 
presence of murine SLPI (10-1000 nM) from day 0 of culture. SLPI-derived DCs 
were counted and analysed on day 10. In addition SLPI-derived DCs were stimulated 
with LPS and were compared to conventionally generated DCs. However, no 
differences were observed between all these treatments upon the presence of SLPI in 
the culture medium (data not shown). 
 
5.2.3.3. Effect of murine α1-PI on DCs 
 
 The  murine  α1-PI expressed by the Ad-α1PI construct was the most potent of 
the three NE-inhibitors transduced into iDCs, inducing the greatest significant Chapter 5: In vitro effects of natural neutrophil elastase inhibitors on dendritic cells 
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increase in CSMs and MHCII compared to control Ad-infected iDCs (see Figure 5.5 
and below). To confirm that Ad-α1PI was able to infect DCs efficiently and that the 
transduced cells were able to transcribe and secrete the murine α1-PI protein, 
supernatants taken from the infected cells were analysed by Western blotting for the 
presence of α1-PI protein. There is ~60% aa identity between the human and murine 
α1-PI proteins (Borriello and Krauter, 1991). Therefore, human recombinant α1-PI 
protein (52kDa) and rabbit anti-human α1-PI Ab (available in the laboratory) were 
used to detect the murine α1-PI protein in these samples. Preliminary experiments 
were undertaken to optimise the system (see Chapter 2, section 2.2.4.2.4 for 
experimental details) and also to determine whether or not the Ab could be used to 
detect murine α1-PI by Western blot analysis.  Indeed the anti-human α1-PI Ab was 
also able to react with murine α1-PI protein, which is ~51-53 kDa in size (Churg et 
al., 2003; Berger and Baumann et al., 1985); when supernatants were analysed from 
Ad-α1PI-infected cells, murine α1-PI was readily detected (Figure 5.9). The slight 
difference between the molecular weight of human and murine α1-PI proteins in 
Figure 5.9 could be due to different glycosylation patterns (post-translational 
modifications) or the difference in the amino acid compositions of these homologous 
glycoproteins. Indeed, the mature form of human α1-PI consists of up to 12% 
carbohydrates by weight, which varies depending the source and preparation of this 
glycoprotein (Kolarich et al., 2006). 
 
Figure 5.9. Detection of α1-PI by infected DCs 
 
DCs were infected with either MOI 100 of Ad-α1PI (lane 1) or Ad-null (control; lane 2) and were 
incubated at 37°C for 48 hours allowing them to produce and secrete detectable concentrations of α1-
PI. Supernatants were collected at the end of the experiment and were kept at -20°C to be analysed by 
Western blot. To detect the secreted α1-PI protein, infected DC supernatants were concentrated 10× 
and ran on a NuPAGE 4-12% Bis-Tris polyacrylamide gel, transferred onto a nitrocellulose membrane 
and probed with rabbit anti-human α1-PI which was shown to also recognise murine α1-PI in 
preliminary experiments. Recombinant human α1-PI was used as control in these experiments (lanes 3 
and 4, 20ng and 40ng loaded respectively).  Representative Western blot of 2 independent 
experiments is shown. 
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  Secondly, to rule out the potential artefactual nature of DC activation 
observed in Figure 5.5, it was deemed necessary to rule out the presence of 
endotoxins in the viral samples used to infect the iDCs in these experiments and in in 
vivo experiments described in Chapter 4. A quick and efficient way to investigate 
this was to employ the RAW 264.7 murine macrophage cell line which is very 
sensitive to endotoxins and routinely used in our laboratory (McMichael et al., 
2005b). Therefore macrophages were stimulated with Ad constructs or LPS, for 4 
hours and the supernatants were analysed for TNF-α by ELISA. These experiments 
showed that macrophages did not release significant concentrations of the pro-
inflammatory cytokine TNF-α in response to MOI 100 of Ad vectors compared to 
PBS treated (Ctrl) cells (Figure 5.10). This suggests that they either did not contain 
any endotoxins or their levels were minimal in the Ad samples and could not 
interfere with the parameters analysed in the experiments.  
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Figure 5.10. Stimulation of RAW 264.7 macrophages with Ad constructs 
 
RAW 264.7 murine macrophages were cultured in 48-well Costar plates overnight. 24 hours later they 
were washed with PBS and incubated with complete medium containing the Ad constructs (MOI=100) 
used throughout this thesis, or LPS (10ng/ml and 20ng/ml) as positive control.  Four hours post 
culture, supernatants were collected and analysed by TNF-α ELISA. Results are presented as pooled 
data from duplicate wells (n=1). Chapter 5: In vitro effects of natural neutrophil elastase inhibitors on dendritic cells 
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In addition to analysing DC CSMs and MHCII following Ad-α1PI infection, 
the supernatant of the infected cells were analysed for presence of IL-12p40 by 
ELISA which, as previously described, is secreted by activated DCs. In line with the 
previous observations that Ad-α1PI infection activated DCs (Figure 5.5), it was 
found that the Ad-α1PI infected DCs also produced higher levels of IL-12p40 
compared to control uninfected and Ad-null infected DCs (Figure 5.11). 
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Figure 5.11. IL-12p40 production by Ad-α1-PI infected DCs 
 
DCs were infected as described in the legend of Figure 5.5 and their supernatants were collected 24 
hours post infection and analysed by ELISA for the presence of IL-12p40. Concentration units are 
expressed as ‘pg/ml’; duplicate wells were used in ELISA (n=2 independent experiments). 
  
Further experiments were carried out to investigate the immunostimulatory 
effects of murine α1-PI on DCs. The first set of experiments aimed to titrate the MOI 
of Ad-α1PI used to infect DCs and investigate if there was a dose dependent effect. 
Here Ad-eotaxin was used as an Ad infection control. As Figure 5.12 demonstrates, 
although Ad-eotaxin titration also had an affect on the expression levels of DC 
surface molecules at higher MOIs, Ad-α1PI infection was able to increase the CSMs 
even when used at an MOI of 10. The expression levels of CSMs and MHCII were 
maximised when Ad-α1PI was used at MOI of 100 and were comparable to the 
expression levels induced by LPS (100ng/ml; Figure 5.12, top histograms). 
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The experiments described hereafter were undertaken to investigate whether 
the stimulatory effects of α1-PI secretion on Ad-α1PI-DCs were via an extra-cellular 
mechanism or an intra-cellular one. One way to answer this was to transfer 
supernatants from Ad-α1PI infected cells onto freshly generated iDCs and assess 
their CSM and MHCII expression levels following treatment. iDCs were infected 
with either Ad-eotaxin (control) or Ad-α1PI in serum
-ve medium for 24 hours and 
supernatants were used to culture freshly generated iDCs. As FACS histograms show 
in Figure 5.13, supernatant transferred from either Ad-eotaxin infected control cells 
or Ad-α1PI infected cells were unable to induce any increase in CD86 and MHCII 
levels. Furthermore incubation of iDCs with recombinant human α1-PI (1µg/ml) did 
not affect the cells (data not shown).  
 
Lastly, attempts were made to inactivate the Ad vectors and examine their 
effects on iDCs. The purpose of this experiment was to fully elucidate whether the 
DC activation following Ad-α1PI infection was due to the expression of the α1-PI 
transgene, or due to other factors that might be influencing DC activation in this 
system, e.g., viral proteins or endotoxin contaminations in viral samples. To perform 
this, the fact that U.V. treatment of Ad vectors inactivates their DNA/transgene 
(while not interfering with Ad uptake by cells, although not tested in the current 
study) was taken advantage of to investigate whether the stimulatory effects of Ad-
α1PI are transgene (α1-PI)-dependent. Preliminary experiments using Ad-GFP 
indicated that exposing small aliquots (10-20 µl/0.5ml Eppendorf tube) of Ad to 
direct U.V. light (which inactivates the Ad DNA and the transgene) for 45 minutes 
resulted in full inactivation of the viral DNA. The inactivation protocol of Ad vectors 
was tested by infecting iDCs with U.V.-treated Ad-GFP constructs and assessing 
GFP expression by these cells using a fluorescence microscope 24 hours post 
treatment (not shown) and by flow cytometry (Figure 5.14 A). Figure 5.14 B and C 
demonstrate that U.V.-inactivation of Ad-α1PI almost halved the expression levels of 
CD86 by DCs compared to those infected with fully active Ad-α1PI (MFI 143 vs 263, 
respectively), indicating that indeed intra-cellular (see Figure 5.13) expression of α1-
PI induced DC activation in vitro. It should also be noted that Ad-eotaxin 
inactivation resulted in a small drop in expression levels of CD86 compared to DCs Chapter 5: In vitro effects of natural neutrophil elastase inhibitors on dendritic cells 
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treated with active Ad-eotaxin (MFI 116 vs 93, respectively), indicating that eotaxin 
expression could have slight modulatory effects on DCs too. Also, compared to 
untreated control iDCs, iDCs infected with inactivated Ad vectors were slightly 
stimulated which could be due interaction of Ad envelope proteins with the DCs 
(Figure 15.14 B). Based on these data (Figure 5.14.), in the case of CD86, 
inactivation of these vectors led to a ~46% drop in DC activation following Ad-α1PI 
infection, compared to only ~19% drop in control Ad-eotaxin-infected cells.  
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Figure 5.12 (Part A). Titration of Ad-α1PI MOI on DCs  
 
DCs were generated and infected with various MOI (10, 25, 50 and 100) of either 
Ad-eotaxin or Ad-α1PI and incubated at 37°C for 24 hours, as previously described. 
Also DCs in one well were left uninfected (negative control) and DCs in another well 
were stimulated with 100ng/ml LPS as positive control for DC maturation. The 
uninfected and LPS-stimulated control cells as well as the infected DC groups were 
washed and stained with FACS Abs to CSMs and MHCII and analysed by flow 
cytometry for their expression levels. Filled grey histograms = uninfected cells; pink 
line = LPS-stimulated DCs, green line = Ad-eotaxin infected DCs; red line = Ad-
α1PI infected DCs. The MFI values of Ad-eotaxin-infected DCs (left) and Ad-α1PI-
infected DCs (right) are indicated on each histogram. Isotype-matched control Ab 
stainings and gates are not shown for simplicity. Representative plots of 2 
independent experiments are shown. 
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Figure 5.12 (Part B, continued). Titration of Ad-α1PI MOI on DCs  
 
DCs were generated and infected with various MOI (10, 25, 50 and 100) of either 
Ad-eotaxin or Ad-α1PI and incubated at 37°C for 24 hours, as previously described. 
Also DCs in one well were left uninfected (negative control) and DCs in another well 
were stimulated with 100ng/ml LPS as positive control for DC maturation. The 
uninfected and LPS-stimulated control cells as well as the infected DC groups were 
washed and stained with FACS Abs to CSMs and MHCII and analysed by flow 
cytometry for their expression levels. Filled grey histograms = uninfected cells; pink 
line = LPS-stimulated DCs, green line = Ad-eotaxin infected DCs; red line = Ad-
α1PI infected DCs. The MFI values of Ad-eotaxin-infected DCs (left) and Ad-α1PI-
infected DCs (right) are indicated on each histogram. Isotype-matched control Ab 
stainings and gates are not shown for simplicity. Representative plots of 2 
independent experiments are shown. 
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Figure 5.13. Ad-α1PI infected DC supernatant transfer 
 
DCs were infected with either MOI 100 of Ad-eotaxin or Ad-α1PI in serum-free 
medium and incubated at 37°C for 24 hours. The supernatants from infected cells 
were collected and transferred onto freshly generated iDCs and incubated for either 4 
hours or 24 hours before cells were being washed and analysed by flow cytometry. 
Representative histograms for CD86 and MHCII are shown (n=3).  
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Figure 5.14. U.V. inactivation of Ad-α1PI 
 
Ad vectors were exposed to direct U.V. light for a period of 45 minutes for complete inactivation and 
then incubated with DCs. A) DCs were infected with active and U.V.-inactivated Ad-GFP and GFP 
expression was assessed by flow cytometry 24 hours post infection. U.V.-inactivated Ad-GFP (filled 
grey histogram) versus active Ad-GFP (filled green histogram). B)  Immature DCs (open pink 
histogram) were infected with either U.V.-inactivated Ad vectors (filled blue histograms) or with 
active Ad-GFP (open green histogram), Ad-eotaxin (open pink histogram) or Ad-α1PI (open red 
histogram) at moi of 100. DC activation status was investigated by flow cytometry 24 hours post 
infection (CD86 expression data shown). Data is representative of two independent experiments. C) 
Pooled data from two experiments shown. * indicates statistical significance (p<0.05) compared to 
control active Ad-α1PI DCs; n=2 of duplicate wells. 
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5.3. DISCUSSION 
 
The principal novel observation arising from the data in this chapter is that 
some NE inhibitors (e.g., α1-PI) may directly be capable of affecting DC phenotype 
and function, suggesting their possible roles in bridging the innate and adaptive 
branches of the immune system. Of the three NE inhibitors investigated, Ad-α1PI 
infection of iDCs resulted in the highest rate of activation, and elafin and SLPI did 
not seem to directly be involved in iDC activation. Discussion of the results 
presented in this chapter will be divided into two separate sections, as follows. 
 
5.3.1. The in vitro effects of elafin on DCs 
 
  The data presented here demonstrated that elafin does not directly activate 
iDCs (Figure 5.5). However, as shown in the previous chapter, in vivo over-
expression of elafin resulted in higher number of mDCs in murine lungs. Therefore it 
was speculated that elafin might act as a chemoattractant to modulate DC migration 
in inflammatory tissue. To test this hypothesis, the ability of elafin-rich media to 
chemoattract iDCs in a transmigration assay was investigated. As shown in Figure 
5.8, preliminary experiments showed that iDCs migrated towards elafin-rich media 
in this in vitro assay. Interestingly, the migration of iDCs towards elafin-rich medium 
was comparable to the migration of iDCs to MIP3α-containg medium (positive 
control). These early data are encouraging and may in part explain how elafin is 
controlling DC movement/activation in vivo. However, one should be very cautious 
in interpreting these data, as they are at the preliminary stage and were not properly 
controlled for. For instance, these experiments did not take into account the random 
movement of iDCs in culture and did not have control wells where elafin-rich 
medium would be placed, either at the top/bottom chamber or in both chambers to 
account for chemokinesis as well as chemotaxis. In addition, the dose of elafin used 
in these experiments was not titrated and thus could make limitations in interpretion 
of the data. Therefore, future studies should expand the controls used in this 
experiment and would ideally have to apply various doses of elafin and different Chapter 5: In vitro effects of natural neutrophil elastase inhibitors on dendritic cells 
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combinations with respect to the top and the bottom chambers to rule out these 
limitations and doubts. 
 
Previously, our group had shown that elafin over-expression enhances human 
neutrophil migration in vitro, and that it also augments LPS-mediated neutrophil 
migration into WT and eTg murine airways in vivo (Simpson et al., 2001a; Sallenave 
et al., 2003; also see Chapter 4). As yet, the mechanism by which elafin 
augmentation enhances neutrophil and monocyte/macrophage/DC chemoattraction in 
our in vitro and in vivo models is unclear. As previously mentioned, data generated 
in Oppenheim’s group shows that β-defensins, epithelial antibacterial cationic 
peptides with six conserved cysteine residues, might have an additional function as 
potential chemoattractants of iDCs through the chemokine receptor CCR6 (Yang et 
al., 1999; Biragyn et al., 2001). In that study Yang et al. (1999) showed that human 
β-defensin was selectively chemotactic for human embryonic kidney 293 (HAK293) 
cells stably transfected to express human CCR6, a chemokine receptor preferentially 
expressed by iDCs and memory T cells. Similarly murine β-defensin-2 was shown to 
act directly on iDCs as an endogenous ligand for TLR4, inducing up-regulation of 
CSMs and DC maturation (Biragyn et al., 2002). The human cathelicidin LL-37 has 
also been shown to use the formyl peptide receptor-like1 to chemoattract neutrophils, 
macrophages and T cells (Yang et al., 2000). Relatedly, chemerin, a novel protein 
abundant in inflammatory fluids (which is structurally and evolutionary related to the 
cathelicidin precursors and cysteine protease inhibitors), has been shown to be a 
potent chemoattractant of iDCs and macrophages, acting at concentrations similar to 
that of most chemokines (10pM to 1nM; Wittamer et al., 2003). Chemerin is a highly 
potent and specific agonist of ChemR23. ChemR23 transcripts are abundant in DCs 
and macrophages, treated or not with LPS, and are related to the subfamilies of 
chemokine receptors (Samson et al., 1998; Wittamer et al., 2003). 
 
In a recent study, Yang and colleagues (2005) generated mutant version of 
SLPI (M73G and M73F) that selectively lost inhibitory function towards 
chymotrypsin and NE. Using these mutants they were able to conclude that 
expression of the SLPI protease inhibition mutants suppressed nitric oxide and TNF Chapter 5: In vitro effects of natural neutrophil elastase inhibitors on dendritic cells 
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production in response to LPS in a similar fashion as WT SLPI in RAW264.7 
macrophages. With this in mind, it would be interesting to generate mutated elafin 
(and oxidised elafin with lost NE inhibitory function) peptides so that they no longer 
can inhibit proteases, and test their abilities to activate and/or influence DC migration 
in vitro and in vivo.  
 
To date no putative cellular receptor(s) for elafin has been characterised. Like 
chemerin (Samson et al., 1998; Wittamer et al., 2003), elafin might have its unique 
receptor(s) on leukocytes. It should be taken into consideration that in addition to 
human leukocytes, our group has shown that human elafin is also chemotactic for 
murine leukocytes in vivo (Simpson et al., 2001a). Therefore, as mice do not have an 
elafin ortholog, it could be speculated that human elafin signals via other common 
receptors shared between human and murine leukocytes (e.g., neutrophils and 
macrophages). Alternatively, it could be speculated that the gene encoding for elafin 
might have been lost during the evolutionary process in mice, but its receptor has 
been conserved.  Since elafin was shown to chemoattract iDCs in vivo (and possibly 
in vitro) in this study, it would be tempting to suggest that, like β-defensins, elafin 
might also interact with CCR6 or other chemokine receptors expressed on iDCs, i.e., 
CXCR4, CCR1 and CCR5. One way to test this would be to use the stably transfect 
HEK293 cells to express these iDC chemokine receptors, as performed by Yang et al. 
(1999), and investigate their migration towards elafin-rich medium. On the other 
hand, neutralising Abs to iDC chemokine receptors could be used to test whether 
they could still migrate towards elafin-rich medium or not in these migration assays.  
 
Taken together, these preliminary observations might help explain the data 
presented in Chapter 4 and could account for at least some of the increase in DC 
numbers upon elafin augmentation in murine lungs (Roghanian et al., 2006b). 
Although, as mentioned above, one should be extremely careful in making an 
interpretation of the data presented in Figure 5.8, as this experiment was only 
performed once and not properly controlled for chemokinesis in addition to 
chemotaxis, and hence would require further validation experiments. 
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5.3.2. Activation of DCs by Ad-α1PI infection 
 
The findings presented in the latter part of this chapter demonstrated that Ad-
mediated expression of murine α1-PI protein was the most potent of the three NE-
inhibitors transduced into iDCs, inducing the greatest significant increase in CSMs 
and MHCII compared to control Ad-infected iDCs (Figure 5.5). Moreover, Ad-α1PI 
infected DCs also produced higher levels of IL-12p40 compared to control 
uninfected and Ad-null infected DCs (Figure 5.11). The effects of α1-PI on DCs 
seem to be due to the intra-cellular effects of murine α1-PI as medium transfer of 
murine α1-PI-containg medium (Figure 5.13) or addition of human recombinant α1-
PI protein to iDCs did not exert such effects (data not shown).   
 
These data suggest the involvement of α1-PI in activating DC intra-cellular 
signalling pathways. Although not performed here, measurement of intra-cellular 
NF-κB levels would help answer this question in future experimental procedures, as 
NF-κB is implicated in control of CSMs and MHCII transcription in these cells 
(Ardeshna et al., 2000; Sun and Fernandes, 2003; Benveniste et al., 2004; Qin et al., 
2005). The activation of DCs by α1-PI is intriguing because most of the previous 
published studies in this field have noted inhibition of inflammatory pathways by this 
NE inhibitor (Stockley et al., 2002; Spencer et al., 2004; Janciauskiene et al., 2004).  
Janciauskiene and colleagues (2004) showed that native α1-PI (inhibitory) as well as 
polymerised and oxidised (non-inhibitory) forms of α1-PI inhibited the secretion of 
IL-1β and TNF-α cytokines by LPS-activated human monocytes, indicating that the 
anti-inflammatory activity of α1-PI is unrelated to its inhibition of serine proteases. 
Interestingly, studies performed by Aldonyte et al. (2004) showed that both the 
native and polymerised forms of α1-PI have similar effects as monocyte activators, 
with pro-inflammatory effects at low doses, and attenuation of pro-inflammatory 
activities at physiologically normal doses. From the Western blot data (see Figure 5.9) 
obtained from supernatants of Ad-α1PI-infected DCs, it was estimated that DCs 
secreted around 0.2µg/ml murine α1-PI over the period of 48 hours. This dose is in 
the range of the lower dose of α1-PI used by Aldonyte et al.’s (2004) and, in 
agreement with their findings, resulted in pro-inflammatory rather than anti-Chapter 5: In vitro effects of natural neutrophil elastase inhibitors on dendritic cells 
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inflammatory activities in DCs. To further confirm the observations described in this 
chapter, future studies should also assess the effects of intra-cellular polymerised and 
oxidised  α1-PI on DCs; investigate whether the activation of DCs by α1-PI is 
dependant on its NE inhibitor activity/concentration or not. Moreover, future in vivo 
studies such as the ones performed in Chapter 4 (Roghanian et al., 2006b) would 
help to examine the effects of α1-PI on DCs in a physiological setting. 
 
In summary, the stimulatory effects of murine α1-PI on iDCs, as suggested by 
experiments presented in the latter part of this chapter, could help establish new 
avenues in this area of research. If these effects are proven in relevant in vivo settings 
and could also be reproduced in a comparable human system, this property of α1-PI 
(in addition to its antiprotease and anti-apoptotic activities; see Chapter 1, section 
1.7.2) could be exploited in vaccination protocols (as an adjuvant to enhance APC 
function) and in boosting the immune system of immunosuppressed patients, such as 
those with COPD and CF, and in α1-PI-deficeint individuals (genetic emphysema). 
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5.4. SUMMARY 
 
 The  in vitro results presented in this chapter demonstrate that NE inhibitors 
might be capable of inducing DC activation and chemotaxis. Although Ad-elafin 
infection of iDCs did not induce significant activation (suggesting an indirect 
mechanism for the in vivo elafin-induced activation of lung DCs described in 
Chapter 4), iDCs were shown to migrate towards elafin-containing medium in 
preliminary experiment. On the other hand, Ad-α1PI infection of iDCs led to their 
activation, possibly via intra-cellular signalling of the α1-PI transgene. 
 
  Taken together, these preliminary novel observations suggest that natural NE 
inhibitors might be able to activate the adaptive immune system by chemoattracting 
or activating iDCs. These properties of NE inhibitors, in addition to their previously 
described functions (e.g., antimicrobial, antiprotease), could be further exploited to 
design vaccines and immunotherapeutic protocols.  
 
    
 
 
 
 Chapter 6: Concluding remarks and future directions 
  216
CHAPTER 6 
 
CONCLUDING REMARKS AND FUTURE DIRECTIONS 
 
It is well accepted that in cystic fibrosis (CF) and chronic obstructive 
pulmonary disease (COPD), such as emphysema, an imbalance between destructive 
proteases secreted primarily by activated neutrophils and their natural inhibitors is a 
determinant factor in the progressive destruction of pulmonary tissue. Indeed, 
neutrophil mediated inflammation is a major component of parenchymal damage in 
COPD and CF lungs, and it is widely believed that neutrophil elastase (NE) may be 
one of the main mediators of such damage. This is because although elafin and other 
NE inhibitors are highly secreted locally during the course of the disease, their 
activities might be rendered due to inactivation, e.g., by oxidants (see Chapter 1, 
section 1.5.1.1). Since the lower airways of most COPD and CF patients are 
colonised by microorganisms, this might suggest that dendritic cells (DC) in the 
lungs of these patients are unable to activate the immune system because they fail to 
efficiently endocytose and/or present antigens. DCs form a network in the upper 
layers of the epithelium of the airways. In normal lungs inhaled antigens are captured 
by mucosal DCs across the epithelial tight junction barriers and presented to T cells 
in local lymph nodes (LN).  
 
In the current study, it was established that exposure of DCs to CSC leads to 
lower levels of co-stimulatory molecules (CSM), possibly due to CSC-induced DC 
necrosis, and that exposure of DCs to NE-rich inflammatory sputum secretions 
collected from COPD and CF patients results in decreased levels of CD80 and CD86 
(but not CD40) cell surface CSMs. Similarly, exposure of DCs to purified human NE 
led to lower levels of CD40, CD80 and CD86, leading to reduced antigen 
presentation and lower Th1 cytokine output (Chapter 3; Roghanian et al., 2006a). 
Although the in vivo effects of these changes remain to be investigated, the reduced 
Th1 cytokine levels induced by NE treatment of DCs may, in part, explain the 
reported Th2 imbalance in the lung immune response to bacteria in patients with CF 
(Brazova et al., 2005; Hartl et al., 2006) and the reported loss of IFN-γ-secreting Chapter 6: Concluding remarks and future directions 
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cells in patients with COPD (Tsoumakidou et al., 2005). This local Th2-biased 
phenotype may be instrumental in the inability of these patients to clear 
semifacultative intra-cellular pathogens in the lung, such as nontypeable 
Haemophilus influenzae (NTHI), Pseudomonas aeruginosa (P.a.) and Burkholderia 
cepacia ( B.c.), as suggested recently by a variety of animal and human studies 
(Moser et al., 1997; Martin and Mohr, 2000; Abe et al., 2002). Although neutrophils 
are important in early immunity to infection and may regulate adaptive immune 
responses indirectly through interactions with DCs (van Gisbergen 2005a and 2005b), 
these data indicate that high numbers of active neutrophils (secreting high levels of 
proteases) could be deleterious to adaptive immune responses. 
 
Further, in the latter part of this thesis, it was demonstrated that over-
expression of an NE specific inhibitor (elafin) in vivo results in a higher number of 
DCs with an activated phenotype in murine lungs, as evidenced by expression of 
higher levels of CSMs, and higher levels of IL-12 and TNF-α in their BAL fluids 
(Chapter 4; Roghanian et al., 2006b). Elafin is normally produced in a variety of 
epithelial and mucosal sites, such as the skin and the lung, and is a remarkable 
effective inhibitor of NE (see Chapter 1, section 1.7.1.1). The production of elafin in 
the lung has been attributed not only to bronchial epithelial cells and alveolar 
epithelial cells, but also to alveolar macrophages (Williams et al., 2006). Elafin was 
chosen in the current study because of its immunomodulatory properties, narrow 
specificity, and its small size (9.9 kDa), which make it a potential candidate for 
therapeutic use. In line with these data, intra-tracheal (i.t.) treatment of murine lungs 
with Ad vectors (e.g., Ad-GFP, or Ad-LacZ) leads to local expression of the 
transgene by the epithelial cells as well as alveolar macrophages, and is an ideal in 
vivo tool for such studies. In addition, the RNA message for human elafin has been 
detected in lung tissues of elafin transgenic (eTg) mice and the protein is also 
detected following LPS treatment of the eTg murine lungs (Sallenave et al., 2003).  
 
In the final part of the study, in vitro infection of DCs with Ad constructs 
expressing one of the three major respiratory system NE inhibitors (either elafin, 
SLPI or α1-PI) showed that only α1-PI-expressing DCs were highly activated Chapter 6: Concluding remarks and future directions 
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(Chapter 5). However, preliminary experiments indicated that elafin might affect 
iDC migration, as iDCs were shown to migrate towards elafin-rich supernatants in 
vitro. This suggests that elafin could directly and/or indirectly affect the number and 
the activation status of DCs and might help to interpret the in vivo data presented in 
Chapter 4. Taken together the novel data presented in this thesis help advance our 
understanding of the interactions of NE and NE inhibitors with DCs, and the ability 
of these molecules to affect the outcome of an immune response. 
 
To complete the data presented here, further investigations into whether 
direct administration or over-expression of endogenous NE inhibitors (e.g., elafin) 
may induce autoimmune responses against such molecules are necessary. It is 
expected that in humans (and the eTg mice) antibodies (Ab) against elafin should not 
be mounted as autoreactive clones would have been deleted in the thymus during 
early development of the immune system. Although low levels of peripheral 
autoreactive T cells could exist, these will not be activated in the absence of danger 
signals. Therefore, in view of the ‘danger model’, it could be speculated that Ad 
vectors may activate DCs which consequently may endocytose locally secreted elafin 
in an activated fashion and then present it to the autoreactive peripheral T cell clones 
and induce autoimmune disease. Alternatively, like other antimicrobial proteins, 
elafin which is up-regulated by inflammatory cytokines/infectious agents (Sallenave 
et al., 1994, Williams et al., 2006) may have the properties of an immune ‘alarmin’
1 
and act as a natural adjuvant during an episode of mucosal infection/inflammation 
(Oppenheim and Yang, 2005, Matzinger, 2002; Gallucci et al., 1999). For instance, 
Biragyn and colleagues (2003) exploited the alarmin property of defensins in 
immunising mice with fusion proteins consisting of murine active β-defensins linked 
to a non immunogenic lymphoma antigen, suggesting that fusion constructs with 
inflammatory mediators targeting immature DCs could elicit protective anti-tumour 
immunity. Furthermore, future experiments should measure the presence of Abs to 
the over-expressed molecule as well as any specific CD4
+ and CD8
+ T cell responses, 
                                                 
1  ‘Alarmin’ is a new terminology recently proposed by Oppenhiem and Yang (2005) to describe 
structurally diverse endogenous mediators of innate immunity which are rapidly released in response 
to infection or tissue injury, have both chemotactic and activating effects on APCs, and exhibit 
particularly potent in vivo immunoenhancing activity. This subset of mediators alerts host defences by 
augmenting innate and adaptive immune responses to tissue injury and/or infection. Chapter 6: Concluding remarks and future directions 
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such as the clones specific to the elafin transgene. Indeed, the medical literature is 
full of claims and counter claims concerning the risk of autoimmune disease as a 
consequence of vaccination (Wraith et al., 2003). Incidentally, the antimicrobial LL-
37, which possesses similar properties to the NE inhibitors, has been shown to inhibit 
leukocyte apoptosis (Barlow et al., 2006). On the other hand, recent data demonstrate 
that inhibition of DC apoptosis can independently result in autoimmunity in mice 
(Chen et al., 2006). Therefore, studying the effects of NE inhibitors on leukocyte 
apoptosis is desirable, as apoptosis in the immune system is critical for maintaining 
self-tolerance and preventing autoimmunity. Recently, the first phase in the clinical 
trial of elafin has been successfully completed by Proteo Biotech AG
2. In this trial, 
elafin was tested on 32 healthy male volunteers in Kiel, Germany. All intravenously 
applied doses of recombinant human elafin were well tolerated and no severe adverse 
events occurred. The successful conclusion of this trial demonstrates that the use of 
human elafin at various doses, without the use of a carrier, for therapeutic purposes 
(inflammatory diseases, particularly in lung and circulatory disorders) could be 
tolerated.  
 
The danger model currently favours the notion that the APC acts as the key 
regulator of the immune system by passively collecting and integrating signals from 
the tissue milieu and then deciding whether to initiate immunity or tolerance. 
Matzinger has recently suggested that the tissues themselves, not the APC, should be 
considered as the ultimate controllers of immunity (Matzinger, 2007). The new 
concept that tissue cells could actively secrete biochemical requests for immunity is a 
radical idea in contrast with the accepted image of immunity as a stand-alone system 
for protecting tissues. As described before, in the steady state, lung DCs do not 
synthesise IL-12 and preferentially stimulate Th2 rather than Th1 immunity 
(Stumbles et al., 1998; Constant et al., 2002) via secretion of anti-inflammatory 
cytokines (e.g., IL-6 and IL-10) or by production of indoleamine 2,3-dioxygenase 
(IDO) which suppresses T cell responses (see Chapter 1, section 1.2.10).  Therefore, 
the local microenvironment is of absolute importance in shaping DC phenotype, and 
the secretion of NE inhibitors such as elafin by the epithelial cells could be directly 
                                                 
2   Proteo owns the rights for the production and exploitation of recombinant elafin. Source: 
www.proteo.de/pages/presse.php?DATUM=2005-12-13&BACK=/pages/presse_01_02.php&lang=en Chapter 6: Concluding remarks and future directions 
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involved in such processes. The observation that the Ad delivery of elafin promotes a 
Th1 response in the mouse lungs leads one to speculate that this response might be 
dependent upon the presence of the Ad vector itself as a type 1 ‘danger signal’ (see 
above; even though such an effect has also been described in eTg mice, 
independently of the Ad mode of delivery) and does not necessarily indicate that 
elafin will always act as a type 1 adjuvant, regardless of the initiating signal. 
However, the very strong type 1 response elicited in both WT mice receiving Ad-
elafin and eTg mice (Roghanian et al., 2006b) indicate that this strategy could be 
used in a variety of other applications, for viral or intra-cellular pathogens (e.g., HIV, 
Mycobacterium tuberculosis, Chlamydia) which normal route of entry are mucosal 
surfaces.  Although cytokines could be used in these approaches as adjuvants, the use 
of elafin, a unique pleiotropic molecule with antimicrobial and anti-NE properties 
would be particularly relevant in anti-infective protocols (see below).  
 
Viruses have acquired numerous biological properties over millions of years 
of evolution which allow them to effectively recognise and enter cells, traffic within 
the cytosol to the nucleus, translocate into the nucleus and express their genes in the 
host cell. If virus constructs are to be used in gene therapeutic protocols to augment 
NE inhibitors in the respiratory tract, further experiments and many more large-scale 
clinical trials are required to examine the direct effect of virus vector-derived 
antigens on host’s immune system and its safety in vivo. Despite the clinical hazards 
associated with viral vectors they, along with liposomes, currently remain amongst 
the vehicles of choice for gene transfer
  in gene therapy trials in the UK and
 
worldwide. In the UK alone, eighty eight clinical trials were
 registered with the Gene 
Therapy Advisory Committee in 2004
3 (Relph et al., 2004).
 Currently, Ad vectors 
remain one of the popular viral vectors in clinical trials because of their ability to 
transduce a broad range of dividing and non-dividing cells. In addition, Ad vectors 
can be produced in high titres, and they replicate episomally and do not insert their 
genome into that of the host cell, which ensures less disruption of vital cellular genes. 
However, the efficacy of Ad delivery might be severely hampered because most 
people have been exposed to natural Ad infections. Therefore, a successful viral gene 
                                                 
3 GTAC webpage: www.advisorybodies.doh.gov.uk/genetics/gtac 
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therapy vector ideally needs to be protected from recipient’s circulating neutralising 
Abs and exhibit a preferential tropism for target cells in the organ where gene 
therapy is aimed at. In a novel approach, Fisher et al. (2001) coated surfaces of Ad 
particles with a multivalent hydrophilic polymer which proved to be an effective way 
of changing its tropism and interaction with the immune system. Nevertheless, as 
mentioned above, Ad vectors remain the most immunogenic of all the viral vectors 
currently in use (Relph et al., 2004) and their use in vivo may cause further 
unpredicted complications. In vivo, Ad vectors at high titers could induce the 
expression of various cytokines and inflammation-associated genes in innate immune 
cells such as macrophages and non-innate targets such as epithelial and endothelial 
cells (Liu and Muruve, 2003).  Indeed, in one of the early clinical trials (The ‘Jesse 
Gelsinger Case’) where a very high dose of Ad vector (3.8×10
13 viral particles) was 
used the patient died only four days post treatment (Lehrman et al., 1999; Ferber, 
2001; Relph et al., 2004). It appeared that, in line with the danger model, his immune 
system had launched a raging attack on the Ad vector, setting off an overwhelming 
cascade of organ failures, starting with jaundice, and progressing to a blood-clotting 
disorder, kidney failure, lung failure, and ultimately brain death. Also Ad might 
indirectly promote leukaemia by perturbing the immune surveillance of a 
spontaneously occurring pre-malignant B cell clone, simply by being present in those 
cells. Certain HLA types that are associated with an increased risk for common acute 
lymphoblastic leukaemias (cALL) potentially cooperate with Ad in this process 
(Dorak, 1996). In addition to developing safer replication-deficient vectors, 
alternative methods of gene delivery with a less invasive nature should be explored 
to over-express NE inhibitors in future studies. For instance, adeno-associated virus 
(AAV), which is far less immunogenic than Ad vectors and is currently one of the 
most popular gene delivery systems in animal experiments (Wu et al., 2006) could be 
employed to over-express NE inhibitors in lungs of people suffering from COPD and 
CF. This is mainly because of the long-term and efficient AAV’s transgene 
expression in various cell types such as lung cells (Flotte, 2005; Halbert et al., 2007).   
 
Future studies in vivo should not be limited to examining the dynamics of 
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crucial role as a first line of defence against viral and bacterial infections. The former 
are a heterogeneous population, expressing a mosaic of inhibitory and activating cell-
surface NK receptors. The balance of inhibitory and activating signals transmitted 
following engagement of NK receptors with their ligands (on target cells) determines 
the response of a particular NK cell (Lanier, 2005). Recent studies indicate that NK 
cells constitute a key component of the response to replication-deficient Ad in vivo 
(Ruzek et al., 2002; Xu et al., 2004). In addition, replication-deficient Ad vectors 
have been shown to stimulate NK cell recognition  (Tomasec  et al., 2007). 
Specifically, Tomasec et al. (2007) showed that primary human fibroblasts 
transduced with replication-deficient Ad vectors were more susceptible to NK cell-
mediated lysis- this was due to the expression of ligands of the potent activating NK 
receptor, NKG2D. NKG2D ligands might act as a CSM for CD8
+ CTLs and γδ T 
cells and might also have a profound effect on stimulating both innate and adaptive 
immune responses through the release of cytokines (Tomasec et al., 2007). 
Consequently, an investigation into the kinetics of NK cells following i.t. Ad-elafin 
treatment would be useful in order to dissect the mechanisms by which elafin 
modulates the immune system. To date no such study has been performed, and as yet 
the effects of NE inhibitors on the phenotype and/or function of NK cells remain 
unexplored. Over-expression of elafin might also affect the cross-talk between NK 
cells and DCs. The cross-talk between NK cells and myeloid DCs leads to NK cell 
activation and DC maturation. During lung inflammation, NK cells are rapidly 
recruited from the blood and engage DCs in a reciprocally regulating interaction. 
Mature DCs (via secretion of IL-12) activate NK cytotoxic function and production 
of TNF-α and IFN-γ, whilst activated NK cells enhance DC maturation and IL-12 
secretion (Moretta et al., 2005). The net result is selection of DCs that polarise naïve 
αβ T cells to a Th1 phenotype, as seen in our study (Roghanian et al., 2006b). 
Therapeutic approaches, like elafin augmentation (Roghanian et al., 2006b), that 
stimulate DCs to produce NK-cell-activating cytokines might directly activate NK 
cells (and consequently augment adaptive immune responses), thus minimising the 
toxic side effects of systemic cytokine administration. 
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In summary, the findings presented in this thesis suggest that, the presence of 
high concentrations of active NE is harmful to DCs in vitro, whereas high 
concentrations of NE inhibitors at the sites of inflammation/infection are essential in 
maintaining DC phenotype and function and therefore may influence the outcome of 
disease pathology and the consequent immune responses. In addition, this study 
established that augmentation of the antimicrobial/NE inhibitor elafin is able to 
bridge between the innate and adaptive arms of the immune system by activating 
DCs in lung, and possibly in other mucosal tissues (not investigated in the current 
study). Recent studies have demonstrated that respiratory pathogens such as 
Chlamydia pneumoniae,  NTHI,  P.a. and B.c. could reside intra-cellularly (Sethi, 
2000), especially
 in macrophages, and in the sub-epithelial zone in human respiratory
 
tissues. These bacteria are protected from antibiotics and bactericidal
 Abs, and may 
act as reservoirs of infection in COPD and CF lungs. Undoubtedly, vaccinating these 
groups of patients (i.e., people prone to developing COPD, and children diagnosed 
with mutations in the CFTR gene), where an imbalance between the NE and its 
inhibitors exists and high incidents of frequent/chronic infections are evident, with a 
Th1-inducing molecule such as elafin against these common respiratory intra-cellular 
pathogens may significantly reduce morbidity and mortality. Indeed, while classical 
adjuvants such as mycobacterium extracts enhance inflammation to provide non-
specific ‘danger signals’ that spark a strong adaptive response, transgene adjuvants 
representing endogenous mediators, such as elafin, are likely to have highly specific 
effects on individual components of the immune response as shown here (see above).  
 
In conclusions, the findings described in this thesis (see Figure 6.1) may 
further contribute to the understanding of the modulation of pulmonary DCs by the 
elastase:anti-elastase molecules of the lung milieu during different episodes of 
inflammation/infection. 
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Figure 6.1. Effects of NE:NE inhibitor imbalance scenarios on DCs 
 
Schematic diagram demonstrating the net effects of imbalance of NE and its 
inhibitors on the phenotype/activation status of DCs. High concentrations of 
uninhibited NE in inflammatory tissues result in down-regulation of DC co-
stimulatory molecules (CSM; namely CD40, CD80 and CD86), and subsequently 
lower secretion of pro-inflammatory cytokines (IL-12 and TNF-α) (left panel; 
Roghanian et al., 2006a). On the other hand, NE inhibitor-rich tissues contain higher 
numbers of activated DCs with increased levels of CSMs, secreting higher 
concentrations of the pro-inflammatory cytokines (right panel; Roghanian et al., 
2006b). References 
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